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Rheumatoid arthritis (RA) is an autoimmune disease characterised by systemic 
inflammation, as well as pain, stiffness and swelling of the joints. Patients with RA have an 
increased risk for cardiovascular diseases (CVD). Poor autonomic nervous system (ANS) 
function, indicated by increased sympathetic and reduced parasympathetic nervous system 
activity, is considered to be one of the underlying factors contributing to the increased risk 
for CVD in RA. This thesis included studies that examined the ANS in patients with RA. 
The first experimental chapter includes a cross-sectional study in which the association 
between a novel measure of myocardial ischemia during an exercise tolerance test (ETT) 
and resting heart rate variability (HRV) was explored in 96 patients with RA. Myocardial 
ischemia was associated with reduced HRV which was indicated by reduced 
parasympathetic nervous system and reduced sympatho-vagal balance. The second 
experimental chapter involves the examination of parasympathetic reactivation using heart 
rate recovery (HRR) following ETT, and the factors associated with HRR including CVD 
risk factors, RA-disease related factors, and measures of wellbeing. Despite several factors 
being associated with HRR, multivariate analyses revealed that none of these was 
independently associated with HRR, but it was the overall CVD risk and disease related 
burden that contributed to variability in HRR. In the third experimental chapter, the effects 
of a three-month semi-supervised exercise intervention on parasympathetic activity using 
HRR, as well as, CVD risks, RA-disease related inflammation, and measures of wellbeing 
were investigated in a longitudinal study in 62 patients with RA. The exercise programme 
was successful in reducing some CVD risk factors and improving some measures of 
wellbeing, however, parasympathetic activity as well as cardiorespiratory fitness did not 
improve. In the last experimental study, a cross-sectional study compared parasympathetic 
activity using HRR between age- and sex-matched RA (N=43) and diabetes mellitus (N=26) 
patients (a population that has a similar CVD risk profile but lower levels of systemic 
inflammation), as well as inflammatory markers, CVD risk factors, and measures of 
wellbeing. There was no difference in HRR or inflammation between the two groups. A sub-
analyses looking at the variables associated with HRR in the whole sample together (RA 
and DM patients) found that cardiorespiratory fitness was an independent predictor of HRR. 
In conclusion, the findings from the studies in this thesis suggest that parasympathetic 
activity in RA associate with several CVD risk factors, and that cardiorespiratory fitness is 
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Rheumatoid Arthritis  
Rheumatoid arthritis (RA) is an autoimmune disease affecting the joints, causing symptoms 
such as pain, stiffness and swelling. The disease can be characterised by high-grade systemic 
inflammation. Patients with RA often experience fluctuations in disease activity, including 
periods of high disease activity with acute episodes of pain and inflammation, known as 
flares, and periods of lower disease activity for a certain period of time with partial absence 
of symptoms, known as remission (1). Despite the advances in treatment, there is no cure 
for RA. Therefore, treatment is focused on controlling disease activity and reducing 
comorbidities. Appropriate control of disease activity is important to reduce pain, minimize 
the articular damage, and maintain mobility (2). The exact aetiology of RA is unknown, 
however, there is evidence that genetic susceptibility and behavioural factors, such as 
smoking, could contribute to the development of RA (3). RA does not only affect the joints, 
there are also extra-articular manifestations in RA, such as an increased risk for 
cardiovascular disease (CVD), which contributes to up 40% of mortality in RA (4). Patients 
with RA also have poor wellbeing, such as higher levels of depression and fatigue (5-7). 
There is an increased healthcare burden of RA compared to another chronic condition (i.e. 
Diabetes mellitus (DM)) in the United Kingdom. The healthcare burden of RA is estimated 
to be £8 billion per year for approximately 690,000 RA patients living in the United 
Kingdom (8), whereas, £9.8 billion per year is the estimated healthcare burden for 3,368,198 
DM patients living in the United Kingdom (9). This may suggest that the individual health 
burden of RA is higher than other chronic conditions such as DM. In the following section, 
a more detailed overview will be provided of the epidemiology, symptoms, treatment and 
extra-articular manifestation of RA.    
 
Epidemiology 
RA is the most common chronic inflammatory disease and affects ~0.8 % of the adult 
population of the United Kingdom (10). As with many autoimmune diseases, the majority 
of patients with RA are women. There are some sex differences in the symptoms of the 




joints involvement in men (hips, knees), and men tend to suffer more from bone erosion 
damage compared to women (11). Despite the increased bone erosion in men, women tend 
to have more orthopaedic surgeries than men due to the increased small joint involvement 
in women and other factors (such as rheumatoid nodules) (11). 
 
Aetiology  
Although the exact cause of RA remains unknown, there are multiple factors that can 
contribute to the onset of RA. A discussion on these factors follows below.  
 
a) Genetic factors 
There is evidence implicating genetic factors in RA. For example, it has been found that first 
degree relatives of patients with RA are more likely to develop RA than the general 
population (12). Furthermore, monozygotic twins have disease concordance rates of 15 – 
30%, and for dizygotic twins this is 5% (13).  
There are also certain genomes that have been implicated in RA. For example, major 
histocompatibility complex (MHC) is an area of genomes that has been linked with RA (14). 
MHC is divided into three classes: class I, class II, and class III. Human leukocyte antigen 
(HLA)-DRB1 is the shared epitope found in MHC class II that has been associated with 
rheumatoid factor (14;15). The function of (HLA)-DRB1 alleles is to encode a sequence of 
amino acids (14). Normally, recognition of viral peptides is performed by HLA through 
encoding viral peptides so that they can be destroyed by T-cells (16), but in RA, it was 
suggested that this function is interrupted due to the structural differences between MHC 
class II and T-cells receptors (known as the shared epitope hypothesis) (17;18).  
There are several other risk alleles that alter the immune regulation functionality such as  
nuclear factor-dependent signalling (kB, TRAF1-C5 and c-REL) (15). Another genome risk 
for RA susceptibility is the gene-gene interactions between HLA-DRB1 and Protein tyrosine 
phosphatase type 22 (PTPN22), which could lead to more severe forms of RA (19). 





b) Gene-environment interaction  
Behavioural factors have also been related to the prevalence of RA. For example, bronchial 
stressors, such as smoking (20) and silica (21), have been shown to increase the risk for 
developing RA. Interactions between such behavioural factors and genetic factors have been 
reported. Even though the mechanism is not fully understood, an interaction has been found 
between smoking and HLA-DR4 alleles, which may trigger immune reactions against 
citrullinated proteins (22). The immune reaction against citrullinated proteins is known to 
precede the development of RA, and results in anti-citrullinated protein antibodies (ACPA) 
(23). Citrullinated protein is the post-translational modification of arginine proteins into 
citrulline via an enzyme called peptidyl-arginine deiminase (PAD) (24). The PAD2 enzyme 
responsible for converting arginine into citrulline has been found to be increased in the 
alveolar tissues among non-RA smokers (25). More importantly, in patients with RA, it was 
found that history of smoking and presence of double copies of HLA-DR shared epitope 
genes increased RA risk 21-fold against non-smokers with no shared epitope genes (22). 
Similarly, it was found that exposure to silica among older men group (50-70 years old) 
increased the risk of developing RA more than 2-fold against non-exposed men of the same 
age group (21). All these findings suggest that inhaled environmental factors may promote 
alterations and citrullination in the alveolar tissue proteins, and, in interaction with genetic 
factors, may increase the risk for RA. 
 
c) Hormonal factors 
The greater prevalence of RA in women compared to men (women to men ratio: 2 - 3:1) 
suggest potential hormonal interference in the onset of RA (10). For example, it is known 
that estrogen has a stimulatory effect on the immune system (26). Further evidence for a role 
of hormones comes from epidemiological studies which have reported remission or at least 
amelioration of symptoms during pregnancy. It has been suggested that antibodies are 
developed during pregnancy to protect against HLA which helps to reduce the severity of 
the disease (27). Additionally, with contradictive findings, hormonal oral contraception pills 
may reduce the severity of the disease (28). Together, this provides some evidence for the 
role of hormones in RA, however, the exact interaction between hormones and the aetiology 





d) Infectious agents 
As with other auto-immune diseases, there are several infectious agents that have been 
linked with development of RA (such as Epstein-Barr virus, cytomegalovirus, proteus 
species, and Escherichia coli) (15). Periodontal disease, which is an inflammation of the soft 
and hard structures of the jaw caused by bacterial infection, has been associated with RA 
(29). Thus, it was postulated that exposure to viruses or bacteria may cause formation of 
immune complexes that may trigger ACPA. The data in the literature support the hypothesis 
of a link between infectious agents and development of RA, however, as this area of research 
is only just emerging, more evidence for this hypothesis and the mechanisms through which 
these infectious agents could lead to the development of RA is required.  
 
Pathogenesis 
Even though the cause of the disease is not known, information is available about the 
physiological processes occurring just before the diagnosis of RA and during the disease.    
During the periarticular phase of RA, autoantibodies such as anti-citrullinated protein 
antibodies (APCA) have been shown to start to develop in large quantities at the synovium, 
and potentially also in regional lymph nodes and bone marrow (15;30). As the onset of the 
disease approaches, the level of these autoantibodies are increased and await to be triggered 
via certain mechanisms (15). The mechanism can be microbial (via nonspecific infection) 
or biomechanical damage (via trauma to the structure of the joint) to the joint capsule. Both 
of these mechanisms trigger an inflammatory cascade (15). Because of the damage to the 
joint capsule, the vasculature becomes more permeable, which allows immunoglobulin 
complexes (IgG) to enter the interstitial fluid of the synovial membrane. Due to the humoral 
adaptive response to antibodies, these immunoglobulin complexes subsequently bind to 
sentinel cells such as dendritic cells, macrophages and mast cells via Fc receptors (a protein 
located on the surface of immune cells) (31). The latter contributes to inflammation of the 
synovium and migration of activated CD4+ T-cells (known as T-helper cells) into the 
synovial membrane (31). Production of pro-inflammatory cytokines such as interleukin (IL)-
1, IL-6, IL-17 and tumour necrosis factor-α (TNF-α) are stimulated by T- cells (32). The 
immune reaction at the synovial membrane starts when the synovial macrophages and 
dendritic cells function as antigen presenting cells (APCs) by forming complexes with MHC 




chemoattractant protein-1 and macrophage inflammatory protein-α are mediators of the 
recruitment of more inflammatory cells (33). This leads to inflammatory exudate that 
contributes to the effusion of the synovium causing what is known as synovitis (34). This is 
followed by an increase in the interaction between leukocytes and the endothelium which is 
facilitated by complement factors such as C3a and C5, which will cause formation of 
adhesion molecules along the endothelial lining (35). Presence of pro-inflammatory 
cytokines also increase the expression of adhesion molecules (36). These series of cellular 
activities result in hyperplasia of the synovial lining and oedema which is clinically 
manifested by pain and swelling of the joint (32). The hyperplasia of the synovium continues 
as the disease progress, leading to a formation of a thick invasive layer termed Pannus (32). 
Angiogenesis is one of the intra-articular manifestations of the disease, which allow further 
infiltration of macrophages, T cells and B cells into the synovium (37). The bone and 
cartilage erosion is caused by macrophages via release of TNF-α, IL-1, and IL-6 which 
promote osteoclast differentiation and activation of the articular cartilage (15).  
 
Diagnosis of Rheumatoid Arthritis 
RA can be difficult to diagnose due to some similarities in disease characteristics with other 
types of diseases that cause inflammation and joint stiffness, such as osteoarthritis and 
fibromyalgia. Diagnosis can be complicated as RA can present with various symptoms. 
According to current guidelines, a referral to a rheumatology specialist should be made when 
a patient present with three symptoms of RA. These symptoms are early morning stiffness 
(should last more than 30 minutes), joint swelling (three joints and more), and compression 
tenderness on squeeze test over the metacarpophalangeal (MCP) or metatarsophalangeal 
(MTP) (38;39). Early referral is recommended by multiple international guidelines (40;41). 
Severe joint damage and further complications of RA can be avoided if RA is detected early. 
This will allow early commencement of pharmacological interventions (e.g. disease 
modifying anti-rheumatic drugs) which improves disease outcomes and reduces the risk for 
associated disabilities (39;42). The American College of Rheumatology (ACR) has 
developed criteria for the diagnosis of RA in 1987 (see Table 1). A patient is diagnosed with 
RA if at least four of these criteria are fulfilled and present for at least six weeks (43). The 
following paragraphs discuss the types of investigations implemented in clinical settings to 





Medical history  
A medical history is taken in which the patient is asked to describe the symptoms, the start 
of these symptoms, and changes in these symptoms over time (44). More information about 
other medical problems such as other comorbidities of the patient may help to make the right 
diagnosis and impact of the disease on patient’s life (44).        
 
Physical examination 
Since synovitis (inflammation of the synovial joints) is a common articular symptom of RA, 
examining tenderness and stiffness of the joints and tendons is important in the process of 
diagnosis. Palpation of each joint to detect soft tissue thickening, swelling, and tenderness 
is carried out to investigate the number of joints affected (39). Redness and observation of 
loss of normal groove between the MCP’s can be a sign of inflammation (39). However, this 
may not always be the case, as some RA patient may have minimal joint swelling, making 
it difficult to detect during physical examination. Thus, the use of other imaging modalities 
may be useful in these cases (39). Imaging using X-rays has a limited role in the early stages 
of RA. However, other types of imaging such as ultrasound with doppler and magnetic 
resonance imaging are useful to assess disease activity, detection of synovitis, and 
visualization of erosions (40;41;45). 
 
Laboratory investigation 
Systemic inflammation can be assessed with C-reactive protein (CRP), erythrocyte 
sedimentation rate (ESR) and fibrinogen. However, CRP and ESR have low specificity for 
RA, as some early RA patients may have normal levels due to involvement of only few 
joints (39;41). CRP and ESR are useful in predicting the radiographic progression, 
monitoring disease activity, as well as the response to treatment (41).  
Another serological factor that can help in the diagnosis of RA is the rheumatoid factor (RF) 
which has a sensitivity of 65 – 73% and a specificity of 82 – 88 % (46). The majority of 
patients with RA have positive RF (autoantibodies to the Fc receptors of IgG), however, it 




erythematosus, hepatitis, and tuberculosis) (41). Therefore, confirming the diagnosis of RA 
cannot be based only on positive RF, but with confirmation of other symptoms of RA, and 
especially with another serological factor such as ACPA (41;45). 
ACPA or another term used for it is anti-cyclic citrullinated peptide antagonist (anti-CCP) 
is more useful in the diagnosis of early RA due to its sensitivity of 62 – 72% and specificity 
of 94 – 97%, which is more than RF (41). ACPA may appear even before the RF or before 
the development of clinical disease (39) which makes it more useful in the diagnosis of early 
RA (41).      
 
Assessment of disease activity  
Disease activity should be monitored regularly once the diagnosis of RA is confirmed. This 
not only helps with quantifying the disease activity, but also evaluating treatment 
effectiveness and disease progression (40). Several disease activity measures have been 
developed with Disease Activity Score 28 (DAS28) being the most commonly used (40). 
DAS28 is a composite measure which takes into account the patient’s perceptions of their 
overall health in the previous week as well as markers of inflammation and swelling. DAS28 
is composed of the 28 tender joints count and 28 swollen joint count (hand, wrist, elbow, 
hip and knee) (47). The final DAS28 score takes into account either the CRP or ESR levels 
and can be calculated online or via downloadable calculators. DAS28 can be calculated 
using four variables (swollen joints, tender joints, CRP or ESR level, and global assessment 
of disease activity or visual analogue scale) or three variables (same variables with the 
exclusion of global assessment of disease activity) with a slight modification when CRP is 
used instead of ESR (see Figure 1). A DAS28 score of ≤ 3.2 is interpreted as low disease 
activity, 3.2 to ≤ 5.1 is interpreted as moderate disease activity, and more than 5.1 is 
interpreted as high disease activity (47). Remission of the disease is indicated by a score of 








Imaging and radiographic changes 
Radiographic changes may be observed after three months’ duration from the onset of 
inflammation (48), and mostly in the hands and feet (49). Despite the limited use of early 
X-rays, disease progression can be monitored via the use of serial X-rays over years, which 
may help in monitoring disease activity and revising or changing treatment strategy (41).  
 
Table 1. The 1987 revised criteria for the classification of RA. Information copied from 
Arnett et al (43)  
Criterion Description 
1. Morning Stiffness Morning stiffness in and around the joints, 
lasting at least one hour before maximal 
improvement. 
2. Arthritis of 3 or more joint areas At least three joint areas (out of 14 
possible; right or left PIP, MCP, wrist, 
elbow, ankle, MTP joints) simultaneously 
have had soft tissue swelling or fluid (not 
bony overgrowth) as observed by a 
physician 
Figure 1. Different formulas for calculation of DAS28. T28; tender joints, SW; swollen joint, 
GH;  general health measured via visual analog scale, (4); including four variables, (3); 




3. Arthritis of hand joints At least one area swollen (as defined in 
criterion two) in a wrist, MCP, or PIP 
joint 
4. Symmetric arthritis Simultaneous involvement (as in criterion 
two) of the same joint areas on both sides 
of the body (bilateral involvement of PIP, 
MCP, or MTP joints without absolute 
symmetry is acceptable. 
5. Rheumatoid nodules Subcutaneous nodules over bony 
prominences or extensor surfaces, or in 
juxta-articular regions as observed by a 
physician. 
6. Serum rheumatoid factor Demonstration of abnormal amounts of 
serum rheumatoid factor by any method 
for which the result has been positive in 
<5% of normal control subjects. 
7. Radiographic changes Radiographic changes typical of 
rheumatoid arthritis on posteroanterior 
hand and wrist radiographs, which must 
include erosions or unequivocal body 
decalcification localized in, or most 
marked adjacent to, the involved joints 
(osteoarthritis changes alone do not 
qualify). 
PIP, proximal interphalangeal; MCP, metacarpophalangeal; MTP, metatarsophalangeal.   
 
Clinical Features of Rheumatoid Arthritis 
When the disease is not treated effectively or discovered in later stages, RA can cause 




space, erosion and deformity. This is manifested clinically by swelling, pain and morning 
stiffness of the affected joints which can eventually lead to limitation of joint motion (50). 
Typically, the most affected joints in the early stages of RA are the hands and feet joints 
including the metacarpophalangeal (MCP), proximal interphalangeal (PIP) and wrist joints 
(50). Other joints, such as distal interphalangeal, sacroiliac joints and lumbar spine can also 
be affected but with a lower rate of involvement and more commonly during advanced stages 
of RA. As the disease progresses without appropriate treatment, severe deformities can occur 
such as “swan neck deformity” as a result of major damage and dislocation of finger joints 
and tendons (50).       
Extra-articular manifestations occur in about 40% of patients during the course of the disease 
(51) and they are more frequent among patients with high disease activity and longer disease 
duration (52). There are also extra-articular manifestations of the disease which are more 
common in men (52). Fever, asthenia, weight loss, rheumatoid cachexia (loss of muscle 
mass and gaining more fat mass especially trunk adiposity), and anorexia are examples of 
constitutional symptoms of RA. Other extra-articular manifestation can involve multiple 
systems including cardiovascular, pulmonary, neurologic, skin, hematologic, renal, and 
gastrointestinal (52). For the aims of this thesis, the focus will be on cardiovascular diseases 
(CVD) as a common co-morbidity of RA.  
In addition to the articular and extra-articular manifestations of the disease, patients with 
RA also may experience compromised wellbeing because of the fluctuation of the disease 
(53;54). Anxiety, depression (55), fatigue, and quality of life can be affected by RA (5).  
Although there is no consensus about the definition of depression in RA, depression 
can be described as a serious mood disorder with a mixture of negative feelings including 
constant feeling of sadness, loss of interest, and lack of sleep (56). Anxiety is also common 
in RA and more likely to develop in depressed RA patients (57). Inability or difficulty to 
perform valued activities can subsequently lead to depression (58). In the literature, 
depression has been found to be prevalent in 13-20% in patients with RA (59;60), and is 
associated with many poor outcomes in RA. For example, depression has been linked with 
increased risk of mortality in RA (61), and has been found to be positively associated with 
disease activity (62), and pain (60). Depression has also been associated with many 
physiological changes including higher sympathetic activity, elevated catecholamine, 




which subsequently can lead to CVD (63;64). Despite all these associations between 
depression and poor outcomes in RA, depression remains unrecognized and undertreated in 
this population (60). This can be due to multiple reasons including the tendency to focus on 
the physical symptoms of the disease, and the misconception that depression is secondary to 
pain and disability which then incorrectly implies that no treatment is needed for depression 
(60). The assessment of depression can be difficult due to the overlap with other symptoms 
such as fatigue and insomnia (65). However, the use of questionnaires such as the hospital 
anxiety and depression scale (HADS) (66) can aid the diagnosis of depression in patients 
with RA (60) and also monitor the psychological wellbeing of RA patients.  
Fatigue can be described as a continuous feeling of exhaustion, reduced ability to 
carry out physical and mental tasks (67), however, there is no consensus about its definition 
in RA. The perception of chronic fatigue has been described by Piper as “unpleasant, 
unusual, abnormal or excessive whole body tiredness, disproportionate to or unrelated to 
activity or exertion and present for more than one month” (cited from (67)). Fatigue is often 
mentioned by patients with RA to be the most debilitating symptom, which has a substantial 
impact on wellbeing. It is therefore not surprising that is has been considered to be an 
important patient-focused outcome measure which should be included in clinical trials (68). 
The prevalence of fatigue has been reported to range between 42 – 80% in patients with RA 
(67). High levels of fatigue have been found to be associated with depression, pain, lack of 
sleep (67, 68), and multivariate analyses revealed pain to be an independent predictor of 
fatigue (69). Quality of life in patients with RA has also been found to be affected by fatigue 
(70). Considering the impact and the association between fatigue and other mentioned 
outcomes in RA, the severity of fatigue should be assessed in clinical practice as there is a 
lack of attention toward assessment or structural discussion about fatigue between health 
professionals and RA patients (67). Given its subjective nature, it is difficult to assess 
fatigue. A systematic review reported multidimensional assessment of fatigue (MAF) (71) 
as one of the six reasonably validated assessments of fatigue in RA (72).    
Quality of life can be described as the perception of the patient about his/her ability 
and limitation to perform activities of daily living and the emotional impact of these 
limitations on health status (73). It has been found that RA has a substantial impact on health 
related quality of life (74). For example, limitation in health related activity, which is closely 
related to quality of life, were twice as common in RA patients compared to a non-RA 




reduced physical function are associated with poorer quality of life (76). There are many 
questionnaires to assess the quality of life. The European quality of life questionnaire 
(EuroQol) (77) has been found to be reliable, simple to use, and was shown to be more 
responsiveness to clinical changes than the 36 short form survey (SF36) (78).     
In summary, it is necessary to assess these aspects of wellbeing to monitor and improve the 
overall wellbeing in patients with RA. There are other types of assessments that can be used 
to assess measures of wellbeing such as subjective vitality scale (79), which is a measure of 
positive wellbeing and assesses the perception of the patients to have energy and being able 
to perform tasks.    
 
Pharmacological approaches in Rheumatoid Arthritis 
To date, there is no cure for RA. However, a variety of medication regimes are used to 
reduce inflammation, alleviate pain, reduce or slow down joint damage and minimize 
deformity. There are many types of medication that can be used in the management of RA, 
and patients are often treated with a mix of medication. The administration of the type of 
medication is based on the concurrent symptoms and severity of the disease. The types of 
medication commonly used in RA are briefly discussed below.  
 
Non-steroidal anti-inflammatory drugs (NSAIDs) 
Classical NSAIDs have been used as a first line of treatment that offer quick onset of 
symptom relief (80). The therapeutic effect of NSAIDs is limited to reducing the associated 
symptoms without altering or reversing the disease (80). NSAIDs (such as aspirin and 
ibuprofen) are prescribed as an adjunct to other types of medications rather than using it 
solely to treat symptoms of RA (80). The main action of classical non-selective NSAIDs is 
to inhibit both cyclo-oxygenase enzyme 1 and 2 (COX 1 and COX 2) to prevent synthesis 
of prostaglandin (81). Inhibition of COX 1 and COX 2 can induce adverse side effects such 
as gastrointestinal intolerance and bleeding, and platelet inhibition (82;83). To avoid or 
lessen these side effects, yet provide similar analgesic and anti-inflammatory effect, a 
selective NSAID class called COX 2 inhibitors has been developed (celecoxib, rofecoxib 




complications compared to COX 1 (80;81). NSAIDs are less commonly used in RA due to 
their increased risk of CVD (84;85). Thus, many international guidelines are suggesting that 
NSAIDs, specifically COX 2 inhibitors, should only be used after careful consideration of 
the risk of cardiovascular disease (40;41;45). 
 
Glucocorticoids  
Glucocorticoids are a type of steroidal medication that is similar to NSAIDs in relieving 
symptoms of RA but act faster (82). However, glucocorticoids (such as prednisolone) can 
have more severe adverse side effects including skin atrophy, hyperglycaemia, weight gain, 
osteoporosis, and hypertension (82). Thus, glucocorticoids are used in low doses and as a 
therapeutic adjunct to other types of medication during high disease activity (flare) (80). In 
addition to symptom relief, some studies report the ability of steroids to slow the 
radiographic changes of RA when combined with other types of medication (86;87). In 
general, in order to minimize the risks of toxicity, the use of glucocorticoids in RA should 
follow the recommendations supported by clinical practice (88), which states that oral 
glucocorticoids should not be administered for routine use, bone density must be monitored 
to avoid osteoporosis with prolonged use, and the combination of glucocorticoids with 
NSAIDs must be avoided (41).  
 
Disease-modifying anti-rheumatic drugs (DMARDs) 
DMARDs are known to have a better therapeutic effect than NSAIDs and glucocorticoids 
not only in relieving symptoms but also in alteration of disease progress (80). Compared 
with NSAIDs and glucocorticoids, DMARDs have a slower onset of action. DMARDs are 
usually taken as a long-term approach to slow the progression of the disease while the use 
of NSAIDs and glucocorticoids aid immediate relief of symptoms. There are many types of 
DMARDs such as Methotrexate, Sulphasalazine, hydroxychloroquine, and Cyclosporin. 
The exact mechanism of action of DMARDs is not fully known, but it has been reported in-
vitro that they modulate distinct facets of the immune system and inflammatory responses 
which are activated in RA, such as cytokine secretion, macrophage function, and inhibition 
of IL-2 production and T-cell cytokines (80). Originally, the initial management of RA 




DMARDs plus glucocorticoids favour earlier control of the disease progression and less 
impairment of the functional statues (89). However, not all patients benefit from DMARDs, 
therefore, some patients may discontinue the course of treatment due to lack of efficacy or 
development of side effects (80). 
 
Tumour necrosis factor- α (TNF- α) inhibitors 
TNF-α inhibitors are a type of biological drugs that have been developed to block specific 
components of the immune system, i.e. TNF-α, which contribute to the aetiology of RA. 
TNF-α over-production by T-cells can have a destructive effect on the cartilage. Thus, the 
therapeutic effect of TNF-α inhibitors is to reduce inflammation and slow disease 
progression. There are three Food and Drug administration (FDA) approved TNF-α 
inhibitors; infliximab, etanercept, and adalimumab (80). Although infliximab (a chimeric 
monoclonal anti-TNF-α antibody) and adalimumab (a human monoclonal anti-TNF-α 
antibody) are different in origin, their mechanism of action is similar, while etanercept (a 
recombinant soluble p75 TNF-receptor-Fc fusion protein) has a different way of inhibiting 
TNF-α (80). Despite the therapeutic effectiveness of these medications in relieving the 
symptoms and halting disease progression, there are some safety concerns that have been 
raised regarding the potential risks and side effects of TNF-α inhibitors such as tuberculosis, 
increase adiposity (especially trunk fat mass), and infection (80). The combination of these 
potential side effects and the cost of this treatment TNF-α inhibitors are mainly used for 
patients with severe RA symptoms who did not benefit from DMARDS agents (40;90). 
 
Non-Pharmacological approaches in Rheumatoid Arthritis 
Chronic diseases such as RA impact on many aspects of a person’s life that cannot be treated 
with medical treatment alone. Reduced physical activity, psychological problems, and 
reduced quality of life are reported to be major consequences of RA (91). Despite the 
effectiveness of pharmacological management of RA, some of the symptoms or 
consequences of RA can benefit from non-pharmacological treatment, such as patient 
education self-management and exercise/physical activity. Non-pharmacological 
interventions aim is to help the patient in coping with the disease, as well as reducing the 




education/self-management, exercise and physical activity programs (including aerobic, 
strengthening, and stretching exercise) were the most effective and recommended non-
pharmacological management in RA (92-94). For the aims of this thesis, the focus will be 
on exercise and physical activity as a strategy to reduce the risk of cardiovascular disease in 
RA, which will be discussed later in this chapter.  
 
Increased risk of cardiovascular disease in Rheumatoid Arthritis    
There is ample evidence that patients with RA are at increased risk of cardiovascular disease 
(CVD) mortality compared to the general population (95;96). Patients with RA may 
experience unrecognized silent ischemic heart disease (IHD) more frequently than non-RA 
control participants (97). This increased risk of unrecognized IHD can be due to patients 
with RA being less likely to report angina symptoms. Indeed, in a follow-up study 
investigating the reoccurrence of ischemic events or death between 40 RA patients and 40 
age- and sex matched patients with acute coronary syndrome, it was found that 82% of RA 
patients had chest pain on presentation compared to 100% of the control group (98). The 
risk of developing myocardial infarction (MI) in RA has shown to be double compared with 
healthy control participants (99). In a large Asian population, the risk of MI in RA was 
increased by 38% compared to the general population, with an even greater risk for younger 
RA patients (100). Furthermore, the development of heart failure (HF) has been found to 
contribute to the increased risk of mortality in RA (101). Similar to MI, the risk of HF is 
doubled in patients with RA compared to non-RA, which was found to be already increased 
soon after the onset of RA (102). Even though the CVD risk is increased in RA, the exact 
reason remains unknown. 
The risk of developing CVD in patients with RA is comparable to that of patients with DM 
and significantly elevated when compared to the healthy control participants (103). Despite 
the similarity in the increased risk of CVD in RA and DM, the risk in RA is less recognized 
compared to DM. As a result, CVD prevention strategies are included in clinical guidelines 
for treatment of patients with DM (104) but less consistently for RA (105), where CVD risk 
management for RA is currently only a recommendation (106).    
There are several traditional CVD risk factors, such as hypertension (107), dyslipidaemia 




that are prevalent in RA which may contribute to the increased risk of CVD mortality in RA 
(100). In addition, inflammation is now established as a risk factor for CVD, and of course, 
one of the characteristics of RA is high-grade systemic inflammation. It is therefore not 
surprising that inflammation, through its influence on the vasculature, has been suggested to 
contribute towards the increase CVD in RA (110). Autonomic dysfunction is another 
emerging factor that has been investigated recently and is suggested as an additional factor 
which contributes to CVD death risk in RA (111). The following paragraphs discuss the 
prevalence of traditional CVD risk factors and the link between inflammation and CVD in 
RA. Since autonomic dysfunction in RA is the main topic of the research reported in this 
thesis, a specific focus will be on the physiology of the autonomic nervous system and its 
control over the heart will follow. 
 
Traditional cardiovascular disease risk factors  
Hypertension       
It is known that hypertension is prevalent in people with RA, with the reported rates ranging 
from 52% to 73% (112). Despite the findings from studies showing no difference in 
prevalence between hypertension in RA and the general population (113), an increase in 
arterial stiffness has been found in a study which examined the arterial pliability in RA 
patients compared with healthy participants (114). This suggests that the arterial system of 
patients with RA is less able to effectively respond to changes in blood volume, which is 
termed as arterial stiffness (115;116). Furthermore, increased systemic inflammation in RA 
has been suggested as a mechanism that contributes to increased prevalence of hypertension 
in RA, as increased levels of CRP can cause a reduction in nitric oxide in the endothelial 
cells causing vasoconstriction (112). Although hypertension is considered to be a risk factor 
for CVD events in the healthy general population, patients with RA tend to suffer from 
multiple factors that influence control of blood pressure, including physical inactivity, 
obesity, and most importantly, the anti-inflammatory medications which may increase the 
chances of developing hypertension (117). It was found that many medications used in the 
management of RA may cause hypertension or alter its control such as NSAIDs, COX 2 
inhibitors, glucocorticoids, and some DMARDs (leflunomide, cyclosporine), even though 
this was not confirmed in all studies (112). Less is known about the influence of biological 




(Etanercept) have been found to reduce arterial stiffness (118;119). Furthermore, there are 
also reports that found that a specific DMARDs (Hydroxychloroquine) has a positive effect 
on reduction of lipid profile (120;121), which may reduce the risk of hypertension (122), 
however, this yet to be proven in patients with RA. Other non-pharmacological treatment 
such as aerobic exercise has shown to improve blood pressure in patient with RA (123).  
 
Dyslipidaemia  
Dyslipidaemia is defined as high levels of low density lipoprotein (LDL) and triglycerides, 
and a low level of high-density lipoprotein (HDL) (115). Dyslipidaemia is known to be a 
strong risk factor for the development of CVD in RA as well as the general population 
(108;124). High levels of cholesterol, in particular LDL, can cause the formation of fatty 
streaks in the coronary arteries. This can develop into an atherosclerotic plaque, which limits 
blood flow to the heart and, when the plaque is ruptured, can cause blockage of an artery 
leading to MI (125). The prevalence of dyslipidaemia in RA is more than 50% (126), which 
appears to be similar to the prevalence in healthy general population (113;127). Recent meta-
analyses revealed that alteration in lipid profile, particularly low HDL (poor lipid profile), 
are common in RA (128). In addition, an interplay between inflammation and lipid 
metabolism is suggested to have a role in increasing dyslipidaemia (108). However, the 
interplay between the effects of medications used in RA on inflammation is complicated, 
and further studies are required in patients with RA, as certain RA anti-inflammatory 
medications may also have a favourable effect on their lipid profile (117). Some studies have 
shown that medications used for RA management including glucocorticoids, DMARDs, and 
TNF-α inhibitors may affect serum lipid profile (128). The evidence related to the use of 
glucocorticoids provides an example of the complexity of the influence of medication on the 
lipid profile. Even though the use of glucocorticoids was not associated with dyslipidaemia 
(129), when glucocorticoids were mixed with DMARDs (methotrexate, and sulfasalazine) a 
favourable effect over the total cholesterol/HDL ratio was produced (128;130). The use of 
TNF-α inhibitors has shown to increase total cholesterol as well as HDL cholesterol, 
however, there was no improvement in total cholesterol/HDL ratio (131). The latter study 
also showed that decreased CRP levels after 30 weeks was inversely associated with increase 
in HDL cholesterol. Based on these studies, it could perhaps be suggested that the more 




with more effect that is evident during early stages of the treatment (128). However, more 
research is needed confirm this hypothesis.  
 
Obesity   
Body mass index (BMI) was developed as a clinical measure for estimation of body fat 
percentage (132). According to world health organization (WHO), category of “obesity” is 
given to individuals with BMI ≥ 30 kg/m2. However, an adjustment of these cut off points 
to 28 kg/m2 has been suggested for patients with RA (133). Using different measurements 
of body fats percentage such as bioelectrical impedance (133), and abdominal CT scans 
(134), patients with RA have shown to have more body fat for a given BMI than healthy 
participants with the same BMI. This may suggest that BMI underestimates the body fat 
composition and may lead to underestimation of BMI as a CVD risk in RA. In several 
studies, the difference in BMI between RA patients and healthy general population varied 
(127;135;136), with ranges between 18-54 % (137-140). However, the biggest problem is 
the assessment tool used (i.e. BMI vs body component) such as BMI which underestimate 
fat in patients with RA. Therefore, it is difficult to conclude the actual prevalence of obesity 
in RA due to the variation between studies in the population considered, disease duration 
and the type of medications used which may have an influence on weight and body 
composition (137). In general, most of the studies using BMI are indicating that obesity in 
RA is similar or slightly higher compared to the healthy general population. 
Obesity was found to be a risk factor for the development of RA (20), as it can contribute to 
low-grade inflammation via accumulated visceral adipose tissue that can release pro-
inflammatory cytokines such as IL-6 and adipocytokine (141;142). Eventually, this can lead 
to increased production CRP (143), which in turn can contribute to development of RA 
(144). Increased visceral abdominal fats also is known to be strongly associated with cardio-
metabolic risk (145), therefore, monitoring the weight and body fat components is 
recommended in patients with RA, as it constitutes high risk for developing CVD. In 
addition, a common condition with increased abdominal fats in RA is to have increased fat 
mass and reduced muscle mass known as rheumatoid cachexia which occurs due to the 




The effect of obesity on the success of anti-inflammatory medication in the management of 
RA has been investigated. Most of the studies found that obese RA patients have poorer 
response to TNF-α inhibitors (e.g. infliximab) and are less likely to achieve remission 
compared to non-obese RA patients (147;148). Similar findings were noticed in patients 
with early RA, where high BMI was associated with failure to reduce disease activity with 
treatment (149;150).   
 
Novel cardiovascular disease risk factors 
Inflammation     
Inflammation is an important factor that contributes to the CVD risk in RA. It is therefore 
not surprising that a reduction of inflammation lowers CVD risk in RA (151-154), and this 
has been mentioned as a main strategy for treating CVD risk in RA (106). The exact 
mechanism of how inflammation contributes to increased CVD risk is not yet fully known. 
However, it is suggested that inflammation plays a pivotal role in the pathogenesis of 
atherosclerosis in general population (155-157), which is mediated via pro-inflammatory 
molecules including cytokines, fibrinogen and CRP (158-160). In patients with RA, the level 
of these pro-inflammatory cytokines are increased and may induce not only structural 
vessels abnormalities (known as endothelial dysfunction) but also contribute to changes in 
lipid levels and insulin resistance (161;162).   
 
Atherosclerosis 
Atherosclerosis is a substantial cause of CVD which develops in stages, starting from plaque 
formation via fatty streaks to plaque rupture and thrombosis. Inflammation contributes to all 
stages of development of atherosclerosis (163). It is known that endothelial dysfunction can 
occur at the early stages of atherosclerosis (164). Endothelial dysfunction can lead to 
increased vascular wall permeability, which allows easy and fast transmigration of 
monocytes, lipids and T-cells into the vascular wall, which can lead to formation of foam 
cells (165). Following development of foam cells, pro-inflammatory cytokines such as TNF-
α, IL-6, and CRP start to accumulate. This inflammatory pathway in the development of 




inflammation in RA (159). Indeed, an association has been shown in patients with RA 
between atherosclerosis and IL-6, which was independent of any CVD risk factors (166). 
As an approach to control or prevent future CVD, two large studies have identified IL-6 
receptors, which could be blocked in order to prevent accumulation of IL-6 (167;168). 
Furthermore, observational studies showed a potential decrease in the risk of CVD in patient 
with RA using DMARDs (169;170), TNF- α inhibitors (171), and recently, cholesterol 
lowering drugs (172).   
In summary, there are many CVD risk factors which are prevalent in RA. Inflammation has 
been linked to increased or accelerated atherosclerosis in RA. It is also important to note 
that most of the traditional CVD risk factors are linked with the increase in pro-inflammatory 
molecules in RA. Thus, management of traditional CVD risk factors as well as inflammation 
and ongoing monitoring and management of the CVD risk factors are necessary to reduce 
the excess risk of CVD in RA (106). 
 
Non-pharmacological strategy to reduce cardiovascular disease risk in Rheumatoid 
Arthritis  
Exercise and physical activity 
Patients with RA suffer from severe joint pain, reduced muscle strength and mass (a 
condition known as rheumatoid cachexia) which may contribute to reduced physical activity 
(173), and increase the risk for CVD (173). Indeed, physical activity and cardiorespiratory 
fitness have been inversely associated with CVD risk (174;175). Thus, encouragement of 
exercise and physical activity are recommended for the management of RA.  
The benefits of exercise in general population are widely acknowledged. Exercise and 
physical activity mainly improve cardiorespiratory fitness, reduce the risk of coronary artery 
diseases, reduce CVD risk factors, and improve psychological wellbeing (173). According 
to recommendations from ACSM for people aged from 50 – 64 with chronic condition (such 
as RA), accumulation of minimum of 30 minutes of moderate intensity exercise on most 
days of the week is required to gain its benefits with an additional stress on strengthening, 
balance, and flexibility exercise for this age group with chronic conditions (176). 
Furthermore, principles of exercise prescription in RA were suggested in a systematic 




should be to maintain optimal musculoskeletal function in order to facilitate exercise for 
cardiorespiratory fitness, and exercise must be tailored according to baseline fitness and 
physical ability (177).  
Beneficial effects of exercise in patients with RA have been revealed in several randomized 
controlled trials. For example, aerobic fitness, and psychological wellbeing were improved 
after 12 weeks’ dance-based exercise program (178). Furthermore, high intensity exercise 
was found to improve functional ability more than routine physical therapy care for patients 
with RA (179). Restoration of lean muscle mass and improvement in muscle strength were 
reported in patients with RA after 6 months of high intensity progressive resistance training 
exercise (180). These studies reported positive effects of exercise without worsening of joint 
damage or pain.  
Despite these positive effects of exercise, the majority of patients with RA are not physically 
active due to the perception that it may increase the damage to the joints and induce more 
pain or due to the lack of education from health professionals (181;182). Furthermore, pain 
and fatigue were found to be important perceived barriers for physical activity and exercise 
in patients with RA (183). In a systematic review, it was found that patients with RA have 
lower level of physical activity when compared with healthy control (184). Therefore, 
increase awareness of the benefits of physical activity and appropriate support for patients 
with RA to become more physically active needs to be considered as an essential part in the 
management of RA. Indeed, according to the European League against Rheumatism 
(EULAR) guideline for the management of CVD risk, exercise training was suggested as a 
way to manage CVD risk in RA, but it has been also acknowledged that more research was 
needed in this area (106).  
In summary, RA is a chronic inflammatory progressive disease that affects joints and causes 









Anatomy and physiology of the heart and autonomic nervous system 
The cardiovascular system, which includes the heart, lungs and the vasculature, is important 
in ensuring that organs are supplied with blood. The cardiovascular system is influenced by 
the autonomic nervous system (ANS). The following section provides an overview of the 
heart, the ANS and the influence of the ANS on the heart.  
 
Anatomy of the heart 
The heart is a muscular organ with the size of a closed fist (185). Its main function is to 
circulate the oxygenated blood from the lungs, via the arteries throughout the body systems. 
The heart is composed of four chambers; right atrium, right ventricle, left atrium and left 
ventricle (185). Between the chambers are valves, which control the flow of the blood in 
one direction. The right atrium receives the deoxygenated blood from the organs via the 
superior and inferior vena cava. By contracting the atrium, the blood moves through the 
tricuspid valve to reach the right ventricle. Once the right ventricle reaches a certain pressure 
within the chamber, the tricuspid valve closes. The right ventricle then contracts, which 
allows the opening of the pulmonic valve and the flow of blood through the pulmonary artery 
to the lungs for re-oxygenation (186). Oxygenated blood travels back via the pulmonary vein 
to the left atrium. Contraction of the left atrium moves the oxygenated blood through the 
mitral valve to the left ventricle. By contracting the left ventricle, the oxygenated blood 
flows through the aortic valve into the aortic artery where it is distributed to all other organs 
(186). This contraction is orchestrated via the conducting system of the heart. The 
conducting system is composed of sinoatrial node (SA) node, internodal pathway, 
atrioventricular (AV) node, atrioventricular bundle or bundle of His, and bundle branches 
(Purkinji fibres) (186).   
The heart's main function is to pump blood to maintain circulation to all organs. Its pumping 
action relies on the performance of the cardiac muscles. In order to do this efficiently, cardiac 
cells (myocytes) have to contract in synergy with each other. Cardiac cells are composed of 
contracting muscle cells and conducting cells (187). The latter is responsible for the heart’s 
unique ability to generate its own electrical impulses (automaticity) required for the muscle 
cells to contract (187). The conducting cells deliver the impulse to the contracting cells via 
intercalated discs. The SA node lies at the junction between superior cava vein and right 




the floor of the right atrium (188). This distribution between the SA and AV node enables 
systematic cardiac pumping activity from base to apex (189).  
A heartbeat is initiated by conducting cells via electrical impulses. The electrical impulse is 
generated at the SA node, which is known as the pacemaker. The impulse is subsequently 
distributed through the arterial wall to start the atrial contraction. Then, the impulse travels 
via the internodal pathway to the AV node, where it is delayed (~ 0.12 seconds) to allow 
time for the atria to empty blood into the ventricles (186). Once the atrium is empty and the 
ventricles are filled with blood, the impulse travels from the AV node to the bundle of His 
through the interventricular septum until it reaches the walls of the ventricles via Purkinji 
fibres leading to ventricle contraction (186). The blood transfer from inside the heart to the 
other body cells is done via the vascular system. The following paragraph discusses the 
mechanism of heart contraction and blood circulation within the cardiovascular system.  
 
Activation of cardiac muscles   
There are many similarities between cardiac muscles and skeletal muscles, yet the 
characteristics of cardiac muscles are unique and different from skeletal muscles. Both have 
the same type of striated muscle cells, with myofibrils containing actin and myosin 
filaments, and both contract according to the sliding filament theory (190). An important 
difference is the reliance on nervous innervation. The activation and contraction of skeletal 
muscle is dependent on stimulation from the central nervous system, whereas, cardiac 
muscles have the ability to generate its own activation and contraction without stimulation 
from the central nervous system. Cardiac muscles and skeletal muscles have similar sodium 
channels, however, cardiac muscles have slow calcium channels which remain open causing 
a plateau in action potential of cardiac muscles. The decrease in potassium outflux during 
this plateau allows a prolonged refractory period in cardiac muscle fibers (0.15-0.30 
seconds) compared to skeletal muscle (191). This refractory period in cardiac muscles does 
not allow re-initiation of the action potential to a cardiac cell, which has not recovered from 
the previous stimulation (192).  
All organs, including the heart muscle (myocardium) require oxygenated blood to survive. 
Therefore, to maintain constant circulation of blood, the heart pumps continuously. This is 




and distribute electrical impulses for the cardiac muscle to contract without the need for 
neural input. However, these cardiac cells can still be regulated extrinsically by the 
autonomic nervous system to maintain the haemostasis of the body to meet the demands of 
all organs (i.e. more oxygen during exercise) (193). The following paragraphs discuss the 
anatomy of autonomic nervous system and its branches to the heart.        
 
Autonomic nervous system  
ANS is part of the central nervous system and consists of the sympathetic nervous system 
and the parasympathetic nervous system. The activity of many organs are regulated by both 
branches of the ANS, including the cardiovascular system, lungs, gastrointestinal system, 
and adrenal glands. The sympathetic and parasympathetic nervous system consist of afferent 
and efferent interneuronal fibres, with the afferent coming from central nervous system, and 
the efferent from the effector organ (e.g., heart) (189). The sympathetic and parasympathetic 
nervous systems respond to metabolic and mechanical changes from the heart and other 
visceral organs via chemoreceptors and baroreceptors, respectively. For example, 
information about pressure in the arterial system are received by baroreceptors, whereas, 
information about the level of oxygen and carbon dioxide in the blood are received by 
chemoreceptors (194). The anatomy of the ANS and its connection to the heart will be 
described in the next paragraphs.  
 
Cardiac sympathetic innervation 
The sympathetic innervation to the heart via neurons originated at the reticular formation of 
the brain stem and the hypothalamus pituitary axis (195). The sympathetic fibres that 
innervate the heart branch from the spinal cord between thoracic vertebrae (T1-T4) as 
preganglionic fibres, then they form synapses with longer postganglionic fibres to reach the 
heart (196). The axons of the sympathetic nerves are connected to the heart by three 
branches; superior, middle, and inferior cardiac nerves (196). The fibres of these nerves 
travel along the epicardial vascular structures of the heart to penetrate the myocardium 
reaching the endocardium where they become sympathetic nerve terminals (189). The 




apex of the heart, however, there is more sympathetic innervation at the atrium where the 
pacemaker SA node is (189).  
 
Cardiac parasympathetic innervation 
The parasympathetic system innervates the heart through the vagus nerve, which originates 
from the medulla oblongata (196). The axons of the vagus nerve are connected to the heart 
with three branches; superior, middle and inferior cardiac nerves (196). These branches 
merge with postganglionic sympathetic neurons to form the cardiac plexus of the nerves at 
the base of the heart (189). The parasympathetic neurons have a homogenous distribution of 
the heart compared to sympathetic neurons, being more concentrated on the SA node and 
the AV node than on the walls of the atrium or ventricles (189).     
 
Chemical neurotransmitters 
The signals of the sympathetic and parasympathetic nervous system are transferred from 
the neurons to the heart by adrenergic or cholinergic chemical neurotransmitters (193). 
Noradrenaline and adrenaline are released by postganglionic adrenergic fibres, which are 
mostly sympathetic, whereas acetylcholine is released by postganglionic cholinergic fibres 
which are mostly parasympathetic. These chemical neurotransmitters activate specific 
receptors within the heart. For example, Beta–1 receptors for the sympathetic stimulation 
and, muscarinic and cholinergic receptors for acetylcholine (193). 
 
Cardiovascular autonomic control 
In terms of regulation of heart activity, both arms of the ANS can control the intrinsic activity 
of the heart’s pacemaker (SA node) which modulates the heart rate and the force of the 
contraction (189). In a healthy state, both systems are functioning in synergy and respond to 
the physiological state of the body. The sympathetic is known to have an excitatory effect 
to increase the heart rate, “fight or flight”, whereas the parasympathetic have an inhibitory 
effect to decrease heart rate, “rest and digest”, and decrease the inotropic state of the heart. 
Further discussion on the physiology of ANS modulation of the heart rate will follow later 




Cardiac pacemaker activation 
The SA node is known as the pacemaker and the primary generator of electrical impulses 
that induce heartbeats (197;198). Although the SA node and the rest of the conducting cells 
are autorythmic and do not need a neural axon to receive impulses from the central nervous 
system, the contraction of the heart can still be regulated by the ANS. The ANS can control 
how fast or how slow the impulses from the SA node are generated, depending on the 
physiological requirement of the body. As such, it regulates the rhythm of the heartbeats. 
During exercise, heart rate tends to increase due to the domination of sympathetic nervous 
system and withdrawal of the parasympathetic nervous system resulting from the actions of 
central command in addition to muscle mechanoreflex inhibition of vagal tone (197;199). 
In this situation, sympathetic nervous system domination is due to the release of adrenaline 
in response to the increased metabolic demands as a result of increased muscle activity 
(200;201). Post exercise and during relaxation, heart rate tends to slow down due to the 
sympathetic withdrawal and parasympathetic reactivation (197;199). As the increased 
sympathetic activation subsides post exercise, heart rate decreases in a gradual manner to 
ensure that there is enough blood circulation to meet the metabolic demands after cessation 
of exercise (202).   
The action potential of the SA node is different from action potentials of the other cardiac 
contracting cells (203), as the SA node cells have fewer myofibrils and organelles (203). 
Another difference is that conducting cells have faster depolarization compared to 
contracting cells. The upstroke of depolarization in the SA node starts with the influx of Na+ 
through Na+ channels which account for the slow increase in membrane voltage from ~ -
65mv (which is the membrane voltage during resting) up to -40mv (204). Once the 
membrane reaches ~-40mv this allows influx of Ca++ ions through T-type calcium gated 
channels which subsequently increases the membrane voltage from -40mv to ~-30mv (204). 
Subsequently, this leads to the activation of the L-type Ca++ voltage gated channels, which 
allows Ca++ entry to the membrane through these channels (204). As such, the membrane 
voltage is further increased until it reaches full depolarization. As the membrane potential 
reaches 0 mv, repolarization starts by inactivation of Ca++ and the opening of K+ gated 
channels, which increase the outflux of K+ channels. Chemical neurotransmitters from the 
ANS have a significant effect on the action potential of the SA node. Adrenalin or bind with 
Beta-adrenoceptors to speed up the depolarization period in the SA node which allows entry 




depolarization rate and longer time to reach depolarization via the binding of ACh with 
muscarinic cholinergic receptors in the SA node, which limits fast entry of Na+ and Ca++ 
ions to the cell (203;205).   
 
Cardiac autonomic balance 
Balanced activity from both sympathetic and parasympathetic is necessary to maintain the 
homeostatic activity of the cardiovascular system. ANS dysfunction, defined by increased 
activity of sympathetic and reduced activity of parasympathetic, impairs the ability of the 
ANS to regulate the cardiovascular system (206), which may lead to CVD (189). Thus, a 
balanced activity of ANS could reduce the risk of developing CVD.  
 
Autonomic dysfunction as a cardiovascular disease risk factor 
Autonomic dysfunction has been suggested as a risk factor for CVD (207). Increased 
sympathetic activity over a long period of time makes it difficult to continue to meet the 
energy demands for the sympathetic system (208). Increased sympathetic activity can lead 
to significant arrhythmias, whereas, parasympathetic activity plays a protective role against 
CVD events (189;209). Major cardiac arrhythmia (e.g. ventricular fibrillation), HF, and MI 
have been associated with increased chemoreceptor sensitivity and reduced baroreceptor 
reflex sensitivity (189;210). Sympathetic activation can lead to high blood pressure (210) 
due to its effect on vasculature (211), and that is a mechanism through which it can lead to 
CVD (212). In contrast, the protective role of the parasympathetic nervous system for CVD 
has been demonstrated in animals, where stimulation of the vagal nerve caused a reduction 
in the secretion of TNF-α (213), which has been implicated in the development of CVD 
(214). Thus, both sympathetic and parasympathetic activation has been related to CVD risk 
factors and it is therefore not surprising that autonomic dysfunction is related to CVD risk.   
 
Autonomic dysfunction as a cardiovascular disease risk in Rheumatoid Arthritis 
Additional to the prevalence of traditional CVD risk factors in RA mentioned earlier in this 
chapter, a recent systematic review regarding autonomic dysfunction in RA revealed that 




also contributes to increased risk of CVD in RA (215). Considering the increased risk for 
CVD in RA, it is perhaps not surprising to find this increased prevalence of autonomic 
dysfunction. However, the exact mechanism of how autonomic dysfunction contributes to 
the increased CVD risk in RA is not fully known and still under investigation.      
 
The association between autonomic nervous system and immune system 
The ANS is part of the central nervous system, and strong associations have been reported 
between the central nervous system and the immune system (216;217). The central nervous 
system responds to increased levels of inflammation to attempt to maintain immune 
homeostasis (216). For example, during exposure to viral or bacterial infection, IL-1 is 
released by macrophages to fight the infection that will appear in the systemic circulation. 
Due to an inflammation-induced increase in permeability of the blood brain barrier, IL-1 
can also enter the brain, where it can act on the hypothalamus pituitary axis (217). More 
specifically, it can stimulate the hypothalamus to release a number of hormones including 
corticotropin-releasing factor (CRF), and noradrenaline (218). Release of CRF results in 
secretion of adrenocorticotropic hormone (ACTH), which in turn results in release of 
glucocorticoids which is known to have a function in the regulation of immune cells (218). 
This in turn leads to sympathetic system activation which results, for instance, in a rise in 
body temperature (217) and increase in heart rate (189). In addition, the activation of the 
sympathetic system results in release of sympathetic neurotransmitters including 
noradrenaline, adenosine triphosphate, neuropeptide Y, and nitric oxide (219). Since 
immune cells have adrenergic and cholinergic receptors (220), it is not surprising to find that 
most of these neurotransmitters can influence immune cells (219). For example, it was found 
that neuropeptide Y can increase the adhesion of leukocytes to the endothelial cells which 
is known to be a step in the initiation of inflammation (219;221). Furthermore, the influence 
of neurotransmitters on immune cells can be facilitated by regulating blood flow, 
distribution and production of lymphocytes (219). Therefore, during inflammation there is 
an increased in hypothalamus pituitary axis activity and sympathetic nervous system activity 
(219). However, if inflammation is chronic, there is still increased sympathetic activity and 
hypothalamus pituitary axis activity but with less ability or inadequacy of the 




chronic inflammation there is an increased demand from the sympathetic nervous system to 
be dominant.  
 
Autonomic nervous system assessment  
There are several methods to assess ANS non-invasively, and the majority of these 
assessments involve cardiovascular parameters e.g. heart rate and blood pressure. The most 
common forms of non-invasive ANS assessment include heart rate variability (HRV), heart 
rate recovery (HRR) and Ewing's test battery. Due to the complexity of the ANS, it is 
difficult to obtain full information about all aspects of the ANS with a single assessment. 
Some assessments reflect both arms of the ANS whereas others focus on one arm only. 
Ewing’s test battery has components that reflect the activation of sympathetic and 
parasympathetic nervous system, HRV has components that reflect parasympathetic activity 
and the balance between sympathetic and parasympathetic activity, whereas HRR post 
exercise testing reflects the reactivation of parasympathetic nervous system following 
exercise testing.  
 
Heart rate variability  
Analysis of HRV is one of the most common non-invasive validated assessments of ANS 
(222;223). It is based on the analyses of the oscillation in the intervals between consecutive 
heartbeats at rest (224). This is obtained from R-wave to R-wave intervals between 
consecutive heartbeats on an electrocardiogram (ECG). The variations in R-R intervals are 
due to the interaction between sympathetic and parasympathetic nervous system at rest 
(225). At rest, parasympathetic activity (vagal activity) is more influential for HRV (225). 
For example, respiratory sinus arrhythmia (shortening of R-R interval during inspiration and 
prolongation of R-R interval during expiration) which is known to be an index of vagal 
activity (226), can lead to variability in heart rate at rest (227). The influence of the 
parasympathetic activity is fast due to the high conduction velocity of the vagus nerve and 
the rapid high fidelity connections between afferent inputs and central cardiovascular control 
areas of the brain, which makes the parasympathetic neuron excitation more evident in the 
next cycle of heartbeat and has therefore more acute influence on heart rate (225). In 




noticeable after 2-3 seconds at resting state. This results in slower oscillation of heart rhythm 
(225;228). A phenomenon that explains why sympathetic effect is smaller during respiratory 
sinus arrhythmia is known as accentuated antagonism, where there is an interaction between 
the sympathetic nervous system effect and parasympathetic nervous system effect via the 
vagal tone (229). This interaction allows inhibition of the cardiac effects from the 
sympathetic nervous system due to presence of background stimulation from the vagal tone 
at rest. However, during stress (i.e. exercise) there is a withdrawal of the parasympathetic 
nervous system and reciprocal excitation of the sympathetic nervous system due to the 
reciprocal innervation of the sympathetic and parasympathetic nervous system.  
The required duration for the heart rate recording to be used for HRV calculation ranges 
from 24 hours to shorter periods (e.g. two to five minutes) (224). Assessment of HRV is 
based on either time domain or frequency domain analyses. 
 
Time domain heart rate variability  
Time domain analysis of HRV is based on the mathematical analyses on R-R interval (224). 
Measures of time domain HRV include standard deviation of R-R intervals (SDNN), the 
square root of mean successive R-R intervals (rMSDD), and the percentage of R-R interval 
that differ by more than 50 ms (pNN50) in the assessed period (224;225).  
 
Frequency domain heart rate variability 
Frequency domain analyses of HRV is based on the spectral analyses of a series of R-R 
intervals (225). Spectral analysis of HRV involves the calculation and measurement of the 
power and magnitude of the oscillation in R-R intervals in separate frequency ranges, which 
is most commonly done with a fast fourier transform (FFT) or autoregressive approach 
(225). According to the Task force of the European Society of Cardiology and the North 
American Society of Pacing and Electrophysiology, frequency domain HRV indices are 
recommended for calculation from short-term recordings (two to five minutes) because of 
the number of R-R intervals (See table 2) (228). These HRV indices include low frequency 
(LF, 0.04 to 0.15 Hz) which is modulated by sympathetic activity and a component of 
parasympathetic activity, high frequency (HF, 0.15 to 0.4 Hz) which is modulated by the 




sympathetic and parasympathetic activity (111). There is an additional component termed 
very low frequency (VLF, below 0.04 Hz) which is used less in studies due to the unclear 
interpretation of its physiological meaning (e.g. hibernation and hormone change) (225). 
Apart from using LF and HF in absolute value of power (ms2), LF and HF can be measured 
in normalized units (nu) which represent the relative power of each component to the total 
power minus the VLF component (228). The advantage of representation of LF and HF in 
(nu) is the minimization of the effect of change in total power on the values of LF and HF 
(228) meaning less fluctuations in readings (e.g. very high numbers then followed by smaller 
numbers) reflected by sympathetic and parasympathetic activity. It should be noted that the 
parasympathetic component has a reflection not only in HF but also in other HRV 
parameters including LF. This was shown with the use of atropine as a parasympathetic 
blockade, which caused decreases in all frequency domain HRV indices. In healthy 
participants, a significant reduction in LF and HF power have been observed following 
atropine injection (230;231). Due to the complexity in LF and its representation of both 
sympathetic activity and parasympathetic components, it cannot be interpreted as a 
reflection of sympathetic activity only (231). 
Time domain analyses provides substantial information; the frequency domain analysis is 
easier to obtain because it can be measured retrospectively from short-term recordings of 
resting ECG, and therefore is commonly used in laboratory based studies. Thus, the study 
in this thesis utilised frequency domain analyses. 
 
Table 2. HRV Indices definition 
HRV parameter Definition 
 
LF power (ms2) 
 
 
Recorded peaks between (0.04-0.15 Hz). Reflects sympathetic effect 
and parasympathetic component 
 
HF power (ms2) 
 
Recorded peaks between (0.15-0.40 Hz). Reflects the parasympathetic 
effect 
LF/HF  





Reflects the relative power of LF (normalized unit) in proportion to the 




Reflects the relative power of HF (normalized unit) in proportion to the 




Heart rate recovery 
HRR reflects cardiac parasympathetic function post exercise. During exercise, sympathetic 
activity is increased and parasympathetic activity is decreased resulting in an increase in 
heart rate (232;233). During post exercise recovery, there is a gradual decrease of heart rate, 
which is mediated by parasympathetic nervous system reactivation and withdrawal of the 
sympathetic nervous system (234). This period of HRR can be measured up to the six 
minutes, however, one minute HRR (HRR1) and two minutes HRR (HRR2) are validated, 
and commonly used (202;235).  
HRR1 is known to reflect the reactivation of parasympathetic nervous system, whereas, 
HRR2 reflects parasympathetic reactivation and sympathetic withdrawal (234). HRR1 can 
be measured as the absolute change from peak heart rate during exercise testing to heart rate 
one minute post peak heart rate, and HRR2 can be measured as the absolute change from 
peak heart rate during exercise testing to heart rate two minutes post peak heart rate 
(235;236). The greater drop in heart rate is a reflective of better parasympathetic and 
sympathetic activity. For example, HRR1 ≤ 12 beats·min-1 was a predictor of overall 
mortality in a population with no history of CVD, independent of CVD risk factors, age, sex 
or medication (199;237). HRR2 ≤ 22 beats·min-1 has been reported to predict mortality in a 
mix of population with and without CVD (235). These studies provide good evidence that 
greater values of HRR are predictive of lower risk for CVD events. However, care should 
be taken when comparing these different cut off points as methodological difference can 
influence the HRR assessments. For example, some studies include a cooling down period 
after the test (199;237), whereas in other studies the assessments were taken with the 
participant in supine position during the recovery period (238). Therefore, utilising these cut 
off points is difficult to generalise to all populations, and there are no established cut off 
points or normative reference values for HRR1 or HRR2. Many CVD risk factors have been 
found to be associated with poor or slow HRR including atherosclerosis (239), pre 
hypertension (240), diabetes mellitus (241), high body mass index (242), and inflammatory 
markers (243). However, in RA patients, the association between HRR and CVD risk factors 
is currently unknown.  
Due to the prognostic value of HRR and its association with many CVD risk factors, it has 
been recommended to be incorporated in the results of exercise testing assessment (244) as 




This would help to risk stratify patients who are at high risk for CVD and further evaluate 
the effect of treatment intervention (244).      
 
Ewing’s test battery (cardiovascular autonomic reflex tests) 
Ewing’s test battery consists of five simple tests examining the two arms of the autonomic 
nervous system. These tests include heart rate response to standing, Valsalva manoeuvre, 
heart rate response to deep breathing, blood pressure response to standing, and blood 
pressure response to sustained handgrip. These tests were originally developed by Ewing 
and colleagues for the assessment of cardiovascular autonomic reflex in diabetic patients 
(245), and has been found to be a valid measure for autonomic function in diabetic patients 
(246). Even though some tests are more reflective of sympathetic or parasympathetic 
activity, together, the test battery provides a good overall reflection of ANS. For example, 
heart rate and blood pressure response to standing are known to reflect sympathetic activity 
and parasympathetic activity, and Valsalva manoeuvre and deep breathing exercise reflect 
parasympathetic activity (247). Heart rate can be monitored via ECG or tachogram to obtain 
information about heart rate as well as R-R intervals. The following paragraphs explain each 
task and the physiological reaction to it.   
 
Heart rate response to standing  
During this test, the response of heart rate to postural change is assessed. Before standing, 
the participant is quietly resting in a supine position for five minutes. Then at the end of fifth 
minute, the participant is asked to stand up unaided. The immediate change in posture from 
supine position to standing causes an increase in blood flow to the lower extremities, and 
distend the veins which decreases the venous return to the heart and reduces stroke volume 
(225). A physiological reaction from the heart is initiated, which is mediated by the 
baroreceptors detecting the drop in blood pressure at the start after standing, which causes 
an immediate vagal response at earlier stages before the 15th beat (1st beat to the 14th beat 
after standing), which is followed by  sympathetic nervous system activation to accelerate 
heart rate normally at the 15th beat from standing, then followed by a period of stabilization 
or reduction of heart rate at the 30th beat from standing (225;245). Thus, the changes in heart 








During this test, the participant is seated on a chair holding a mouthpiece with a pressure 
bar. The participant is asked to blow into the mouthpiece with closed glottis at a pressure of 
40 mmHg for 15 seconds. During this manoeuvre, heart rate increases due to elevated 
intrathoracic pressure, followed by a decrease in heart rate after the manoeuvre (225;245). 
The changes in heart rate are quantified as the ratio of the longest R-R interval after the 
manoeuvre to the shortest R-R interval during the manoeuvre. Usually, the average of three 
successive valsalva manoeuvres is used. The greater the ratio is reflective of better 
parasympathetic activation.  
 
Heart rate response to deep breathing 
During this test, the participants is asked to conduct six deep breaths in a minute while 
seated. Participant is asked to do this at a rate of five seconds for inspiration and five seconds 
for expiration. The test is repeated three times and the mean difference between maximum 
heart rate and minimum heart rate during each minute is calculated (245). Deep breathing at 
the rate of six breaths per minute makes the phenomenon of respiratory sinus arrhythmia 
more prominent (225), and this test is therefore a good reflection of parasympathetic activity. 
The greater the difference between the maximum and minimum heart rate is a reflection of 
better parasympathetic activity.   
 
Blood pressure response to standing up 
At the start of this assessment, the participant is lying quietly in a supine position for five 
minutes, before being asked to stand up. Blood pressure is measured while the participant is 
lying down (preferably between the third or fourth minute) and measured again after 
standing up. The difference in systolic blood pressure between standing up and lying down 
is calculated (245). The gravitational change in this test causes an immediate response from 




balance between sympathetic and parasympathetic nervous system, with a lesser drop 
reflective of better sympathetic activity.   
 
Blood pressure response to sustained handgrip   
To start this assessments, resting blood pressure is measured while the participant is seated 
on a chair. With the aid of a dynamometer, maximum voluntary handgrip force is measured. 
Subsequently, the participant is asked to maintain 30% of maximum voluntary handgrip 
force for five minutes, while blood pressure is measured each minute. The response is 
measured by calculating the difference in diastolic blood pressure just before the start of the 
test and before the release of the handgrip (245). The test induces an increase in diastolic 
blood pressure (often used as a reflection of total peripheral resistance) which results from 
both an initially vagally mediated increase heart rate and cardiac output, as well as a 
progressive increase in vascular resistance. (225). A greater difference between the diastolic 
pressure measurements is reflective of higher sympathetic activity.  
 
Analyses of the results of Ewing’s test battery (cardiovascular reflex test) 
Ewing et al. (244) suggested multiple ways of categorizing the results of the tests. However, 
the most commonly used way in clinical research is by scoring each test based on the 
reference values. For example, 0 is given for a normal score, 1 is given for an abnormal 
score, and 0.5 is given to a borderline score (245). Therefore, the total score ranges from 0 
– 5, with higher numbers indicating greater abnormality. Some of these tests are associated 
with age including heart rate response to standing, heart rate response to deep breathing, and 
blood pressure response to sustained handgrip in women only, therefore, during analyses of 
these tests, age must be considered as a confounding variable (245).  
Similar to the other methods of ANS assessment, ANS dysfunction assessed by Ewing’s test 
battery has been associated with increased risk of CVD, mortality, and sudden cardiac events 
(248).  
In summary, non-invasive assessment of autonomic function can be simple and easily 
implemented in clinical research, however, the interpretation of what these tests reflect 




important for successful implementation in clinical practice (225). Clear interpretation may 
contribute to better understanding of the role of ANS dysfunction in the development of 
CVD, which would improve screening strategies to control the risk of CVD (224).  
 
Autonomic nervous system in Rheumatoid Arthritis 
In RA, the majority of the studies assessing ANS have used the methods mentioned above.  
However, a few other assessments have been used including: skin conductance (249), cold 
pressor (250), pre-ejection period (251), blood assessment for chemical neurotransmitters 
(e.g. adrenaline) (252), and pupillography (light reaction) (253). Some of these tests were 
used in conjunction with the aforementioned ANS assessments (HRV, Ewing’s test battery) 
or used with individual or multiple tasks of Ewing’s test battery. Table 3 provides an 
overview of all the studies exploring ANS in RA.  
As is evident from Table 3, HRV is most frequently used to assess ANS in RA. Some studies 
have used both time domain and frequency domain (215;254;255), whereas some have used 
time domain only (256) or frequency domain only (252;257). In general, these studies 
showed that patients with RA have significantly reduced HRV indicating poorer ANS 
compared with healthy control participants (215;254-256) or patients with spondyloarthritis 
(an inflammatory condition of the vertebrae of the spine) (257). 
Only two studies have explored HRR in patients with RA (see Table 3). Both studies 
reported on the changes in HRR following an exercise programme and both showed 
improvements in HRR. The first study showed greater improvements in HRR following 
aerobic exercise compared to anaerobic exercise in a large group of RA and osteoarthritis 
patients (258), and the other study revealed also an improvement in HRR following ten 
weeks of high intensity exercise in a small group of women with RA (259). The high 
intensity exercise programme improved cardiorespiratory fitness and BMI, but associations 
between the changes were not reported.  
There are numerous studies that used all the five tasks of Ewing’s test battery to compare 
ANS between RA and healthy control participants (260;261) or other types of autoimmune 
diseases (262-264). The comparisons between RA and healthy control participants revealed 
equivocal results, with some showing poorer ANS in RA (261;262) whereas others showed 




manoeuvre, were used in the assessments (249-251;253;265;266), with some showing 
differences (249;250;266) and others reporting no differences (251;265). It is worth noting 
that age did influence the differences between RA and healthy control participants and could 
perhaps provide an explanation for the equivocal findings. For example, a difference was 
found between RA and healthy participants in younger participants (younger than 60 years), 
whereas those older than 60 years had similar ANS function (261).  
ANS was also compared between patients with RA and other autoimmune conditions, with 
systemic lupus erythematosus (SLE) being the most commonly used comparison group. 
Similar to the comparison with healthy control participants, the findings of these studies are 
equivocal. Some have reported poorer ANS in RA compared to SLE (262), others no 
differences (264) and some poorer ANS in SLE (263). It is difficult to explain the reason 
why there was a difference in findings with regard to the comparison of ANS between RA 
and SLE, as the samples included in these studies vary with regards to age, disease duration, 
and sample size, which could have all contributed to these findings.   
Several studies have used more than one assessment to investigate ANS in the same 
participants. Poorer ANS in RA was reported based on HRV and Ewing test battery 
compared to healthy participants in some studies (267;268). Contradicting findings were 
reported in a comparison study between RA patients and healthy participants using HRV 
and measures of adrenaline, a sympathetic neurotransmitter (252). Whereas no differences 
were observed in HRV between the groups, adrenaline levels indicated higher resting 
sympathetic activity in patients with RA (252). The lack of difference in the HRV may be 
due to the smaller sample size than previously mentioned studies, although differences in 
adrenaline levels were detectable despite the sample size. 
As mentioned before, some studies compared RA patients and healthy control participants 
using some of the tasks of Ewing’s test battery and other forms of ANS assessments (249-
251). Poorer ANS in RA compared to healthy control participants was reported based on 
some of tasks of Ewing’s test battery and skin conductance (249), a measure that reflects the 
sympathetic activation of sweat glands in the palms of the hands or soles of the foot via 
electrical stimulation (225). Both types of assessments indicated that RA patients have 
poorer sympathetic and parasympathetic activity than healthy control participants (249). 
Similar findings were reported in another study using some tasks of Ewing’s test battery and 




in heart rate or blood pressure resulting from immersion of one hand into cold water (225), 
compared to healthy control participants (250). Again, all types of assessments indicated 
poorer ANS in patients with RA than healthy participants. Contradictory findings were 
reported in a comparison study between RA and healthy participants using heart rate 
response to deep breathing (as a reflection of parasympathetic activity) and pre-ejection 
period, which measures the time duration between stimulation of the heart and the start of 
ejection as a reflection of sympathetic activity (251). Whereas no difference was observed 
in parasympathetic activity between the two groups, lower pre-ejection period indicated 
higher sympathetic activity in patients with RA (251).  
Not all the studies compared RA with healthy control participants. An observational study 
investigated the prevalence of ANS dysfunction using some tasks of Ewing’s test battery as 
well as pupillary autonomic function (253). The pupillary autonomic function was measured 
using the latency time in pupillary reflex to the light as an indication of parasympathetic 
function, and the maximal pupillary area in the darkness as an indication of sympathetic 
function (253). The results of the study showed that 60% of RA patients demonstrated 
abnormal response either in the tasks of Ewing’s test battery or pupillary autonomic 
function. Moreover, in longitudinal analyses, difference were in autonomic function were 
found between those who died during the 8-year follow up period and those who did not.  
More specifically, parasympathetic activity indicated by heart rate response to deep 
breathing, Ewing’s test battery and pupillary autonomic function were all poorer among 
those who died due to heart failure, immune deficiency, and sudden cardiac death during a 
follow-period compared to those who stayed alive (253).  
 
Association between autonomic nervous system and cardiovascular disease risk factors  
It is surprising that only limited studies have investigated the association between HRV and 
CVD risk factors (see Table 3). Age was related to reduced HRV in some (254;257), but not 
all studies (256) and also not with ANS assessed with Ewing’s test battery (268). It is 
difficult to conclude if obesity is related to ANS, as one study reported no association (268), 
whereas another did (263). In separate studies, smoking (256) and blood pressure (249;263) 
were related to ANS, but no association was found with sex (268). 
Even though little is known about the association between ANS and CVD in RA, more 




associated with reduced HRV including triglycerides, systolic blood pressure, BMI, and 
waist to hip ratio in both diabetic and age-sex matched non-diabetic participants (269). Using 
HRR, many CVD risk factors including systolic blood pressure, triglycerides, and waist to 
hip ratio were inversely associated with HRR in healthy children and adolescents (270). Poor 
HRR was also found to be associated with higher BMI, and higher blood pressure in 
apparently healthy participants (271). In patients with DM, an inverse association between 
HRR and triglycerides was reported (272). These studies suggest that there is an association 
between CVD risk factors and ANS in different populations; however, this association is 
less investigated in RA.     
 
Association between autonomic nervous system and inflammation 
Several studies explored the associations between inflammation and ANS with equivocal 
findings. Reduced HRV was found to be associated with higher level of CRP (257), 
leukocytes (256), and Rheumatoid factor (254) but no association was reported between 
HRV and ESR. Measures of disease activity, which includes inflammation as well as the 
patients’ perception of pain or general health and swelling, were related to HRV in some 
(254;256) but not all (268) studies. Most of the studies that utilised Ewing’s test battery 
reported no association between this measure of ANS and inflammatory markers, disease 
duration, and CRP (249;261-263;265;266).  
In summary, the literature review described above tends to show that ANS is poorer in 
patients with RA compared to healthy control participants. There are many studies that 
investigated ANS in RA using HRV, and Ewing’s test battery (all tasks or multiple 
individual cardiovascular reflex tasks). However, the results from these studies are 
controversial and contradictory. Furthermore, in general, the studies do not provide enough 





















Table 3. Overview of studies assessing ANS in patients with RA. 
Authors  participants Type of ANS 
test  
Main Findings  Association 
between measure 




measure of ANS 
and CVD risks 
Yadav et al. (254) 45 RA (39 ♀), and 45 





Reduced HRV in RA  HRV inversely 
associated with DAS28 
and Rheumatoid factor  
 
HRV inversely 
associated with age  
Evrengul et al. (215) 42 RA (35 ♀), and 44 





Reduced HRV in RA HRV not associated 
with inflammation or 
disease duration    
NA 










HRV inversely  
associated with 
smoking  
Lazzerini et al. (257) 
 
101 (50 ♀) with 
chronic inflammation 
including 25 with RA 
HRV (frequency 
domain) 
Reduced HRV in RA with high inflammation  HRV inversely 
associated with CRP 
HRV inversely 
associated with age  





in supine and 
standing position 
Reduced HRV in RA NA NA 
Vlcek et al. (252)  
 








and adrenaline and 
neuropeptide 
No difference in HRV. Higher baseline 






Milovanovic et al. (267) 52 SLE (46 ♀), 38 
RA (32 ♀, and 41 




and Ewing’s test 





Reduced HRV and poorer ANS response for 
Ewing’s test in RA than SLE and HCP 
 
NA NA 
Aydemir et al. (268) 36 RA (30 ♀), 38 
SLE (32 ♀), and 40 







handgrip)   
Reduced HRV and poorer ANS response for 
Ewing’s test in SLE than RA and HCP  
 
No association Both measures of 
ANS not associated 
with and age, or BMI 
Minor et al. (258) 120 (40 RA 85% ♀, 
80 OA 80% ♀) 
HRR change in 5 
minutes  
RA patients and OA patients had significant 
improvement in HRR after three times/week 
of moderate to high intensity aerobic 
exercise training for 12 weeks compared to 
the same population who had three 
times/week anaerobic exercise training for 12 
weeks 
NA NA 
Sandsted et al. (259) 7 RA and 11 Juvenile 
idiopathic arthritis (all 
♀) 
HRR one minute RA patients, as well as juvenile idiopathic 
arthritis, had improvement in HRR, 
cardiorespiratory fitness, and BMI after two 
times/week of high intensity training for ten 
weeks  
NA NA 
Bekkelund et al. (260)  43 RA, and 61 HCP 
(all ♀) 
Ewing’s test  No difference in Ewing test between RA and 
HCP 
NA NA 
Maule et al. (264) 34 connective tissue 
(17 SLE 17 RA), and 
25 HCP (all ♀) 
Ewing’s test  
 
No difference in Ewing’s test between RA 
patients and SLE patients or between patients 
(RA and SLE) and HCP 
NA  NA 
Sandhu and Allen. (261) 
 
 
62 RA (39 ♀), and 41 
HCP (21 ♀) 
 
Ewing’s test  Poorer ANS response for Ewing’s test in RA  No association between 
ANS measures and 





Louthrenoo et al. (262) 34 RA (30 ♀), 37 
SLE (34 ♀, and 62 
HCP (50 ♀) 
Ewing’s test  Poorer ANS response for Ewing’s test in RA 
than SLE and HCP 
No association between 
ANS measures and 
ESR, disease duration, 
and rheumatoid factor 
NA 
Stojanovich et al. (263) 125 Autoimmune 
disease [39 RA (33♀), 
54 SLE (49 ♀), 20 
primary Sjögren 
syndrome (19 ♀), 8 
polymyalgia 
rheumatic (6 ♀), 4 
scleroderma (3 ♀)] 
and 35 HCP (19 ♀)   
 
Ewing’s test  Poorer ANS response for Ewing’s test in 
SLE than RA and HCP 
No association between 
ANS measures and 
inflammation 
Abnormal responses 
of Ewing’s test 
associated with  
obesity in RA 
Piha et al. (265) 34 RA, 76 DM, and 
67 HCP (all ♀) 
Valsalva 
manoeuvre, heart 
rate response to 
deep breathing, 
and heart rate 
response to 
standing.  
Poorer ANS responses in DM than RA and 
HCP. No difference in the ANS responses 
between RA and HCP  
No association between 
ANS measures and 
ESR 
NA 
Toussirot et al. (266) 
 
50 RA (32 ♀), and 82 
HCP (49 ♀) 
Valsalva 
manoeuvre, heart 
rate response to 
deep breathing, 
and heart rate 
response to 
standing 
Poorer ANS response in RA than HCP  
 
No association between 
ANS measures and 
inflammation, or 
disease duration  
NA 
Saba and Sultan. (249) 25 RA (22 ♀), and 30 
HCP (27 ♀) 







Poorer ANS response in RA than HCR  No association between 




response to standing 
inversely associated 
with systolic blood 
pressure  




rate response to 
No difference in heart rate response to 
standing, Lower pre-ejection period in RA 










Bidikar et al. (250) 50 RA (46 ♀), and 50 








Poorer ANS response in RA 
 
NA NA 
Schwemmer et al. (253) 30 RA (17 ♀) 
(observational and 
follow up study) 
Ewing’s test 
battery and   
Pupillography test 
(light reaction) 
60% had poor ANS response. During follow 
up, most of the non-survivors had either 




      
ANS; autonomic nervous system, RA; rheumatoid arthritis, HCP; healthy control participants, SLE; systematic lupus erythematosus, OA; osteoarthritis, NA; not assessed, HRV; heart rate 








Overview and aims of thesis 
RA associated with increased risk of CVD and increased risk of premature mortality from 
CVD. A factor that may contribute to that increased risk of CVD is ANS dysfunction, an 
imbalance between the activity of the ANS manifested by increased sympathetic and decreased 
parasympathetic activity. Even though studies have reported ANS dysfunction in RA, little is 
known about the associations between ANS with CVD risk factors, disease-related factors and 
measures of wellbeing in this particular population. Therefore, the overarching aim of this 
thesis is exploring factors related to ANS in RA. In the separate chapters of this thesis, this aim 
is addressed using different hypotheses and study designs, including cross-sectional and 
longitudinal designs.    
 
Specific aims and hypotheses      
Chapter 2 
The aim of the study presented in chapter 2 was to investigate the association between a marker 
of myocardial ischemia during an exercise tolerance test and 2-min short term resting HRV. 
Induced ST segment depression during exercise testing is known as an identification of 
ischemic changes of the heart (273). However, this conventional method requires high 
workload intensities to detect significant ST segment depression that defines clinically positive 
myocardial ischemic changes, and patients with RA may not be able to work at this high 
intensity due to joint problems. Therefore, heart rate adjusted ST segment (i.e. the ST/HR 
index) was used as a novel method to detect ischemic changes during exercise testing (274). 
The advantage of this method is that it does not rely on the workload intensity achieved, and 
changes in ST segment are taken into account from resting to the maximum induced ST 
segment depression during exercise testing. Since reduced HRV has been found to be 
associated with ischemic changes of the heart, it was hypothesized that ST/HR index will 
associate with reduced HRV, an indication of reduced parasympathetic activity and increased 








The aim of the study in chapter 3 was to explore the factors associated with parasympathetic 
reactivation following an exercise tolerance test. The study explored the association between 
HRR, as a measure of parasympathetic activity, and a range of factors reflecting CVD risk, 
RA-related disease activity, and measures of wellbeing. HRR is a predictor of CVD and has 
been associated with inflammation in healthy population. Therefore, it was hypothesized that 




The data presented in chapter 4 involves an exercise intervention study. Exercise has been 
shown to be one the best behavioural interventions to reduce the risk of CVD in many clinical 
populations, including RA (275). However, little is known about the effect of exercise training 
on ANS, in particular, parasympathetic nervous system using HRR, in patients with RA. To 
the best of our knowledge, a pilot study investigated the effect of exercise training on 
parasympathetic function in a relatively small group of women (259) is the only investigation 
of the effect of this. Therefore, this study aimed to investigate the effects of three months semi-
supervised exercise training programme on parasympathetic activity (HRR) in patients with 
RA. Secondary aims involved the investigation of the effects of the exercise programme on 
CVD risk factors (including cardiorespiratory fitness), RA-related disease activity and 
measures of wellbeing, as well as the associations between the changes in these measures with 
the changes in HRR in response to the exercise programme. It was hypothesized that 3-month 
semi-supervised exercise intervention would improve HRR. It was further hypothesised that 
the exercise programme would induce changes in CVD risk factors, RA-related disease activity 
and measures of wellbeing, and that the changes in these factors would be related to the 
expected changes in HRR.   
 
Chapter 5 
In the final experimental chapter of this thesis, a comparison is made between HRR in patients 
with RA and patients with DM. As reported above, the CVD risk in patients with RA is 




the level of systemic inflammation. Whereas patients with RA can be characterised by high-
grade systemic inflammation, patient with DM have low-grade systemic inflammation. 
Therefore, the comparison between ANS in patients with RA and patients with DM allows for 
the assessment of the impact of inflammation on ANS and in particular the parasympathetic 
nervous system. Therefore, the aim of the study was to compare parasympathetic activity using 
HRR between age- and sex-matched RA and DM patients. The secondary aim of the study was 
to compare inflammation as well as CVD risk factors and measures of wellbeing and its 
association with HRR in these populations. It was hypothesized that HRR would be poorer in 
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Introduction Coronary artery disease (CAD) is one of the causes of increased mortality in 
patients with rheumatoid arthritis (RA). CAD can be undetected, especially in RA, and can 
lead to myocardial infarction (MI). Heart rate adjusted ST segment (ST/HR index) is a novel 
method used to assess ischemic changes of the heart during exercise testing. Autonomic 
dysfunction, reflected by increased sympathetic activity and reduced parasympathetic activity, 
measured by heart rate variability (HRV) while resting, has been suggested as factor 
contributing to the risk of developing MI. The associations between autonomic function, 
assessed by HRV, and ST/HR index are currently not known in RA. Therefore, the study aimed 
to explore the association between resting HRV indices and ST/HR index in patients with RA.  
Methods 96 RA patients (54.4±12.6 years, 68% women) completed a treadmill exercise 
tolerance test (ETT) as part of a baseline assessment for an exercise intervention study. While 
resting, two minutes beat to beat R-R interval data from ECG were recorded. Low frequency 
(LF; 0.04-0.15 Hz), and high frequency (HF; 0.15-0.40 Hz) spectral powers, LF/HF ratio, and 
the normalized units (nu) of LF and HF were used as HRV indices to measure cardiac 
autonomic control. In addition, ST/HR index was measured as the difference between ST 
segment depression at rest and maximum ST segment depression during ETT divided by the 
absolute change from resting heart rate (HR) to the corresponding HR of maximum ST 
depression during ETT.  
Results Mean ST/HR index was 2.6 ± 1.7v µV·bm-1·min-1. Mean or median values for HRV 
indices were LF (nu) [60.4 (41.7-76.1)], HF (nu) (43.0 ± 24.4), LF/HF ratio [1.5 (0.7-3.1)] 
Pearsons moment correlation revealed that LF/HF ratio and LF (nu) were correlated with 
ST/HR index, whereas, HF (nu) was inversely correlated with ST/HR index. However, when 
these correlated variables entered in a linear regression model using enter method, the variation 
in ST/HR index was not explained (R2 = 0.08, p = 0.08), and no individual HRV variable was 
independently associated with ST/HR index. 
Conclusion ST/HR index was associated with reduced parasympathetic tone (as indicated by 
HF) and reduced sympatho-vagal balance (as indicated by LF/HF). However, these variables 
did not explain the variance in ST/HR index and none was independently associated with 






Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease that causes 
progressive damage to the joints, eventually leading to functional disability (1). In addition to 
the disease-related manifestations, RA is also associated with increased risk of mortality from 
cardiovascular disease (CVD), which accounts for more than 40% of deaths in RA (2). 
Moreover, coronary artery disease (CAD) has been suggested as a major cause of increased 
cardiovascular mortality in patients with RA (3;4). This may be further supported by the fact 
that the risk of hospitalization due to CAD is three times higher in RA compared to non-RA 
cohorts, and the risk of unrecognized myocardial infarction is more than five times higher in 
RA compared to non-RA (5). CAD is most commonly caused by the development of 
atherosclerosis in coronary arteries of the heart (6), which is driven by inflammation (7). As 
such, it seems reasonable to suggest that one of the main reasons that RA patients experience 
increased risk for CAD, may be due to inflammation.  
Myocardial ischemia is caused by decreased oxygenated blood flow to the heart muscles, most 
likely due to stenosis in the coronary arteries or arterial stiffening. The twelve lead 
electrocardiogram (ECG) is the most commonly used non-invasive method to detect 
obstructive changes in the coronary arteries of the heart. Conventionally, these changes are 
identified via exercise induced ST segment depression. In the absence of existing pathology, 
there are no or minimal changes in ST segment before exercise testing, but as the intensity of 
test increases, the myocardial demands increase, and thus, any limitations in coronary blood 
flow will be manifested by further changes in ST segment depression. However, due to the 
great dependence of this conventional method on workload intensity (8), it has been debated 
that it has poor sensitivity to detect ischemic changes in certain circumstances, especially in 
patients with RA who may have early termination of the exercise test due to joint problems. 
Thus, adjusting the ST segment against a dynamic factor that causes ST segment depression to 
change during progressive workload may help to distinguish the ischemic changes during the 
test, regardless of the ability to achieve maximum workload intensity. Adjusting ST segment 
against the changes in heart rate (i.e. the ST/HR index) is a novel method which has been 
established to increase the sensitivity in detection of ischemic changes during exercise testing 
(8;9). Furthermore, predictability of ST/HR index has been reported to be better than the 
conventional method in prediction of CVD events in a low risk population (women and men) 
from the Framingham offspring study, and prediction of CVD mortality in high risk 




One of the factors that can cause myocardial ischemia is the imbalanced activity of the 
autonomic nervous system (ANS) which manifests as increased sympathetic and decreased 
parasympathetic tone, commonly termed as ANS dysfunction (11-13). Heart rate variability 
(HRV) is a valid, reliable, non-invasive measure for the activity of these two arms of the ANS 
(14-16), with different aspects of HRV reflecting different information about ANS. The high 
frequency component of HRV is known to be a reflection of parasympathetic/vagal activity 
(e.g. increased higher frequency indicates increased parasympathetic activity), whereas, the 
low frequency component and the ratio of low and high frequency component are proposed as 
a reflection of sympathetic and parasympathetic balance (16-18). Generally, increased HRV is 
an indication of better ANS modulation of the heart. Previous studies have shown that reduced 
HRV (characterized by less vagal activity indicated by HF component and reduced sympatho-
vagal balance indicated by LF and LF/HF) is associated with sudden cardiac death in patients 
with RA (19-21), and patients with CAD (22). Due to the increased risk of CAD and 
cardiovascular mortality in patients with RA, identification of autonomic factors associated 
with myocardial ischemia may lead to better screening and strategies in CAD prevention in 
this population. Given the dearth of relevant studies, this study’s main aim is to investigate the 
association between resting HRV and myocardial ischaemia (via heart rate adjusted ST 
segment) during treadmill exercise testing in RA patients. It was hypothesized that heart rate 
adjusted ST segment (ST/HR index) associates with sympatho-vagal imbalance indicated by 
LF and LF/HF ratio and reduced parasympathetic activity indicated by HF.  
 
Methods 
Study population  
Ninety-six RA patients (fulfilling the revised American College of Rheumatology criteria (23)) 
were recruited from outpatient clinics of the Dudley Group NHS Foundation Trust, UK from 
October 2011 to 2014 to participate in an exercise intervention study Trial registration number: 
ISRCTN04121489). Exclusion criteria were: fibromyalgia, recent joint surgery (in the 
preceding six months), current flare of the disease, comorbidity incompatible with exercise as 
per American College of Sports Medicine (ACSM) guidelines (24), atrial fibrillation, and 
established CVD. The study was approved by the National Research Ethics Service and all 





Patients were invited to the research laboratory of the Russell’s Hall Hospital, Dudley Group 
of Hospitals NHS Foundation Trust, for a treadmill exercise tolerance test (ETT). During this 
visit, all participants were measured for: height (Seca 214 Road Rod), weight and BMI (Tanita 
BC 418 MA Segmental Body Composition Analyser, Tanita Corporation, Tokyo, Japan). An 
electronic sphygmomanometer (Datascope Accutor, Mahwah, NJ, USA) was used to measure 
brachial blood pressure while the patient was seated using standardised procedures (25). Then, 
every participant was fitted with a 12-lead electrocardiography (ECG) (12-channel ECG custo 
cardio 200, Custo Med, Liepzig, Germany). While patients were seated, resting heart rate was 
recorded for two minutes. This was followed by an ETT and six minutes’ post ETT recovery 
period during which heart rate was continuously monitored. 
 
Exercise tolerance test  
All patients performed an individualized treadmill (HP Cosmos Mercury, Nussdoerf-
Traunstien, Germany) ETT. As per current practise, all patients were familiarised with the ETT 
testing procedures. The ETT protocol was modified according to each patient’s fitness and 
physical abilities (26), an approach previously utilised in RA patients (27). The test was started 
at a speed of the patient’s preference (approximately three mph) and 0% inclination for two 
minutes; the starting speed was identified and agreed with the patient during the familiarisation 
phase with the ETT. Thereafter, according to the patient’s ability, the speed was increased 
gradually to the level of maximum brisk walking. 
The test started at the end of the two minutes warm up with the preferred speed, and the 
inclination of the treadmill was increased by 1% every minute while maintaining the same 
speed. ECG was recorded throughout the ETT and during recovery period. The test was 
terminated if volitional exhaustion was reached, or any of the relative or absolute 
contraindications of ACSM’s guidelines were met (24). Six minutes of recovery were given to 
patients while seated after termination of the test. All tests were supervised throughout by an 







Heart rate variability indices 
The acquisition of HRV was done by extraction of the resting beat-to-beat R-R interval 
duration from the ECG recorded during the two minutes before the start of the test while the 
patient was seated. R-R interval was determined manually during 2-min baseline resting and 
then entered manually into a notepad after deletion of artefacts (i.e. ectopic beats) encountered 
during ECG reading. Spectral analysis of R-R intervals was made using version 2.2 Kubios 
software (University of Eastern Finland, Kubio, Finland). Two patients did have less than 2-
minutes of resting R-R interval data and were therefore excluded from the statistical analyses. 
Mean R-R interval and standard deviation of all normal R-R interval (SDNN) were not used as 
they require longer resting ECG recording to be valid, according to guidelines and literature in 
this field (16;28). Frequency domain results of the 2-min resting HRV parameters were used 
including, low frequency (LF; 0.04-0.15 Hz), and high frequency (HF; 0.15-0.40 Hz) spectral 
powers, LF/HF ratio, and the normalized units of LF and HF were used as the HRV indices to 
measure cardiac autonomic control. The Fast Fourier transform (FFT) algorithm was used to 
compute the frequency domain measures including LF, HF and LF/HF. An example of the 
frequency domain spectrum is shown in Figure 1. The standard duration for HRV measurement 
for frequency domain analyses is five minutes, however, as per guidelines, it has been 
suggested that the minimum requirement to assess HF component is one minute, and for LF 
minimum of two minutes (16). The validity and reliability of short term HRV were tested 
including 10 seconds (29), and one minute in healthy (30;31), and patient with diabetes (32). 
 
Figure 1. A typical example from one of our RA patients showing the frequency domain 
spectrum using Fast Fourier Transform method. VLF; very low frequency, LF; Low frequency, 










The ST segment was measured during the two minutes resting and throughout the ETT in five 
ECG leads (I, aVF, V2, V4, and V5) (9). Resting ST segment was calculated by taking the 
average of ST segment from these five leads every 10 seconds. During ETT, the lead with the 
maximal ST segment depression was used as the maximum during ETT. ST/HR index in 
µV·bm-1·min-1 was calculated by dividing the difference between the maximum ST segment 
depression and resting ST segment depression of the same lead divided by the difference 
between resting HR and the exercise-induced changes in HR (the correspondent maximum HR 
to the maximum ST segment depression). The ST segment depression was measured by 
computer at 60 ms after the j-point (34). The formula used for calculation is 
ST/HR index = (Maximum ST [(Exercise ST-Resting ST)  over five leads])/((exercise induced 
changes HR-Resting HR)) (9).  
 
Statistical analyses 
The normality of all variables was tested using the Kolmogorov-Smirnov test. All non-
normally distributed variables were log-transformed [LF power (ms2), HF power (ms2), LF/HF, 
and LF (nu)] and were presented as median and interquartile range. Normally distributed 
variables were presented as mean and standard deviation. The relationship between HRV 
indices and ST/HR index was tested using bivariate correlation (correcting for sex as a possible 
confounder) using Pearsons moment correlation coefficients. Normally distributed variables 
and log-transformed variables were included in bivariate correlation (correcting for sex). To 
identify if HRV parameters were independently associated with ST/HR index, linear regression 
was used via enter method (correcting for sex). ST/HR index was used as the dependent 
variable while the HRV indices that were significantly associated with ST/HR index in the 
previous correlation analysis, were the independent variables. Additional analyses were 
conducted to explore the association between age and HRV indices using Pearsons moment 
correlation coefficients was used to determine if age was a confounding variable. The level of 
significance for all analyses was set at .05. Statistical analyses was performed using SPSS20 







Patient characteristics  
Demographic characteristics of the 96 RA patients (66 women, 30 men) are presented in Table 
1. The results of the spectral analysis of baseline 2-min HRV and the ST/ HR index calculated 
during the exercise test are presented in Table 2. According to the established cut-off points for 
ST/HR index, which indicate the value of  ST/HR index ≥ 1.6 µV/beats/min as abnormal (8;35), 
a majority (69.4%) of the patients showed abnormal ST/HR index 2.6 ± 1.7 µV·bm-1·min-1.    
Table 1. Demographic characteristics of rheumatoid arthritis patients (N=96).  
 Characteristics  Value  
 Age (years) 54.4 ± 12.6 
 Height (m) 1.7 ± 0.1 
 Weight (kg) 79.3 ± 18.5 
 BMI (kg·m-2) 27.8 (23.9 – 31.0) 
 Heart rate Rest (bpm) 80 ± 13 
 Resting SBP (mmHg)  134 ± 17 
 Resting DBP (mmHg) 81 ± 10  
 Disease duration (years) 7.9 ± 9.1 
 Hypertension 33% 
 Diabetes 8% 
 Current smokers 9% 
 Previous smokers 44% 
Medication  
 Methotrexate 74% 
 Biologic DMARDs 52% 
 Non-biologic DMARDs 3% 
 Anti TNF-α 12% 
 Predinsolone 16% 
 NSAID 35% 
 Analgesics 37% 
 Cholesterol Lowering 27% 
 Anti-hypertension 24% 
Values are presented as means ± standard deviation, or median (25th to 75th percentile values) as appropriate or percentage. BMI, body mass 
index; SBP, systolic blood pressure; DBP, diastolic blood pressure; DMARDs, disease modifying anti-rheumatic drugs; TNF-α, tumour 
necrosis factor- alpha; NSAID, non-steroidal anti-inflammatory drugs.  
 
 
Table 2. Results of HRV parameters and ST/HR index of rheumatoid arthritis patients (N= 
96) 
Variable  Value Normative values (36) 
Frequency domain 
parameters  
 Mean SD Median Range 
LF power (ms2) 227.5 (86.0 – 523.5) 519 291 458 193 - 1009 




LF/HF 1.5 (0.7 – 3.1) 2.8 2.6 2.1 1.1 – 11.6 
LF (nu) 60.4 (41.8 – 76.1) 52 10 54 30 – 65 
HF (nu) 43 ± 24.4 40 10 38 16 - 60 
Marker of ischemia  Percentage of normal and abnormal values  
  Normal < 1.6  Abnormal ≥ 1.6 
ST/HR index ( 
µV·bm-1·.min
-1) 
2.6 ± 1.7 N= 26 (30.6 %) N= 59 (69.4%) 
 Values are presented as means ± standard deviation, or median (25th to 75th percentile values) as appropriate. Normative values for HRV are 
obtained from healthy participants. SD; standard deviation, LF; low frequency, HF; high frequency. (nu); normalized units.  
 
Correlations  
Higher sympatho-vagal imbalance (i.e. both LF/HF ratio and normalized units of LF) were 
positively associated with ST/HR index (r (81) = .28, p = .01, and r (81) = .23, p = .03, 
respectively), whereas, parasympathetic activity (i.e. normalized units of HF) (r (81) = -.27, p 
= .01) were inversely associated with ST/HR index (Table 3).  
 
Table 3. Correlation of ST/HR index with HRV indices of rheumatoid arthritis patients 
(N=96). 
 ST/HR index 
Variable  r p 
LF power (ms2) .18 .11 
HF power (ms2) -.04 .69 
LF/HF .28 .01 
LF (nu) .23 .03 
HF (nu) -.27 .01 
All correlations are corrected for sex. P value in bold indicate statistical significance 
 
Linear regression 
Linear regression was used to identify if the HRV variables were independently associated with 
ST/HR index. Only the variables were correlated in the bivariate analyses; LF/HF, LF (nu), 
and HF (nu) were included as independent variables while ST/HR index was the dependent 
variable in the linear regression analyses. Due to the lack of significant correlation between 
HRV indices and age (data not reported), the linear analyses were corrected for sex only as a 




explain the variation in ST/HR index (F (4, 78) = 2.23, p = .08), and none of the variables were 
independently associated with ST/HR index (Table 4).  
 
Table 4. Linear regression model for HRV indices associated with ST/HR index in 
rheumatoid arthritis patients (N=96). 
 ST/HR index  
Variable  β t-value p 
Sex  0.62 0.15 .88 
LF/HF 0.61 0.61 .55 
LF (nu) 0.43 0.48 .63 
HF (nu) 0.001 -0.04 .97 
R2 and p-value of the 
model 
R2  p 
 .08  .08 
All variables corrected for sex. 
 
Discussion 
This cross sectional study explored the association between ANS using resting HRV and 
ST/HR index as a marker of myocardial ischemia during exercise testing. As hypothesized, 
reduced HRV characterized by increased sympatho-vagal imbalance (i.e. both LF/HF ratio and 
normalized units of LF) and reduced parasympathetic (i.e. normalized units of HF) activity was 
associated with ST/HR index. However, the linear regression revealed that variance in ST/HR 
index was not explained by the studied HRV variables used in the current study, and none of 
the HRV variables were independently associated with ST/HR index. The results of this study 
suggest that it may be the overall increased sympatho-vagal imbalance indicated by LF and 
LF/HF combined with the reduced parasympathetic activity indicated by HF was associated 
with myocardial ischemia during exercise testing in patients with RA.  
Relative to normative values obtained from healthy participants, HRV values in our RA 
patients tend to be slightly different from normative values (i.e. LF power, HF power, LF/HF 
are lower than normative values, whereas, LF (nu), HF (nu) are slightly higher). It is worth 
mentioning when these normative values were established, there was a variation between males 
and females which make these normative values not a generalizable reference. Therefore, the 
current findings suggest that some HRV parameters demonstrated higher value, but whether 




studies as the interpretation of these data is difficult considering the absence of normative data 
for clinical populations. Our data suggests that there is an association between ANS and CVD, 
but no definite conclusion can be drawn from it.  
To our knowledge, this is the first study to investigate the association between HRV as a 
measure of ANS and ST/HR index as a marker of myocardial ischemia in patients with RA. 
Many studies have shown that reduced HRV is known to predict the development of CAD 
(37;38). In the current study, ST/HR index was associated with sympatho-vagal balance as 
indicated by the ratio between LF and HF (LF/HF), and LF (nu) collectively, whereas, reduced 
parasympathetic, indicated by HF (nu) was inversely associated with higher ST/HR index. This 
is in line with relevant findings suggesting that heightened sympathetic activity and reduced 
parasympathetic activity is linked with CAD (19;22). However, some of these studies included 
multiple populations with autoimmune diseases and used long term end points of 
cardiovascular disease or death. Most of the previous studies associating reduced HRV with 
CAD in asymptomatic healthy individuals reported no association between LF/HF with CAD 
(37;39), whereas, Miyase et al. (40) concluded that LF/HF is a predictor of CAD. LF/HF ratio 
is known as an indicator of sympatho-vagal balance (16). The lower LF/HF ratio is considered 
to be a better indication of sympatho-vagal balance (e.g. lower number indicate dominance of 
parasympathetic) (16). It is difficult to compare the current study with other studies due to 
either the differences in methodology (using short term and long term HRV) or the use of long 
term end points (i.e. established CAD). Although LF is a representation of both sympathetic 
and parasympathetic activity, the current study showed that LF/HF and LF (nu) are positively 
associated with ST/HR index; based on this it can be speculated that the sympatho-vagal 
balance is disrupted due to increase sympathetic activity. There is a possible explanation to the 
relationship between symbatho-vagal imbalance and myocardial ischemia. It is known that 
sympathetic activation increases vasoconstriction of blood vessels, which makes the vascular 
wall vulnerable to mechanical injuries, a process aiding the development of atherosclerosis 
(41). This may be especially relevant in patients with RA who are known to be vulnerable for 
endothelial dysfunction (42). In contrast, the parasympathetic nervous system has shown a 
protective role from significant arrhythmia and experimental acute MI in animals (43). This 
protective mechanism was mediated via stimulation of muscarinic cholinergic receptors to 
inhibit the release of chemical neurotransmitters of sympathetic nerve terminals (i.e. 




Another noteworthy finding in this study is that none of the HRV indices were independently 
associated with ST/HR index. Furthermore, the model created with associated HRV parameters 
including LF/HF, LF (mu), and HF (nu) in the bivariate analyses with ST/HR index did not 
significantly explain the variance in ST/HR index. Possible reasons for this include the 
existence of other factors that contribute to the variance in the ST/HR index that were not 
included in the model, or the lack of adequate sample size to perform this investigation, or the 
use of 2-min short term HRV (i.e. too few intervals). This warrants further research in a larger 
sample using long term HRV in this area to explore the other factors along with HRV associated 
with ST/HR index.  
There is some controversy about the diagnostic use of ST/HR index. Although, some studies 
are suggesting heart rate adjusted ST segment analyses can add substantial diagnostic benefits 
in exercise ECG more than conventional method (44;45), other studies did not confirm 
this(46;47). Furthermore, the clinical usefulness of ST/HR index in detection and assessment 
of CAD has been found to be better than the conventional method (measuring ST-segment 
depression) (34). Moreover, a study showed that abnormal ST/HR index can identify 
individuals with no symptoms of CAD who can benefit from risk factors reduction programs 
(10). To our knowledge, this is the first study to utilise ST/HR index as a measure of myocardial 
ischemia in patient with RA. Using such a novel method in clinical practice may help early 
detection of myocardial ischemic changes especially in patients with RA who are more likely 
to develop silent MI (5). However, this has to be proven in follow up clinical trials where RA 
patient can be followed up for a period of time, or by investigating patients with more invasive 
assessments for CAD.   
The study has some limitations. Conventionally, HRV is based on several hours or minutes of 
heart rate recording, which can provide a wealth of information. However, this might be 
difficult in population-based studies and epidemiological research (48). Published 
recommendations indicated that one minute is the minimum requirement for heart rate 
recording to obtain HF power and two minutes is the minimum duration required for LF power 
(16). During the two minutes’ assessment before exercise testing, breathing rate was not 
controlled which may have influenced HRV indices. Assessment of the causality between 
variables is not possible due to the cross-sectional design of the study. For ethical reasons, 
patients continued taking their medication on the day of assessment, which may interfere with 




appropriate statistical power to explore the influence of medication on HRV. Furthermore, the 
participants included in this study had well-controlled disease activity, which makes it difficult 
to generalize the findings of this study to RA patients with worse disease activity. 
Unfortunately, DAS28 was not available for all the participants, therefore, was not included in 
the analyses. Future research should explore the association of HRV with ST/HR index in 
patient with RA with various levels of disease activity.  
In conclusion, the results of the study showed that depressed HRV, reflective of increased 
sympatho-vagal imbalance and reduced parasympathetic activity, associate with ST/HR index, 
reflective of myocardial ischemia during ETT. This may suggest that patients with RA may 
benefit from early pharmacological interventions (49) or non-pharmacological interventions to 
improve parasympathetic activation (50). Using ST/HR index could be particularly useful for 
RA patients in early detection of ischemic changes during ETT. In addition, LF/HF ratio, LF 
(nu), HF (nu) did not explain the variance in ST/HR index, and none of these variables was 
independently associated with ST/HR index. This suggests that other factors may contribute to 
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Factors associated with parasympathetic reactivation following exercise in 
















Introduction Patients with rheumatoid arthritis (RA) have an increased risk for cardiovascular 
disease (CVD) with poor parasympathetic function being implicated as an underlying factor. 
Factors related to parasympathetic function, commonly assessed by heart rate recovery (HRR) 
following maximal exercise, are currently not known in RA. The study aimed to explore the 
association between HRR with CVD risk factors, inflammatory markers, and wellbeing in 
patients with RA.  
Methods 96 RA patients (54.4±12.6 years, 68% women) completed a treadmill exercise test, 
during which heart rate (HR) was monitored. HRR1 and HRR2 were defined as the absolute 
change from HR peak to HRR 1 minute post HR peak and 2 minutes post HR peak, 
respectively. Cardiorespiratory fitness, CVD risk factors, and serological markers of 
inflammation were measured in all patients. The Framingham Risk Score (FRS) was used as 
an assessment of global risk for CVD events, and wellbeing was assessed by questionnaires. 
Results Mean HRR1 and HRR2 were 29.1±13.2 bpm and 46.4±15.3 bpm, respectively. CVD 
risk factors as well as most inflammatory markers and measures of wellbeing were inversely 
correlated with HRR1 and HRR2. Multivariate regression analyses revealed that 27.9% of the 
variance in HRR1 and 37.9% of the variance in HRR2 was explained collectively by CVD risk 
factors, measures of inflammation, and wellbeing (p=0.009, p=0.001 respectively), however 
no individual measure was independently associated with HRR1 or HRR2.  
Conclusion Parasympathetic reactivation was associated with overall CVD risk, arthritis-













Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic systemic 
inflammation affecting approximately 1% of the general population (1). The main symptoms 
are pain, stiffness and swelling of joints. However, there are also extra-articular aspects in RA, 
such as an increased risk for cardiovascular disease (CVD), which causes more than 40% of 
the deaths in RA (2). Although the mechanisms for the increased risk for developing CVD in 
RA remain to be elucidated, several risk factors for CVD are prevalent in RA, such as 
hypertension (3) dyslipidemia (4), physical inactivity (5), inflammation (6) and obesity (7). 
This increased prevalence of CVD risk factors has been associated with abnormalities in 
vascular function and morphology (8), which could lead to CVD and even CVD-related death 
(9). More recently, in a systematic review by Adlan et al. (10), autonomic dysfunction has been 
suggested as another factor which contributes to the CVD death risk in RA.  
 
The autonomic nervous system (ANS) is divided into the sympathetic and the parasympathetic 
nervous systems, which, in a healthy state, work together to maintain cardiovascular autonomic 
balance. Autonomic dysfunction, an increased activity of the sympathetic tone and less 
parasympathetic tone at rest (11), has been associated with increased risk of CVD (12) and all-
cause mortality (13). Inflammation has been related to autonomic dysfunction in clinical (14), 
and healthy populations (15). However, little is known about the factors that contribute to 
autonomic dysfunction in a population with a high long-term inflammatory burden, such as 
patients with RA (16).  
 
A common method to assess autonomic function, and in particular parasympathetic tone, is 
heart rate recovery (HRR). The rapid fall in heart rate immediately following an exercise 
tolerance test (ETT) is suggested to represent reactivation of the parasympathetic tone (17). 
HRR is a predictor of CVD and all-cause mortality (17), and has been associated with 
inflammation levels in a healthy population (15). HRR is commonly assessed one or two 
minutes post exercise, which is thought to reflect the parasympathetic activity and withdrawal 
of sympathetic activity, respectively (18). Even though autonomic function has been explored 
in RA using different methods (16;19-41), to our knowledge, HRR following exercise has only 
been investigated in a pilot study involving RA and Juvenile idiopathic RA (42). However, the 
study was looking at the improvement post exercise intervention and there was no investigation 




HRR post ETT and explore factors associated with HRR in RA. It was hypothesized that HRR 




Ninety-six RA patients (fulfilling the revised American College of Rheumatology criteria 
(43)), were recruited from outpatient clinics of the Dudley Group NHS Foundation Trust, UK 
from October 2011 to 2014  to participate in an exercise intervention study (Trial registration 
number: ISRCTN04121489). Exclusion criteria were: fibromyalgia, recent joint surgery (in the 
preceding six months), current flare of the disease, comorbidity incompatible with exercise as 
per American College of Sports Medicine (ACSM) guidelines (44), atrial fibrillation, and 
established CVD. Ethical approval was obtained by the National Research Ethics Service and 
all patients provided written informed consent prior to participation.  
 
Protocol 
Participants were invited to visit the research laboratory on two different occasions. During 
visit one, a fasted blood sample was taken and questionnaires were completed. During visit 
two, brachial blood pressure was taken using an electronic sphygmomanometer (Datascope 
Accutor, Mahwah, NJ, USA) while the patient was seated. Height was measured to the nearest 
0.5 cm using a standard height measure (Seca 214 Road Rod), and weight and BMI were 
measured using a Tanita BC 418 MA Segmental Body Composition Analyser (Tanita 
Corporation, Tokyo, Japan). Subsequently, the patients were fitted with an appropriate size 
mask to cover the nose and mouth securely for the purpose of inspired and expired gas analysis, 
and electrocardiography (ECG) (12-channel ECG custo cardio 200, custo med, Liepzig, 
Germany) electrodes were attached. Resting heart rate and volumes of O2 consumption were 








Exercise Tolerance Test (ETT) 
ETT was performed on a treadmill (HP Cosmos Mercury, Nussdoerf-Traunstien, Germany). 
All patients performed an individualized treadmill ETT which was modified according to their 
fitness and physical abilities (45). The starting speed of the test was set based on the patient’s 
preference (approximately three mph) and 0% inclination. Thereafter, the speed was gradually 
increased until a maximum brisk walking was reached, again based on the patient’s ability. 
 
After two minutes warming up at the preferred speed, the test started. The inclination increased 
by one percent every minute while keeping the speed constant. Breath by breath gas analyses 
(Metalyzer 3B, Cortex, Liepzig, Germany) were recorded throughout the exercise task, which 
was used to calculate peak volume of O2 uptake (VO2 peak). ECG was recorded throughout the 
exercise task and recovery period. The test was terminated if patients reached volitional 
exhaustion, or any of the relative or absolute contraindications of ACSM’s guidelines (44) were 
met. Following the termination of the test, patients were asked to rest on a chair for a minimum 





Heart Rate Recovery 
HRR was measured at 1 minute and 2 minutes following peak heart rate during exercise. Heart 
rate recovery 1 minute (HRR1) was defined as the absolute change from peak heart rate to heart 
rate 1 minute post peak heart rate (HRR1 = peak heart rate – heart rate at 1 minute post peak 
heart rate). Similarly, heart rate recovery 2 minutes (HRR2) was calculated as the absolute 
change from peak heart rate to heart rate 2 minutes post peak heart rate. Peak heart rate was 
identified as the maximum heart rate during the exercise protocol.  
 
VO2 peak 
Aerobic capacity (VO2 peak) was measured during treadmill ETT via a breath by breath gas 
analyser. The inspired and expired gases data from the analyser were averaged every two 
seconds. To avoid spikes and fluctuations of the VO2 ml.min
-1
 readings, these data were 





-1). VO2 peak was defined as the highest VO2 during the test and was expressed 
asml.kg-1.min-1. 
 
Serological assessments  
The blood samples were analysed for serological risk factors for CVD: total cholesterol, high 
density lipoprotein (HDL), low density lipoprotein (LDL), and triglycerides. Homeostasis 
models assessment (HOMA) was utilized to assess insulin resistance (46). Inflammatory 
markers were assessed including erythrocyte sedimentation rate (ESR), high sensitivity C-
reactive protein (hsCRP), fibrinogen, and white blood cells (WBC). Analyses were carried out 
using routine laboratory procedures in the hospital’s laboratory.   
 
Global cardiovascular risk 
In order to measure the probability of occurrence of cardiovascular events within 10 years 
period, the Framingham risk score (FRS) was utilized (47).  
 
Measures of wellbeing  
Functional ability, psychological and general wellbeing were assessed using health assessment 
questionnaire (HAQ) (48), hospital anxiety and depression scale (HADS) (high score is 
indicative of worse anxiety or depressive symptoms) (49), subjective vitality scale (high score 
is indicative of better vitality) (50), multidimensional assessment of fatigue (MAF) (high score 
is indicative of greater levels of fatigue) (51), and the European quality of life questionnaire 
(EuroQol) (low score is indicative of poor quality of life) (51). 
 
Statistical analysis 
Statistical analysis was performed using SPSS20 (Chicago, IL, USA). Kolmogorov-Smirnov 
test was used to test the normality of all variables. Log-transformation was performed for non-
normally distributed variables (BMI, triglycerides, LDL, hsCRP, ESR, HOMA, FRS, HADS 
depression, EuroQol). All normally distributed variables were presented as mean and standard 
deviation, whereas, non-normally distributed variables were presented as median and 




normally distributed variables, bivariate correlation (correcting for sex as a possible 
confounder) using Pearsons moment was used. Bivariate correlation was performed on 
normally distributed variables and after log transformation for the skewed variables. To assess 
factors associated with HRR at both time points, two multivariate linear regression were used 
using enter method (correcting for sex) where HRR (HRR1 and HRR2 separately) was the 
dependent variable, while the independent variables were all the variables that came out 
significantly associated with HRR1 and HRR2 separately in our correlation analysis. The level 




Demographic characteristics as well as CVD risk, markers of inflammation and wellbeing of 
the 96 RA patients (66 female, 30 male, disease duration 7.9 ± 9.1 years) are presented in Table 
1. The most common comorbidities were hypertension (33%) and diabetes (8%), and 9% were 
current smokers whereas 44% of the patients were previous smokers. The types of medication 
used included: Methotrexate (74%), other non-biologic disease modifying anti-rheumatic drugs 
(DMARDs) (52%), anti-tumor necrosis factor (12%), other biologic DMARDs (3%), 
prednisolone (16%), non-steroidal anti-inflammatory drug (35%), analgesics (37%), 
cholesterol-lowering (27%), and anti-hypertensive (24%). Patients were requested to maintain 
their course of treatment during the study. The results from the exercise tests, including HRR1 
and HRR2, are presented in Table 2. On average, the overall fitness level of the participants 
was low as indicated by their mean VO2 peak 20.6 ± 5.1 ml·kg
-1·min-1 (53). 
 
Table 1. Demographic Characteristics, CVD risk, inflammatory                                          
markers, and measures of wellbeing in rheumatoid arthritis patients (N=96)  
 Characteristics  Value  
Cardiovascular risk factors   
 Age (years) 54.4 ± 12.6 
 Height (m) 1.7 ± .09 
 Weight (kg) 79.3 ± 18.5 
 BMI (kg·m-2) 27.8 (23.9 – 31.0) 
 Heart rate Rest (bpm) 79.7 ± 12.5 
 Resting SBP (mmHg)  134.2 ± 17 
 Resting DBP (mmHg) 81 ± 9.7  




 Triglycerides (mmol·L-1) 1.1 (0.8 – 1.4) 
 HDL (mmol·L-1) 1.4 ± 0.38 
 LDL (mmol·L-1) 3.1 (2.5 – 3.6) 
 HOMA 1.5 (0.94 – 2.05)  
 Framingham Risk score 7.0 (4 – 13) 
Inflammatory markers  
 WBC (109·L-1) 6.8 ± 2.4 
 Fibrinogen (g·L-1)  4.7± 1.1 
 HsCRP  (mg·L-1) 4.6 (1.6– 8.8)  
 ESR (mm·hr-1)  10 (5 – 21.5) 
Wellbeing  
 Vitality 4.1 ± 1.6 
 HADS anxiety 6.7 ± 4.2 
 HADS depression 4.0 (2 – 7 ) 
 Global Fatigue 25.8 ± 11.8 
 EuroQol 0.7 (0.6 – 0.8) 
values are presented as means ± standard deviation, or median (25th to 75th percentile values) as appropriate. BMI, body mass index; SBP, 
systolic blood pressure; DBP, diastolic blood pressure; HDL, high density lipoprotein; LDL, low density lipoprotein; WBC, white blood cells; 
HsCRP, high sensitivity C-reactive protein; ESR, erythrocyte sedimentation rate; HOMA, homeostasis model assessment insulin resistance; 
Vitality, score ranges 1 (low vitality) – 7 (high vitality); HADS, hospital anxiety and depression scale (0-21); Global fatigue, score ranges 
from 0 (no fatigue) – 50 (severe fatigue)  EuroQol, European assessment for quality of life. 
 
Table 2. Exercise related variables in rheumatoid arthritis patients (N=96) 
Variable  Value (Mean ± SD) 
Heart Rate Peak (bpm) 153.4 ± 19.7  
VO2 peak (ml·kg
-1·min-1 ) 20.6 ± 5.1 
RER (VCO2·VO2
-1) 1.2 ± 0.1  
HRR1 (bpm) 29.1 ± 13.2 
HRR2 (bpm) 46.4 ± 15.3  
VO2 peak, highest volume of oxygen; RER, respiratory exchange ratio; HRR1, the difference between HR peak and heart rate 1 minute post 




Correlational analyses were conducted to explore the associations between HRR and risk 
factors for CVD and wellbeing. With regards to CVD risk factors, results revealed that HRR1 
and HRR2 were inversely associated with age and serum triglycerides, whereas resting SBP 
was only inversely associated with HRR2 (Table 3). HRR2 was inversely associated with 
HOMA (r (87) = – .27, p = .009). VO2 peak was positively associated with HRR1 and HRR2 
(r (93) = .33, p = .001 and r (93) = .41, p < .001, respectively). HRR1 and HRR2 were both 
inversely related to FRS. WBC, Fibrinogen, hsCRP, and ESR were all inversely associated 




With regards to measures of wellbeing, EuroQol and vitality were positively associated with 
HRR1 (r (90) = .26, p = .01 and r (88) = .30, p = .004), respectively, whereas, only vitality 
was significantly associated with HRR2 (r (88) = .21, p = 0.05). Additional non-parametric 
correlational analyses (Spearman correlation) were conducted between HRR and those 
variables which were not normally distributed. These analyses revealed similar associations as 
the Pearsons correlations reported on the log-transformed data (data not reported).  
 
Table 3. Correlation of HRR1 and HRR2 with CVD risk, inflammatory markers, and 
wellbeing in rheumatoid arthritis patients (N=96) 
   HRR1 HRR2 
 Variable  r p r p 
Cardiovascular risk factors     
 Age -.27 .006 -.44 <.001 
 BMI -.15 .14 -.08 .43 
 Resting SBP -.18 .08 -.28 .005 
 Resting DBP -.09 .38 -.10 .33 
 Triglycerides -.31 .003 -.27 .008 
 HOMA -.14 .18 -.27 .009 
 VO2 peak .33 .001 .41 <.001 
 Framingham risk score  -.29 .005 -.45 <.001 
Inflammatory markers   
 WBC -.23 .02 -.22 .04 
 Fibrinogen  -.32 .001 -.27 .009 
 hsCRP -.22 .03 -.15 .13 
 ESR -.26 .01 -.21 .03 
Wellbeing     
 Vitality .30 .004 .20 .05 
 HADS depression -.18 .07 -.03 .81 
 HADS Anxiety -.02 .87 .12 .21 
 Global fatigue -.19 .054 -.03 .75 
 EuroQol .26 .01 .12 .24 









In order to identify if the variables were independently associated with HRR, all variables 
which were significantly correlated with HRR were subsequently entered in multivariate linear 
regression analyses (see Table 4). A model (based on the correlated variables in the univariate 
analyses) which included age, triglycerides, VO2 peak, FRS, WBC, CRP, ESR, fibrinogen, 
vitality, and EuroQol accounted for 29.7% of the variation in HRR1 (F (11, 67) = 2.57, p = 
.009, R2 = 0.29). However, even though almost a third of the variance in HRR1 was explained 
by these variables, none of the variables were independently associated with HRR1. For HRR2, 
using the same method, a model which included age, resting SBP, triglycerides, HOMA, VO2 
peak, FRS, WBC, ESR, fibrinogen and vitality accounted for 37.9% of the variation in HRR2 
(F (11, 65) = 3.6, p =  .001, R2 = 0.37). Similar to HRR1, none of the variables were 
independently associated with HRR2. Data was checked for collinearity, but was revealed not 
to influence the data. Additionally, in a different analyses, using age as a confounding factor 
along with sex did not change the model presented in table 4 (data not reported).  
 
Table 4. Linear regression model for factors associated with HRR1 and HRR2 in rheumatoid 
arthritis patients (N=96) 
       HRR1        HRR2 
Variable         β          t (p) β        t (p) 
Cardiovascular risk factors         
Age -0.26 -1.25 (.21) -0.46 -1.91 (.06) 
Triglycerides -21.69 -1.48 (.14) -6.03 -0.37 (.71) 
VO2 peak 0.05 0.11 (.91) 0.45 -0.98 (.32) 
Framingham risk score 0.09 0.01 (.99) -2.72 -0.25 (.79) 
Resting SBP *   -0.07 -0.69 (.48) 
HOMA *   -2.51 -0.16 (.86) 
Inflammatory markers      
WBC -0.57 -0.66 (.51) -0.01 -0.02 (.98) 
Fibrinogen -3.18 -1.36 (.17) -2.24 -0.94 (.34) 
hsCRP ** 0.86 0.16 (.87)   
ESR 4.49 0.70 (.48) 6.62 0.99 (.32) 
Wellbeing     
Vitality 1.27 0.98 (.32) 2.09 1.78 (.07) 
EuroQol ** 33.65 1.09 (.27)   




R2 and p-value of the model R2 p R2 p 
  0.297 .009 0.379 .001 
* Indicates variable that was not correlated with HRR1 in univariate analyses, therefore, was not included in model 1. ** Indicates variable 
that was not correlated with HRR2 in univariate analyses, therefore, was not included in model 2. 
 
Discussion 
To our knowledge, this is the first study to assess the relationship between HRR and CVD risk 
factors, disease-related measures and indicators of wellbeing in RA patients. As expected, 
many CVD risk factors, inflammatory markers and some measures of wellbeing were 
correlated with HRR. However, multivariate analyses revealed that the variance in HRR was 
explained by a group of factors including CVD risk factors, inflammatory markers and some 
measures of wellbeing, but none of the variables tested were independently associated with 
HRR. This may suggest that it is the overall CVD risk and disease-related burden that 
contributes to changes HRR, instead of one or several individual factors.  
The current study is the first to reveal that HRR was associated with individual CVD risk 
factors in RA. In line with other populations (54), an association was found between 
triglycerides and HRR, which is not surprising given the association between lipid metabolism 
and the ANS (55). As expected based on findings from other populations (56), 
cardiorespiratory fitness was also correlated with HRR, a phenomenon mainly attributed to 
improved baroreflex sensitivity (57). Moreover, our results revealed that age was inversely 
associated with HRR which is in line with some (31;36), but not all studies (28;32) in this field. 
Similar equivocal findings have been found between autonomic function and body composition 
(25;28). The variation in findings of the available studies is probably due to the differences in 
the ANS assessment.  
  
To our knowledge, this is the first study to report an association between global CVD risk 
(FRS) and HRR in RA. The effect size of the associations between global CVD risk and HRR 
were greater than the effect sizes of the associations between individual risk factors and HRR. 
Given that FRS comprises of multiple variables, this association, together with the finding that 
none of the individual risk factors were independently associated with HRR in multivariate 
analyses, suggests that rather than individual risk factors, the overall RA- and CVD related 





In line with cross-sectional and experimental studies in other populations (15;58), disease-
related inflammation was inversely associated with HRR. In RA patients, however, the results 
are equivocal. As recently reviewed, the majority of studies do not find an association between 
inflammation or disease activity and autonomic function in RA, even though there are  
exceptions (10). For example, CRP (36), and leukocytes (35) were reported to be related to 
autonomic dysfunction, but more studies reported no such association (16;20;24;25;34). 
Similar to inflammation, disease activity (DAS28) was found to be associated with autonomic 
function in some (21;31;35), but not all studies (16;20;24;25;32;34). Comparison between the 
different studies is difficult given the different methods used to assess autonomic function (i.e. 
heart rate variability (HRV) (37), pupillary response to light (32), Ewing test (23), and HRR as 
in the current study). When exploring the available studies in more detail, it is worth noting 
that studies that reported no association between autonomic function and inflammation used 
the Ewing test battery as a method of assessment (16), whereas those who did report an 
association measured autonomic function using HRV (36). The Ewing test battery consists of 
five separate assessments with a dichotomized response to each test and the total score is the 
sum of all the responses (59). HRV and HRR in contrast, use continuous heart rate readings to 
derive a measure of autonomic function. Therefore, it could be argued that statistically HRV 
and HRR are more sensitive tests for exploring associations compared to the Ewing test battery. 
However, without making a direct comparison between factors associated with the Ewing test 
battery and HRV or HRR in the same population, this suggestion remains speculative.  
 
The associations between inflammation and HRR1 and HRR2 in the current study were slightly 
different; CRP was associated with HRR1 which is related to parasympathetic reactivation, but 
not HRR2, which is reflective of sympathetic withdrawal (18). Similarly, inducing 
inflammation (e.g. via flu vaccination) reduced HRR1 but not HRR2 in healthy participants 
(15). Interestingly, the evidence for parasympathetic dysfunction is also more evident in RA 
compared to sympathetic dysfunction (10). From a theoretical standpoint, the association 
between inflammation and the parasympathetic nervous system is not unexpected. This could 
be explained via the mechanism of the cholinergic anti-inflammatory pathway, where release 
of inflammatory markers such as tumor necrosis factor-α and interleukin-1 is controlled by the 
vagus nerve which is part of the parasympathetic system (60). However, future research is 





The first two minutes of HRR are the most validated (61) and commonly used method in 
studies, and have been suggested to be a better predictor of mortality and coronary artery 
disease (CAD) (62). The subtle differences in the other factors related with HRR1 and HRR 
could  be again due to the different aspects of ANS which are reflected by HRR1 and HRR2: 
HRR1 is known to represent reactivation of parasympathetic nervous system, whereas, HRR2 
represent reactivation of parasympathetic and withdrawal of sympathetic nervous system (63). 
In the current study, SBP and insulin resistance were significantly associated with HRR2 but 
not HRR1. Interestingly, insulin has been found to have a stimulatory effect on the sympathetic 
nervous system (64), and metabolic risk factors have been more strongly related to HRR2 than 
HRR1 in healthy participants. However, this complex interaction between the two systems in 
controlling post exercise HRR still needs further clarification.  
 
To our knowledge, this is the first study to explore associations between markers of 
psychological wellbeing and autonomic function in RA. This is surprising given that 
psychological factors have been associated with CVD, and autonomic function has been 
implicated as an underlying pathway by which psychological wellbeing contributes to the 
pathogenesis of CVD (65). Indeed, history of anxiety and depression (66), as well as emotional 
stress (67), have been associated with lower parasympathetic activity. In the current study, even 
though no significant relationship was found between either depression or anxiety and HRR, 
vitality and quality of life (EuroQol) were related to HRR. This may suggest that maintaining 
a good quality of life and the perception of feeling energized and capable of doing tasks may 
favor a balanced activity of the ANS.     
 
There are number of limitations in this study. The cross-sectional design does not allow for the 
assessment of causality between variables. The current study did not have a comparison group, 
however, as the aim of the current study was to explore factors associated with parasympathetic 
activity in RA, the focus was specifically on RA patients. Without a control group, a direct 
comparison between parasympathetic activity in RA and other populations is not possible. 
Comparing HRR in this well-controlled cohort of RA patients from this study to HRR reported 
in healthy participants in other studies (68;69), reveal similarities in parasympathetic function. 
Caution should of course be taken when comparing different studies as variations in the 
methods are likely to influence the findings. Therefore, future studies should examine the 
differences between HRR in RA and other populations as well as exploring factors associated 




medication prior to the assessments. As is common in this population, the patients included in 
this study were on a mix of medications, which means that we did not have appropriate 
statistical power to explore the influence of medication on HRR. Further research should 
investigate the potential influence of medications on HRR in patients with RA. The disease 
activity of most of the RA patients involved in this study was well-controlled; therefore, it is 
difficult to generalize these findings to RA patients with higher disease activity. Unfortunately, 
DAS28 data was not available for all participants, therefore, it was not included in the analyses. 
It is possible that patients were not able to exercise to their maximum cardiorespiratory ability 
due to problems with their joints, which could have influenced their HRR (18). However, based 
on respiratory exchange ratios (RER) which reflect the amount of energy metabolized to 
provide energy, we are confident that most of the participants in our study were able to exercise 
until exhaustion. Future research should also explore the association between CVD risk, 
inflammation, and wellbeing with other measures of ANS, such as HRV.  
 
In conclusion, the results of this study showed that CVD risk, disease related inflammation, 
and wellbeing associate with HRR in RA. As there is ample evidence that HRR is related to 
CVD mortality in other populations (17), further research should explore if HRR is also 
predictive of hard CVD endpoints in RA. In addition, given that exercise interventions can 
reduce CVD risk in RA (70), and improve parasympathetic reactivation (71), further research 
should also examine the effects of an exercise intervention on HRR in this population. The 
results of this study suggest that reducing CVD risk in RA is likely to require interventions to 
improve classical CVD risk factors, inflammation, physical fitness, and psychological well-
being. HRR could be used as an overall marker of patients at risk of developing CVD and, 
therefore, can be used as a marker to see whether an intervention is effective in this cohort. 
However, this will need further research to investigate the effectiveness of an intervention 
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Effect of three months exercise training on parasympathetic function– 

















Introduction Cardiovascular disease (CVD) is the leading cause of death in patients with 
rheumatoid arthritis (RA). Poor parasympathetic function has been suggested as a factor 
contributing to the increased risk of CVD in RA. Heart rate recovery (HRR) following maximal 
exercise testing is a non-invasive assessment for parasympathetic function. Exercise has been 
shown to reduce the overall risk for CVD in RA, but the effects on HRR are unknown. 
Therefore, this study aimed to investigate the effect of 3-month exercise programme on HRR 
in patients with RA.  
Methods 97 RA patients enrolled in a 3-month exercise programme consisting of two semi-
supervised sessions and one session at home. Out of 97, 62 RA patients (55.5 ± 12.7 years, 
67.7% women) completed baseline and post intervention assessments including exercise 
tolerance test (ETT). At baseline and post intervention, heart rate recovery (HRR) was 
measured: HRR1 and HHR2 were defined as the absolute change from heart rate (HR) peak 
during ETT to HR 1 minute post HR peak and 2 minutes post HR peak, respectively. 
Cardiorespiratory fitness (VO2 peak), individual CVD risk factors, 10 years CVD risk, 
serological markers of inflammation, and measures of wellbeing were measured at baseline 
and post intervention.   
Results ANOVA revealed no significant changes in HRR1 (p=.31), HRR2 (p=.67), and VO2 
peak (p=.17) after the 3-month exercise training programme. There were significant 
improvements in systolic blood pressure (p=.01), diastolic blood pressure (p=.001), Qrisk2 
(p=.04) and vitality (p=.02) post intervention. Additional analyses revealed that patients who 
improved HRR at both time point post intervention were the ones with poorer HRR as well as 
CVD risk profile at baseline.  
Conclusion Three semi-supervised exercise training sessions per week for three months was 
not sufficient to improve parasympathetic function and cardiorespiratory fitness in patients 









Rheumatoid arthritis (RA) is a chronic systemic inflammatory autoimmune disease which 
affects approximately 1% of the United Kingdome adult population (1). RA impacts on the 
joints of the body, causing pain, stiffness, and swelling of the joints, but can also extend to 
other organs. Cardiovascular disease (CVD) is a common extra articular manifestation of RA, 
which contributes to more than 40% of mortality in RA (2). The mechanisms underlying the 
increased risk for CVD in RA remain to be fully understood, however, several CVD risk factors 
are prevalent in people with RA such as hypertension (3), inflammation (2), dyslipidaemia (4) 
and lack of physical activity (5). These factors do not explain the reason why RA associates 
with increased risk of CVD, as all of these factors may contribute individually and/or 
collectively to increase the risk of CVD in patients with RA. Furthermore, autonomic 
dysfunction (unbalanced activity of the autonomic nervous system) has recently been identified 
recently in a systematic review as a factor to contribute to the development of CVD in RA (6).  
The autonomic nervous system consists of the sympathetic and parasympathetic nervous 
system. These systems work in synergy to regulate and coordinate multiple body functions 
such as maintaining cardiovascular autonomic balance. Autonomic dysfunction occurs when 
this balance is disrupted, which is manifested by increased sympathetic activity and decreased 
parasympathetic activity (7), and this has been recognized as a predictor of CVD and 
cardiovascular mortality (8;9). It is therefore not surprising that autonomic dysfunction is 
prevalent in RA (6;10) and it has been related to the overall cardiovascular and arthritis related 
disease burden (11). Therefore, interventions aimed to reduce CVD risk and disease burden are 
hypothesized to improve autonomic function in patients with RA.   
Exercise is a commonly used behavioural intervention to reduce CVD risk (12). Exercise 
programmes have also been shown to improve autonomic function in clinical populations with 
increased levels of inflammation, such as chronic obstructive pulmonary disease (13), coronary 
artery disease (14), and chronic heart failure (15). Both physical activity (5), which is lower in 
patients with RA compared to the general population (16), and physical fitness (17) have been 
related to CVD risk in RA, and exercise has been shown to be successful in decreasing CVD 
risk in patients with RA (18;19). However, little is known about the effect of exercise on 




A common method to assess autonomic function is heart rate recovery (HRR) which reflects 
parasympathetic activity and can be easily conducted in a clinical setting, as no sophisticated 
equipment or analyses techniques are necessary (20). Following maximal exercise testing, the 
reactivation of the parasympathetic activity is represented by the rapid fall in heart rate (21). 
(22). Two previous studies have shown positive effects of supervised exercise on autonomic 
function using different ways of measurement in a relatively small group of women with RA 
(23;24). However, little is known about the effect of semi-supervised exercise interventions on 
HRR. Given that the costs associated with a semi-supervised exercise programme would be 
less, it is suggested that this would be more feasible to incorporate in the healthcare system. 
Therefore, the primary aim of this study was to investigate the effect of a 3-month semi-
supervised exercise intervention on heart rate recovery one minute post peak heart rate (HRR1), 
heart rate recovery two minutes post peak heart rate HRR2, and cardiorespiratory fitness as 
indicated by the peak volume of oxygen (VO2 peak) during exercise. The Secondary aim was 
to investigate the effect of the exercise intervention on CVD risks, markers of inflammation 
and measures of wellbeing in a sample of men and women with RA. It was hypothesized that 
exercise training will improve the HRR1, HRR2, and VO2 peak, which will be associated with 




Ninety-seven RA patients were recruited from rheumatology outpatient clinics of the Dudley 
Group NHS foundation Trust. All patients met the revised criteria of the American College of 
Rheumatology (25). Patients were recruited to participate in a 3-month exercise intervention 
study (ISRCTN04121489) (26). Patients were assessed before enrolment into exercise 
intervention programme, then re-assessed within 1 month after the completion of the exercise 
programme. Exclusion criteria were joint surgery in the preceding 6 months, fibromyalgia, 
established CVD, current flare of disease activity, comorbidity incompatible with exercise as 
per American College of Sports Medicine (ACSM) guidelines (27). Ethical approval was 
obtained from the appropriate National Research Ethics Service and all patients provided 






The exercise intervention was conducted at two separate exercise centres in close vicinity of 
the hospital and with comparable equipment (Action Heart and Dudley Leisure Centre). The 
instructors of both centres received training related to RA and the exercise programme. All 
patients received the same exercise programme; however, those who exercised in Action Heart 
also received personal consultations. As the primary aim of this study is to investigate the effect 
of effect of a 3-month semi-supervised exercise intervention on HRR, data for the participants 
was treated as one group.   
The exercise programme started with an induction session to familiarise the patient with the 
equipment and exercises. Following this, the patient started the 3-month exercise programme 
in a semi-supervised setting, with instructors available when needed. The 3-month 
individualized exercise programme was based on the baseline assessment of the 
cardiorespiratory fitness, and all available equipment (e.g., treadmill, cycle ergometer, hand 
ergometer, rowing machine) were used based on patient’s preference and abilities. The total 
duration of each exercise session was 55 minutes which included 10 minutes’ warm-up, 30-40 
minutes’ main session, and 5-10 minutes cooling down. The intensity of exercise was 
monitored by the patients using a heart rate monitor, and patients were asked to exercise at a 
heart rate corresponding to 70% of VO2 peak for a minimum of 30 minutes during each exercise 
session. The frequency of exercise sessions was three per week, two sessions were conducted 
in a semi-supervised setting within the centres and patients were encouraged to complete one 
session in non-supervised setting (e.g., patient’s home). Attendance to the exercise programme 
was monitored throughout the three months.  
 
Assessment Protocol 
All patients were assessed before starting the intervention and upon completion of the exercise 
programme. The assessment protocol was the same for both time points, and included two 
separate visits to the laboratory, at least 1 week apart. During the first visit, a fasted blood 
sample was taken and questionnaires were given to the patients to complete at home. During 
the second visit, blood pressure was measured using electronic sphygmomanometer on the arm 
(Datascope Accutor, Mahwah, NJ, USA). Height was measured to the nearest 0.5cm using a 
standard height measure (Seca 214 Road Rod), weight and BMI were measured using a Tanita 




the patient was fitted with the appropriate equipment, the patient sat quietly for two minutes, 
which was followed by the exercise tolerance test and a post exercise recovery period in a 
sitting position. Heart rate was recorded throughout these periods.    
 
Exercise tolerance test 
Before commencing exercise tolerance test, the patient was fitted with an appropriate size mask 
for the purpose of inspired and expired gas analyses, and 12 leads electrocardiography (ECG) 
(12-channel ECG custo cardio 200, custo med, Liepzig, Germany) were attached. To measure 
cardiorespiratory fitness, treadmill exercise testing was performed on all patients (HP Cosmos 
Mercury, Nussdoerf-Traunstien, Germany). An individualized ramp protocol test was used 
which was modified according to the patient’s fitness and physical abilities (28). For the 
purpose of familiarization, two minutes warm up was used which also informed the initial 
speed of the test. The starting speed was set based on the patient’s preference typically 
(approximately 3 mph) and 0% inclination. Thereafter, speed was gradually increased to the 
level of maximum brisk walking based on each patient’s ability. Following the two minutes 
warming up, the test started. During the test, speed was kept constant (at maximum brisk 
walking) whereas the inclination was set up to increase by 1% every minute. To calculate peak 
oxygen consumption (VO2 peak) throughout the exercise test, breath by breath gas analyses 
were recorded (Metalyzer 3B, Cortex, Liepzig, Germany). ECG was recorded throughout the 
exercise task and recovery period. The test was terminated when patients reached volitional 
exhaustion, or any of the relative or absolute contraindications of ACSM’s guidelines (27) were 
met. Following termination of the test, patients were asked to rest on a chair for the minimum 
of six minutes’ recovery while blood pressure was measured every two minutes. The test was 
supervised by a cardiac physiologist and an exercise physiologist. 
 
Outcome measures 
Heart rate recovery 
HRR was measured at two time points: at one minute and two minutes following cessation of 
exercise. Heart rate recovery one minute (HRR1) was defined as the difference between peak 
heart rate and heart rate one minute post peak heart rate (HRR1 = peak heart rate – heart rate 




defined as the difference between peak heart rate and heart rate two minute post peak heart rate 
(HRR2 = peak heart rate – heart rate at two minutes post peak heart rate). Peak heart rate was 
defined as the maximum heart rate during the exercise test.  
 
VO2 Peak 
Maximal aerobic capacity was determined using maximal oxygen uptake (VO2 peak) which 
was measured via a calibrated breath by breath gas analyzer. The inspired and expired gases 
data from the analyser were averaged every two seconds. These data were smoothened by 
taking the average of VO2 every 28 seconds (taking the average of 14 readings of VO2 ml·min
-





Blood samples were analyzed for total cholesterol, high density lipoprotein (HDL), low density 
lipoprotein (LDL), and triglycerides. To assess insulin resistance, Homeostasis models 
assessment (HOMA) was utilized (29). Erythrocyte sedimentation rate (ESR), high sensitivity 
C-reactive protein (hsCRP), fibrinogen, and white blood cells (WBC) were assessed and 
categorized as markers of inflammation. Analyses were carried out using routine laboratory 
procedures in the hospital laboratory.  
 
Global cardiovascular risk 
Two global cardiovascular risk scores were used to measure the probability of developing 
cardiovascular events within 10 years period: Framingham risk score (FRS) (30), and Qrisk2 
(31). FRS, and Qrisk2 scores were calculated via entering the data online into the main website 






Measures of wellbeing  
Multiple assessments were used to subjectively assess functional ability, psychological and 
general wellbeing; including hospital anxiety and depression scale (HADS) (high score is 
indicative of worse anxiety or depressive symptoms) (32), subjective vitality scale (high score 
is indicative of better vitality) (33), multidimensional assessment of fatigue (MAF) (high scores 
is indicative of greater level of fatigue) (34) and the European quality of life questionnaire 
(EuroQol) (low scores is indicative of poor quality of life) (35).  
 
Statistical analyses 
Statistical analysis was performed using SPSS22 (Chicago, IL, USA). Normality of variables 
was tested using Kolmogorov-Smirnov test. All normally distributed variables were presented 
as mean and standard deviation. Non-normally distributed variables (BMI, triglycerides, HDL, 
LDL, HOMA, FRS, hsCRP, ESR, vitality, HADS Anxiety, HADS Depression, global fatigue 
index, and EuroQol) were used after log-transformation and were presented as median and 
interquartile range. As patients exercised in two separate locations, two groups (Action Heart, 
Dudley Leisure Centre) by two time (baseline, 3-months) repeated measures analyses of 
variance were conducted to explore group differences in the responses to the exercise 
intervention. As no group differences were evident for any of the outcome measures, data is 
presented for all patients as one group. Differences in variables between baseline and post 
exercise intervention were evaluated using two time (baseline, post intervention) ANOVAs. 
Pearsons moment correlation was used to assess the relationship between attendance and HRR, 
as well as the relationship between changes in HRR and changes in other variables. In order to 
explore the potential influence of age on the effects of the exercise, Pearsons moment 
correlational analyses were conducted. ANOVAs were used to explore the difference in means 
of outcome measures between males and females. Given the aim of the study to explore the 
factors contributing to changes in autonomic function, further analyses were conducted to 
compare those patients who showed an improvement in autonomic function and those who did 
not show such improvement. Two group (improver, non-improver) ANOVAs were conducted 
to explore differences in baseline between improvers and non-improvers in HRR1 and HRR2. 





Ninety-seven patients completed baseline ETT and 62 completed the second ETT assessment 
after the 3-month exercise programme. No differences in baseline variables were found 
between those who completed the second assessment (N = 62) and those who did not (N = 35) 
(data no reported). The most common reasons for drop out were medical reasons and being 
unable to contact for follow up assessment as indicated in Figure 1. Baseline characteristics of 
the 62 patients (42 female, mean age 55.5 ± 12.7 years) included in these analyses are reported 
in Table 1. Patients continued their course of treatment throughout the duration of the study. 
The average number of attended exercise sessions in the exercise facility was 13.4 ± 8.5 out of 
24 (55.8 % attendance). Unfortunately, due to some practical complications, it was not possible 
to obtain full information about adherence and compliance to the exercise programme from the 
participants.   
 
Figure 2. Flow diagram of the rheumatoid arthritis patients of the study  
 
Table 1. Characteristics of rheumatoid arthritis patients at baseline and post intervention 
 Variable  Baseline Post  intervention P value 
Cardiovascular risk factors    
 Weight (kg) 77.7 ± 16.3 78.4 ± 16.9 .60 
 BMI (kg·m-2) 27.5 ± 4.9  26.7 (24.4 – 31.2) .45 
 Resting SBP (mmHg)  133 ± 17 128 ± 15 .01 
Completed baseline assessment N = 97
Included 
N = 62 completed baseline and post 
intervention assessment
Dropped out N = 35
N = 13 Medical reasons (e.g., high blood pressure, 
heart irregularities)
N = 3 unable to schedule for assessment due to 
other time commitments
N = 15 unable to contact at follow up




 Resting DBP (mmHg) 81 ± 10 78 ± 9.0 .001 
 Total Cholesterol (mmol.L-
1) 5.1 ± 1.0 4.9 ± 1.0 .16 
 Triglycerides (mmol·L-1) 1.1 (0.8 – 1.4) 1.00 (0.8 – 1.5) .83 
 HDL (mmol·L-1) 1.3 (1.1 – 1.) 1.4 ± 0.4 .69 
 LDL (mmol·L-1) 3.1 ± 0.8 3.0 ± 0.8 .50 
 HOMA 1.46 (1.1 – 2.1) 1.49 (1.1 – 2.3) .09 
 Framingham Risk score 3.0 (1.0 – 8.5) 2.0 (1.0 –  6.8) .51 
 Qrisk2 16.9 ± 13.6 15.1 ± 13.1 .04 
Inflammatory markers    
 WBC (109·L-1) 6.4 ± 2.3 6.2 ± 2.1 .33 
 Fibrinogen (g·L-1)  4.6 ± 0.8 4.6 ± 0.9 .84 
 hsCRP  (mg·L-1) 3.8 (1.5 – 8.4) 3.8 (1.1 – 7.5) .36 
 ESR (mm·hr-1)  10.5 (5.0 – 21.0) 12.0 (5.0 – 19.5) .48 
Wellbeing     
 Vitality 4.0 (2.6 – 5.9) 4.8 (3.4 – 5.6) .02 
 HADS anxiety 7.0 (5.0 – 10.0) 6.0 (3.3 –  8.0) .15 
 HADS depression 4.0 (2.0 – 7.0) 3.3 (2.0 – 5.8) .09 
 Global Fatigue 27.4 ± 10.8 24.2 (15.0 – 35.1)      .41 
 EuroQol 0.7 (0.6 – 0.8) 0.7 (0.6 – 0.8) .08 
Values are presented as means ± standard deviation, or median (25th to 75th percentile values) as appropriate. BMI, body mass index; SBP, 
systolic blood pressure; DBP, diastolic blood pressure; HDL, high density lipoprotein; LDL, low density lipoprotein; Qrisk, is an algorithm 
used to predict 10 years’ probability of cardiovascular diseases; WBC, white blood cells; HsCRP, high sensitivity C-reactive protein; ESR, 
erythrocyte sedimentation rate; HOMA, homeostasis model assessment insulin resistance. HADS, hospital anxiety and depression scale 
EuroQol, European assessment for quality of life. P in bold indicate statistical significance.  
 
 
Table 2. Heart rate recovery and VO2 peak at baseline and post intervention. 
Variable  Baseline Post intervention P value 
Outcome measures    
 HRR1 (bpm) 29.6 ± 11.4 27.8 ± 10.1 .31 
 HRR2 (bpm) 48.8 ± 12.1 49.4 ± 11.5 .67 
 VO2 peak (ml·kg-1·min-1 ) 21.3 ± 4.5 21.7 ± 4.4 .17 
Values are presented as means ± standard deviation. HRR1, the difference between HR peak and heart rate 1 minute post HR peak; HRR2, 
the difference between HR peak and heart rate 2 minute post HR peak. VO2 peak, highest volume of oxygen. 
 
Effects of Exercise on HRR and VO2  
HRR at baseline and post intervention are presented in Table 2. Results revealed no increase 
in HRR1 (F (1, 52) = 1.04, p = .31), HRR2 (F (1, 49) = .18, p = .67) and VO2 (F (1, 54) = 1.93, 






Effects of exercise on CVD risk, inflammation, and measures of wellbeing 
Baseline and post intervention values of the CVD risk factors, markers of inflammation and 
wellbeing are displayed in Table 1. Only SBP (F (1, 53) = 6.96, p = .01), DBP (F (1, 54) = 
11.47, p = .001), and Qrisk2 (F (1, 51) = 4.52, p = .04) were significantly lower, and subjective 
vitality higher (F (1, 51) = 5.66, p = .02) post intervention compared to baseline.  
Given that the aim of the study was to explore the effects of exercise on autonomic function 
and factors related to these changes, subsequent analyses were conducted to explore if there 
were differences at baseline between those who improved HRR following exercise (N=24 for 
HRR1, N=25 for HRR2) and those who did not (N=29 for HRR1, N=24 for HRR2). There was 
no difference in attendance between those who improved HRR and those who did not. As can 
be seen from Table 3 (HRR1) and Table 4 (HRR2), those who showed an improvement in 
HRR1 and HRR2 after the intervention had poorer baseline HRR than non-improvers. 
Additionally, patients who improved HRR1 had significantly lower HDL (F (51) = 6.97, p = 
.011), higher FRS (F (50) = 12.92, p = .001) and Qrisk2 scores (F (49) = 4.48, p = .039). Those 
who showed an improvement in HRR2, only had significantly higher resting DBP (F (47) = 
5.54, p = .02).  
 
Factors associated with heart rate recovery  
Given the individual differences in changes in HRR1 and HRR2 after exercise intervention, 
further analyses were conducted to explore if changes in HRR were related to changes in other 
outcome measures. These analyses yielded no significant correlation between attendance and 
HRR1 or HRR2. Correlation analyses between changes in HRR1 and HRR2 and changes in 
other variables revealed no significant associations (data not reported). Additional analyses 
revealed no difference between males and females in changes from baseline to post intervention 
in any outcome measure (data not reported). Correlation analyses between age and change in 
scores revealed that age was positively associated with the difference in anxiety and fatigue (r 
(50) = .35, p = .01, and r (38) = .33, p = .04, respectively), and was inversely associated with 
change in scores in vitality and Qrisk2 (r (52) = -.29, p = .03, and r (52) = -.29, p = .04, 





Table 3. Baseline characteristics of those who improved and those who did not improve 
HRR1 
Variable  Improvers (N=24) Non-improvers (N=29)  P value  
Cardiovascular risk factors    
HRR1 (bpm) 22.3 ± 8.7 35.7 ± 9.6 <.001 
HRR2 (bpm) 41.0 ± 9.8 55.0 ± 10.1 <.001 
VO2 peak (ml·kg
-1·min-1 ) 21.1 ± 3.9 21.7 ± 5.0 .59 
Age (years) 58.7 ± 11.0 51.3 ± 13.4 
.04 
Resting SBP (mmHg) 134 ± 18 133 ± 17 .76 
Resting DBP (mmHg) 82 ± 8 80 ± 11 .58 
BMI (kg·m2) 27.3 ± 4.6  26.7 ± 4.7 .67 
Total Cholesterol (mmol·L-1) 5.1 ± 1.2 5.0 ± 0.9 .78 
Triglycerides (mmol·L-1) 1.2 (0.8 – 1.7) 1.0 ± 0.5 .06 
HDL (mmol·L-1) 1.2 (1.1 – 1.5) 1.5 ± 0.3 .01 
LDL (mmol·L-1) 3.2 ± 1.0 3.1 ± 0.7 .71 
HOMA 1.5 (1.1 – 2.3) 1.4 (0.9 – 1.9) .27 
Framingham risk score 5.5 (2.3 – 13.5) 1 (1.0 – 3.0) .001 
Qrisk2 20.6 ± 13.9 6.7 (3.3 – 24.7) .04 
Inflammatory markers    
WBC (109·L-1) 6.7 ± 2.1 5.8 ± 2.2 .14 
Fibrinogen (g·L-1) 4.6 ± 0.9 4.5 ± 0.8 .66 
hsCRP (mg·L-1) 5.0 ± 4.2 3.6 (1.2 – 6.7) .58 
ESR (mm·hr-1) 9.0 (5.0 – 15.0) 10.0 (5.5 – 15.8) .76 
Wellbeing    
Vitality 4.0 (2.6 – 6.0) 4.1 ± 1.5 .83 
HADS Anxiety 6.9 ± 3.8 8.1 ± 3.9 .28 
HADS Depression 5.9 ± 4.1 4.3 ± 2.6 .29 
Global fatigue index 25.7 ± 11.8 29.5 ± 10.5 .19 
EuroQol 0.7 ± 0.2  0.7 (0.6 – 0.8) .72 
Values are presented as means ± standard deviation, or median (25th to 75th percentile values) as appropriate. HRR1, the difference between 
HR peak and heart rate 1 minute post HR peak; HRR2, the difference between HR peak and heart rate 2 minute post HR peak.. VO2 peak, 
highest volume of oxygen,; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; HDL, high density 
lipoprotein; LDL, low density lipoprotein; HOMA, homeostasis model assessment insulin resistance; Qrisk2, is an algorithm used to predict 
10 years probability of cardiovascular diseases ;WBC, white blood cells; HsCRP, high sensitivity C-reactive protein; ESR, erythrocyte 
sedimentation rate;. HADS, hospital anxiety and depression scale EuroQol, European assessment for quality of life. P in bold indicate 
statistical significance. 
 
Table 4. Baseline characteristics of those who improved and those who did not improve 
HRR2 
Variable  Improvers (N=25)  Non-improvers (N=24) P value  
Cardiovascular risk factors    
HRR1 (bpm) 26.4 ± 12.3 33.6 ± 9.9 .03 
HRR2 (bpm) 43.9 ± 11.3 53.8 ± 11.1 .003 
VO2 peak (ml·kg




Age (years) 56.2 ± 10.6 52.3 ± 15.0 .30 
Resting SBP (mmHg) 132 ± 17 133 ± 17 .81 
Resting DBP (mmHg) 84 ± 10 77 ± 9 .02 
BMI (kg·m-2) 26.7 ± 4.8 27.5 ± 4.8 .58 
Total Cholesterol 
(mmol·L-1) 
5.2 ± 1.2 4.9 ± 0.9 .44 
Triglycerides (mmol·L-1) 1.0 (0.8 – 1.4) 1.1 (0.6 – 1.3) .47 
HDL (mmol·L-1) 1.4 ± 0.3 1.5 ± 0.3 .30 
LDL(mmol·L-1) 3.3 ± 1.0 3.0 ± 0.7 .34 
HOMA 1.0 (0.9 – 2.0) 1.4 (1.1 – 2.2) .98 
Framingham risk score 3.5 (1.0 – 11.5) 1.0 (1.0 – 4.0) .06 
Qrisk2 16.3 ± 11.2 7.9 (1.6 – 24.9) .70 
Inflammatory markers    
WBC (109·L-1) 6.1 ± 2.2 6.1 ± 2.1 .99 
Fibrinogen (g·L-1) 4.4 ± 0.9 4.6 ± 0.9 .37 
hsCRP (mg·L-1) 3.0 (1.2 – 6.3) 3.6 (1.2 – 7.9) .77 
ESR (mm·hr-1) 9 (2.0 – 13.0) 11 (7.0 – 21.0) .19 
Wellbeing    
Vitality 4.2 ± 1.6 4.1 ± 1.4 .93 
HADs A 7.3 ± 4.1 7.7 ± 3.8  .63 
HADS D 4 (2.0 – 9.0) 4.5 ± 3.0 .97 
Global fatigue index 24.6 ± 12.1 29.8 ± 9.5 .07 
EuroqOol 0.7 (0.5 – 0.8) 0.7 (0.6 – 0.8) .51 
Values are presented as means ± standard deviation, or median (25th to 75th percentile values) as appropriate. HRR1, the difference between 
HR peak and heart rate 1 minute post HR peak; HRR2, the difference between HR peak and heart rate 2 minute post HR peak.. VO2 peak, 
highest volume of oxygen,; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; HDL, high density 
lipoprotein; LDL, low density lipoprotein; HOMA, homeostasis model assessment insulin resistance; Qrisk2, is an algorithm used to predict 
10 years probability of cardiovascular diseases ;WBC, white blood cells; HsCRP, high sensitivity C-reactive protein; ESR, erythrocyte 




This study explored the effect of a 3-month semi-supervised exercise intervention on 
parasympathetic function in patients with RA, using HRR as a measure of parasympathetic 
activity. HRR and VO2 peak did not improve after the exercise intervention. The exercise 
intervention did not influence the majority of the CVD risk factors, or measures of wellbeing, 
except for blood pressure, Qrisk2, and vitality, which were all improved post intervention. 
None of the inflammatory markers were changed by the exercise intervention. Additional 
analyses revealed that those who improved HRR, had lower baseline HRR, HDL, global CVD 
risk, resting diastolic blood pressure and were older.       
To our knowledge, only two studies investigated the effects of exercise training on autonomic 




improvement in HRR1 (24) and three months of moderate intensity exercise induced an 
improvement in heart rate variability (HRV) (23). There are notable differences between these 
studies and the current one which could perhaps explain the different findings. Previous studies 
used a supervised exercise setting in a relatively smaller sample of women with RA (23;24), 
whereas, the current study employed a semi-supervised setting in a larger group of men and 
women with RA. There have also been variations in the intensity of the exercise programme, 
with a decrease in HRR seen following a high-intensity programme (24), which is in line with 
the suggestion that the intensity of exercise during an intervention may influence HRR 
improvements (36). It is noteworthy to mention that an improvement in VO2 peak was gained 
in Sandstad et al study (24), whereas, in the current study no improvement in VO2 was found. 
Even though not confirmed in all studies (37), the positive effects of exercise training on 
autonomic function are commonly found to be accompanied with an improvement in fitness in 
other clinical populations such as patients with congestive heart failure (38) and patients with 
coronary artery disease (39). In patients with RA, a previous study found a significant 
improvement in VO2 peak and many CVD risks, and disease related risk factors after six 
months individualized aerobic and resistance high intensity exercise training (40). More 
importantly, it was found that the change in VO2 was the strongest predictor for improvement 
in the assessed CVD risk factors, and disease related risk factors. Thus, it can be speculated 
that the differences between the programmes in patients with RA with regards to intensity and 
compliance to the intensity, and the level of supervision (supervised and semi-supervised) have 
contributed to the lack of improvements in VO2 peak, which on its turn resulted in a lack of 
improvement in HRR. It is important to note that prescribed exercise intensity in the current 
study was the same as a previous exercise study in patients with RA (40). However, there were 
notable differences between the level of supervision in the current study and the previous study.  
In the previous study, all participants had two exercise instructors who were dedicated to the 
project. In the current study, participants were supervised in a community-based leisure centre.  
It is likely that this difference in supervision and attention, has had an impact on the compliance 
with the exercise programme.  However, without data regarding adherence and compliance, 
this remains speculative. 
It is not just the exercise programme which is different between the current study and the 
previous work, there are also differences in the patient characteristics which could contribute 
the different findings. Apart from the inclusion of males, the most obvious difference is the age 




compared to the previous studies (46.81 ± 9.23 years) (23) and (32.4 ± 8.3 years) (24). The 
associations between age and the effectiveness of the intervention are interesting. Those who 
showed an improvement in HRR were older, but age was also related to attenuated benefits in 
anxiety, fatigue, vitality and global CVD risk. Therefore, the associations between age and the 
effects of an exercise programme warrant further examination.  
Additional analyses comparing improvers and non-improvers in HRR revealed baseline 
differences between the two groups, i.e. poorer HRR, lower HDL, higher FRS, Qrisk2, and 
blood pressure. This could indicate that those with poorer parasympathetic function and CVD 
risk at baseline are more likely to benefit from the exercise intervention. In concordance with 
the current study, Yayali et al. (41), reported improvement in HRR1 only in patients with poor 
abnormal baseline HRR (<12 bpm). It is also worth noting that baseline HRR in the current 
population was similar to that reported in healthy populations (42;43). This may suggest that 
patients with poorer clinical characteristics could benefit more from therapeutic interventions.  
The exercise programme was successful in improving blood pressure, which is in line with 
healthy normotensive, hypertensive (44) and clinical populations (45), as well as patients with 
RA (40). Hypertension is common in RA and has been implicated as a factor contributing to 
the increased risk for CVD (3). Therefore, interventions which can reduce blood pressure are 
needed. In a population who already takes a mix of medications, a behavioral intervention like 
exercise could be an appealing alternative to treating high blood pressure. A possible 
mechanism underlying reduction of blood pressure post exercise training is through decreased 
total peripheral resistance of the vascular system, which is mediated by a reduction in both 
sympathetic nervous system and renin-angiotensin II production (46). Future studies are 
needed to tests these hypotheses.   
The current study explored the effect of exercise intervention on two CVD risk algorithms 
(FRS and Qrisk2) in patients with RA, and only Qrisk2 was significantly improved after the 
exercise intervention. Both of these algorithms predict the 10 year probability of CVD events, 
and both incorporate age, sex as well as individual CVD risk factors like blood pressure, 
smoking, cholesterol, and HDL levels. Qrisk2 also incorporates other comorbidities such as 
diabetes, history of angina in relatives, chronic kidney diseases, atrial fibrillation, and RA in 
the calculation of global CVD risk. Thus, it can be argued that Qrisk2 is more suitable as a tool 
of measuring the risk of CVD in RA. Surprisingly, to our knowledge, no study has explored 




reported after exercise training in other clinical populations (47), but not in all studies (48). The 
current study suggests that the use of CVD risk algorithm, in particular Qrisk2, may be a useful 
tool to assess the impact of an intervention on reduction of CVD risk in patients with RA.  
As expected, the exercise intervention caused an improvement in subjective vitality. Vitality 
has been consistently reported to improve after exercise training in people with medical 
conditions (49) and in cancer patients (50;51). The current study suggests that an exercise 
programme can impact on positive psychological wellbeing, even without inducing a 
significant increase in cardiorespiratory fitness.  
The current study is not without limitations. The power calculation for the study was done for 
the main outcome of the initial study which is VO2 peak, therefore, it is unknown whether the 
sample was adequate to investigate HRR. Another limitation is the absence of a control or a 
comparison group. However, given the known benefits of exercise, it was deemed unethical to 
have a no-exercise control group. It should also be acknowledged that our sample consisted of 
well-controlled RA patients, which makes it difficult to generalize the results of this study to 
RA patients with more severe disease activity. Unfortunately, this limitation is not restricted to 
this exercise intervention, as with many exercise intervention, only those participants with 
controlled disease activity tend to participate. Therefore, it would be interesting to explore 
suitable programmes for patients with more disease activity. Furthermore, DAS28 was not 
available for all the participants, therefore, it was not included in the analyses to investigate the 
effect of the exercise intervention on DAS28.     
In conclusion, the results of this study showed that a 3-month exercise programme was not 
sufficient to produce positive changes on parasympathetic activity in patients with RA, but did 
improve blood pressure and subjective vitality. Given the differences in the characteristics 
between those who improved and those who did not improve, future research should explore 
the impact of these factors on the effectiveness of an intervention to improve autonomic 
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Inflammation and parasympathetic activity: a comparison between 
















Introduction Rheumatoid arthritis (RA) and diabetes mellitus (DM) share relatively similar 
risk factors that may contribute to increased risk of cardiovascular disease (CVD), but differ 
with regards to the levels of inflammation. Autonomic dysfunction implicated by increased 
sympathetic activity and reduced parasympathetic activity contribute to the risk of CVD. Poor 
parasympathetic activity, measured by heart rate recovery (HRR) associates with CVD. Given 
that inflammation contribute to the development of CVD and it associates with 
parasympathetic activity, the aim of this study was to compare parasympathetic activity using 
HRR in RA and DM.  
Methods 26 DM patients (60.8 ± 10.4 years, 38.5% female) were matched 1:2 for age and sex 
with 46 RA patients (59.8 ± 9.6 years, 39.5% female) who completed a treadmill exercise 
tolerance test (ETT), during which heart rate (HR) was monitored. The parasympathetic 
function was measured at one minute post peak exercise (HHR1) and two minutes post peak 
exercise (HHR2). Parasympathetic activity (HRR), cardiorespiratory fitness (VO2 peak), 
markers of inflammation, CVD risk factors, 10 years CVD risk (Qrisk2), and measures of 
wellbeing (via questionnaires), were compared between RA and DM patients.   
Results ANOVA revealed no differences in HRR1 (p=.79), HRR2 (p=.83), and in any of the 
inflammatory markers (p’s>.05) between RA and DM patients. Total cholesterol (p=.05) and 
high density lipoprotein (p=.02) were higher in RA, whereas, weight (p=.04), BMI (p=.001), 
HOMA (p=.001), and overall CVD risk measured by Qrisk (p<.001) were significantly higher 
in DM patients. Patients with RA reported lower levels of wellbeing including vitality (p=.005), 
and quality of life (p<.001), and higher depression (p=.02), and greater fatigue (p<.001). With 
the two groups combined, multivariate linear regression revealed that VO2 peak was an 
independent predictor for HRR1 and HRR2.  
Conclusion Although, parasympathetic activity and inflammatory markers were similar 
between RA and DM patients, DM patients had some higher CVD risks factors, whereas, RA 
patients had poorer measures of wellbeing. Cardiorespiratory fitness was an important factor 








Rheumatoid arthritis (RA) is a chronic autoimmune disease characterised by increased 
systemic inflammation (1). There is increasing evidence that patients with RA are at risk of 
developing CVD, with more than 40% of patients dying due to CVD (2-4). The reason for this 
increased CVD risk is currently unknown. Several CVD risk factor, such as hypertension (5), 
dyslipidaemia (6), lack of physical activity (7), low cardiorespiratory fitness (8), and systemic 
inflammation (9) are prevalent in patients with RA and are likely to contribute to the increased 
risk for CVD mortality. More recently, autonomic dysfunction, which is another potential CVD 
risk factor, has been shown to be prevalent in RA patients (10). 
Diabetes mellitus (DM) is a metabolic disorder characterized by elevated levels of blood 
glucose (hyperglycaemia) and disturbances of fat, protein and carbohydrate metabolism (11). 
Patients with DM have an increased risk of CVD (12), which accounts for 60% of deaths in 
this population (13). Similar to RA, a cluster of CVD risk factors including hypertension, 
insulin resistance, dyslipidaemia, and obesity (14) are prevalent in patients with DM. 
Interestingly, low grade inflammation was found to be involved in the pathogenesis of DM 
(15), which indicate presence of subclinical inflammation in this population. In addition, 
autonomic dysfunction, which is associated with inflammation in patients with DM (16), is 
also prevalent and contribute to the increased risk of CVD in this population (17;18).  
Autonomic nervous system (ANS) is part of the central nervous system. ANS consist of two 
branches, the sympathetic nervous system and the parasympathetic nervous system, which play 
a major role in regulatory processes amongst multiple physiological systems (19). For example, 
there is ample evidence that ANS can mediate the interaction between the brain and the immune 
system (19-21). The activity of both the sympathetic and the parasympathetic nervous system 
is influenced by levels of inflammatory cytokines, such as interleukin-1, interleukin-6, and 
tumour necrosis factor-α in the blood (19). In the case of chronic inflammation, there is constant 
increased activity of the sympathetic nervous system with inadequate regulation of the immune 
cells (22). Autonomic dysfunction is implicated when there is increased activity of the 
sympathetic and less activity from the parasympathetic nervous system. Inflammation 
associates with autonomic dysfunction not only in conditions with chronic inflammation such 
as RA (23) or patients with diabetes mellitus (DM) (24) but also in healthy population (25). In 
patients with RA, an inverse association has been identified between various inflammatory 




There are many non-invasive methods to assess autonomic function. Heart rate recovery (HRR) 
following an exercise tolerance test (ETT) is a method to assess parasympathetic activity that 
can be easily incorporated in clinical practice. The parasympathetic activity is represented by 
the immediate fall in heart rate following an ETT (27). Epidemiological studies have shown 
that HRR strongly associates with CVD and all-cause mortality (27;28). HRR measured after 
one (HRR1) or two minutes (HRR2) post ETT are the most validated and commonly used in 
research (29), with HRR1 reflecting parasympathetic reactivation and HRR2 reflecting further 
parasympathetic reactivation as well as sympathetic withdrawal (30).   
We have shown that parasympathetic activity using HRR in patients with RA was associated 
with the overall burden of inflammation, CVD risk factors, and wellbeing (26). To explore 
more specific associations of inflammation with parasympathetic activity, it would be 
interesting to compare two groups who are similar with regards to CVD risk profile, but 
differ with regards to inflammation. This allows for an examination of the additional impact 
of inflammation on the parasympathetic activity. The majority of CVD risk factors are 
relatively similar between patients with RA and patients with DM including systolic and 
diastolic blood pressure, however, some factors are different including BMI, total cholesterol 
and the level of inflammation which is higher in RA (31;32). Although, autonomic 
dysfunction is prevalent in RA patients (33 to 86%) (10) as well as in DM patients (20 to 
80%) (33) and contributes to increased CVD risk in both populations, to our knowledge, only 
one  study has compared autonomic function between these populations. This study 
compared autonomic function using cardiovascular reflex tests (e.g. orthostatic stress test, 
valsalva manoeuvre, and deep breathing) in females of 34 RA, 76 DM ( including both type 1 
and type 2), and 67 healthy controls  (34). This study revealed that responses in valsalva 
manoeuvre and deep breathing test (both tests reflect the activity of the parasympathetic 
nervous system) were significantly poorer in the DM group more than in the RA group. 
Unfortunately, in thisstudy, no information was provided about the impact of inflammation 
on these findings. Therefore, the main aim of this study was to compare parasympathetic 
activity using HRR following an exercise tolerance in patients with RA with age- and sex-
matched patients with type 2 DM/pre-diabetes. A second aim was to compare inflammatory 
markers as well as other CVD risk factors and measures of wellbeing between these two 
groups. A third aim was to investigate the factors associated with parasympathetic activity in 




differences in inflammation. It was hypothesized that HRR will be poorer in patients with RA 
and inflammation will be higher in RA patients.    
 
Methods 
Study population  
Twenty-six patients with type 2 DM (HbA1C > or = 48 mmol·mol-1, and fasting glucose > 7.0 
mmol) or pre-diabetes (HbA1C 42-47 mmol·mol-1 or fasting glucose 6.1-7.0) recruited from 
diabetes educational classes at Brierley Hill Health and Social Care Centre, Dudley, UK. The 
26 DM patients were matched in 1:2 ratio for age (within five years range) and sex with 46 
patients with RA (meeting the revised American College of Rheumatology criteria (35)) from 
an existing cohort of RA patients (N=97). Patients in this cohort were recruited from 
Rheumatology outpatient clinics of the Dudley Group NHS Foundation Trust and they were 
on stable medications as they were about to participate in an exercise intervention study (Trial 
registration number: ISRCTN04121489). The data presented in this chapter relate to the 
baseline assessment of this cohort. Patients with a comorbidity incompatible with exercise as 
per American College of Sports Medicine (ACSM) guidelines (36), atrial fibrillation, current 
flare of disease in RA,  and established CVD were excluded. Established DM for RA patients 
and established RA with DM patients were additional exclusion criteria. The study was 
approved by National Research Ethics Committee (IRA ID: 169234, Ref: 15/EM/0138) and all 
patients provided written informed consent prior to participation.  
 
Protocol   
Participants were invited to visit the research laboratory on two different occasions. During 
visit one, height was measured to the nearest 0.5 cm using a standard height measure (Seca 214 
Road Rod), weight and BMI were measured using a Tanita BC 418 MA Segmental Body 
Composition Analyser (Tanita Corporation, Tokyo, Japan), brachial blood pressure was taken 
using electronic sphygmomanometer (Datascope Accutor, Mahwah, NJ, USA) while the 
patient was seated a fasted blood sample was taken. On the second visit, both patient groups 
(RA and DM/pre-diabetes) undertook an exercise tolerance test following the same protocol. 
An appropriate mask was fitted to the patient covering the nose and mouth for analysis of 




Germany) electrodes were attached. Two minutes’ baseline measurement was used to measure 
resting heart rate and O2 consumption while seated, followed by an exercise tolerance test 
(ETT), and six minutes’ post ETT recovery period.   
 
Exercise Tolerance Test (ETT) 
Before commencing ETT, a mask was fitted and 12 leads ECG were attached to the patient. 
ETT was performed on a treadmill (HP Cosmos Mercury, Nussdoerf-Traunstien, Germany). A 
minimum of two minutes was given to the patient for familiarization purposes before 
commencing the individualized ramp protocol test, which was modified according to the 
patient’s fitness and physical abilities (37); an approach that we have previously used in RA 
patients (38). During this familiarization period, the speed was set at the patient’s preference 
(approximately three mph) with 0% inclination for two minutes. Thereafter, the speed of 
treadmill was increased up to the level of maximum brisk walking based on patient’s ability. 
Then, the speed was set to be constant (maximum brisk walking) throughout the test, while 
increasing the inclination by 1% every minute. Peak oxygen consumption (VO2 peak) was 
calculated using breath by breath gas analyses (Metalyzer 3B, Cortex, Liepzig, Germany). 
Heart rate was recorded before the commencement, throughout the ETT and during recovery 
period using ECG. If volitional exhaustion was reached during ETT, or any of the relative or 
absolute contraindication of ACSM’s guidelines were met (36), the test was immediately 
terminated. Upon termination of the test, the patient was seated on the chair for up to six 
minutes as a recovery period. All the tests were supervised by a cardiac physiologist who 
monitored the relative and absolute contraindications. The cardiac physiologist was blinded 
from the aim of the study.  
 
Outcome measures 
Heart rate recovery      
The rapid fall in heart rate (HRR) after peak exercise was measured at two time points. Heart 
rate recovery one minute (HRR1) was defined as the absolute difference between peak heart 
rate and one minute post ETT heart rate (HRR1 = peak heart rate – one minute post peak heart 
rate). Similarly, heart rate recovery two minutes (HRR2) was defined as the absolute difference 




minutes post peak heart rate). Peak heart rate was defined as the maximum heart rate reached 
during ETT.   
 
VO2 peak    
Peak aerobic capacity (VO2 peak) was measured via calibrated breath by breath gas analyser 
during treadmill ETT. Inspired and expired gas data were averaged every two seconds. VO2 
readings data were further smoothened by taking the average of VO2 every 28 seconds (taking 
the average of 14 readings of VO2 ml·min
-1). VO2 peak was defined as the highest VO2 during 
the test and was expressed as ml·kg-1·min-1. 
 
Serological assessments 
Blood samples were analysed for erythrocyte sedimentation rate (ESR), high sensitivity C-
reactive protein (hsCRP), fibrinogen, and white blood cells (WBC) as markers of inflammation. 
Total cholesterol, triglycerides, high density lipoprotein (HDL), and low density lipoprotein 
(LDL) were analysed and categorised as risk factors for CVD. Insulin resistance was analysed 
using homoeostasis models assessment (HOMA) (39).  
 
Global cardiovascular risk 
Qrisk2 score was used to measure the probability of developing cardiovascular events within 
10 years period via entering the data online into the main website (40). Data required for the 
calculation of the score include age, sex, smoking status, diabetes diagnosis, diagnosis of 
angina or heart attack in first degree relative <60, chronic kidney disease (stage 4 or 5) 
diagnosis, atrial fibrillation diagnosis, rheumatoid arthritis diagnosis, cholesterol/HDL ratio, 
systolic blood pressure, and BMI.   
 
Measures of wellbeing 
Hospital anxiety and depression scale (HADS) (high score is indicative of worse anxiety or 
depressive symptoms) (41), subjective vitality scale (high score is indicative of better vitality) 
(42), multidimensional assessment of fatigue (MAF) (high score is indicative of greater levels 




indicative of poor quality of life) (44) were used to assess psychological wellbeing and quality 
of life by questionnaire.  
 
Statistical analysis 
Statistical analyses were performed using SPSS20 (Chicago, IL, USA). Kolmogorov-Smirnov 
test was used to test variables for normality. Normally distributed variables were presented as 
means and standard deviation. Skewed variables (weight, BMI, total cholesterol, triglycerides, 
HOMA, HDL, ESR, hsCRP, HADS depression, and EuroQol) were log-transformed and 
presented as median and interquartile range. The comparison between the two populations was 
performed using analysis of variance (ANOVA). Bivariate Pearsons moment correlation 
(correcting for patient group, and sex) for normally distributed and log-transformed variables 
were used to assess the relationship between HRR1, HRR2 separately and other variables. To 
identify independent factors associated with HRR at both time points in both groups joined 
together, two models were analysed using linear regression (using enter method) in which 
patient group, and sex were entered in the first block. Thereafter, another block included only 
the significantly correlated variables in the univariate analyses as an independent variable and 
HRR1 and HRR2 as dependent variables, separately. The level of significance for all analyses 
was set at .05. 
 
Results 
Patient characteristics  
26 DM patients [(60.8 ± 10.4 years, 38.5% female) type 2 DM or pre- DM] were matched with 
46 RA patients based on age and sex. Three RA patients were excluded due to presence of DM, 
thus, the final RA group consisted of (N=43) (59 ± 9.6 years, 39.5% female). The demographic 
characteristics of the two groups are reported in Table 1. There was no difference in HRR, 
CVD risk factors, inflammatory markers or measures of wellbeing between the matched 
(N=43) RA and the remainder of the cohort of RA patients from the exercise intervention study 
(N=54) (data not reported).  
CVD risk factors, inflammation, and measures of wellbeing of all participants, and the 
comparison between the two groups are reported in Table 1. Weight (F (1, 67) = 4.39, p = .04), 




= 40.03, p = <.001) were significantly higher in patients with DM, whereas total cholesterol (F 
(1, 65) = 4.19, p = .05) and HDL (F (1, 65) = 5.96, p = .02) were higher in patients with RA. 
Vitality (F (61, 1) = 8.60, p = .005) and EuroQol (F (1, 64) = 5.78, p = .02) were significantly 
poorer in patients with RA, HADS depression (F (1, 63) = 5.41, p = .02), global fatigue index 
(F (1, 61) = 47.01, p = <.001) were significantly higher in patients with RA. No differences 
were observed in inflammatory markers between the two groups. 
 
Table 1. Demographic characteristics, CVD risk, inflammatory markers, and measures of 
wellbeing of RA and DM patients. 
Variable  RA (N=43) DM (N=26)   P value 
Cardiovascular risk factors    
Age (years) 59.2 ± 9.6 60.8 ± 10.4 .65 
Sex, F (%)  17 (39.5) 10 (38.5) .57 
Height (m) 1.7 ± 0.1 1.6 ± 0.1 .11 
Weight (kg) 77.1 (70.4 – 93.9) 91.9 (70.8 – 103.7) .04 
BMI (kg·m-2) 27.3 (23.8 – 30.3)  30.8 (29.1 – 36.7)  .001 
Heart rate rest (bpm) 79 ± 14 71 ± 12 .05 
Resting SBP (mmHg) 137 ± 18 132 ± 16 .26 
Resting DBP (mmHg) 82 ± 10 80 ± 10 .34 
Total cholesterol (mmol·L-
1) 
4.9 (4.4 – 6.0) 4.4 (3.9 – 5.3)  .05 
Triglycerides (mmol·L-1) 1.2 (0.8 – 1.9) 1.4 (0.9 – 1.9)  .89 
HDL (mmol·L-1) 1.4 (1.1 – 1.6) 1.2 (1.0 – 1.3) .02 
HOMA  1.5 (1.0 – 2.3) 2.3 (1.5 – 4.5) .001 
Qrisk2 20.2 ± 12.7 38.7 ± 10.9 <.001 
Inflammatory markers    
WBC (109·L-1) 6.9 ± 2.1 6.3 ± 1.8 .20 
Fibrinogen (g·L-1) 4.8 ± 1.1 4.5 ± 0.8 .39 
hsCRP  (mg·L-1) 5.4 (1.9 – 10.5) 3.1 (1.4 – 7.4)  .18 
ESR (mm·hr-1) 11 (5.0 – 18.8) 9.5 (5.0 – 19.8) .89 
Wellbeing    
Vitality 3.9 ± 1.5 4.9 ± 1.3 .005 
HADS anxiety 6.5 ± 3.7 5.1 ± 4.1 .16 
HADS depression 4.5 (2.6 – 7.0) 3.0 (1.0 – 6.0) .02 
Global Fatigue 27.6 ± 11.1 9.9 ± 7.1 <.001 
EuroQol 0.7 (0.6 – 0.8) 0.8 (0.7 – 0.8) .02 
Values are presented as means ± standard deviation, or median (25th to 75th percentile values) as appropriate. BMI, body mass index; SBP, 
systolic blood pressure; DBP, diastolic blood pressure; HDL, high density lipoprotein; Qrisk2, is an algorithm used to predict 10 years 
probability of cardiovascular diseases;WBC, white blood cells; HsCRP, high sensitivity C-reactive protein; ESR, erythrocyte sedimentation 
rate; HOMA, homeostasis model assessment insulin resistance; Vitality, score ranges 1 (low vitality) – 7 (high vitality); HADS, hospital 
anxiety and depression scale (0-21); Global fatigue, score ranges from 0 (no fatigue) – 50 (severe fatigue)  EuroQol, European assessment for 





Table 2. HRR and exercise-related variables in RA and DM patients.  
Variable  RA (N=43) DM (N=26)   P value 
Heart Rate Peak (bpm) 147 ± 20 145 ± 19  .69 
VO2 peak (ml·kg
-1·min-1) 21.1 ± 4.8 22.3 ± 4.5 .35 
HRR1 (bpm) 24 ± 11 24 ± 7  .79 
HRR2 (bpm) 42 ± 13 42 ± 9 .83 
Values are presented as means ± standard deviation, or median (25th to 75th percentile values) as appropriate. LF, low frequency; HF, high 
frequency; VO2 peak, highest volume of oxygen; HRR1, the difference between HR peak and heart rate 1 minute post HR peak; HRR2, the 
difference between HR peak and heart rate 2 minute post HR peak.  
 
Comparison in parasympathetic function between RA and DM patients  
No differences between RA and DM were observed in HRR1 (F (1, 64) = 0.07, p = .79) or 
HRR2 (F (1, 64) = 0.05, p = .83) following ETT, as presented in Table 2. In addition, overall 
fitness was similar in both groups as indicated by VO2 peak (F (1, 64) = 0.88, p = .35). 
 
Factors associated with HRR  
Correlational analyses were used to assess the factors associated with both measures of HRR 
including HRR1 and HRR2 with adjustments for patient group and sex. Age was inversely 
associated only with HRR2 (r (62) = -.28, p = .03). VO2 peak was associated with HRR1 and 
HRR2 [(r (62) = .31, p = .01), (r (62) = .41, p = .001) respectively]. Thus, older patients had 
poorer HRR, and better levels of fitness were related to better HRR.   
To identify independent associations between variables and HRR as well as investigating if the 
patient group associates with HRR, significantly correlated variables with HRR were entered 
in linear regression analyses (see Table 4). Analyses revealed that a significant model which 
included patient group and sex as a first entry then VO2 peak as independent variables and 
HRR1 as a dependent variable accounted for 9.5% of the variation of HRR1 (F (62, 1) = 6.53, 
p = .01, R2 = .09). VO2 peak was observed as an independent variable for the variation in HRR1 
in this model (see Table 4). A significant model for HRR2 which included patient group and 
sex as independent variables, then age and VO2 peak as independent variables and HRR2 as a 
dependent variable accounted for 19.3% of the variation of HRR2 (F (61, 2) = 7.74, p = .001, 
R2 = .19). In HRR2 model, sex and VO2 peak were the independent variable for the variation 




Table 3. Factors associated with HRR1 an HRR2 in RA and DM patients 
Variable HRR1 HRR2 
 r p r p 
Cardiovascular risk factors     
Age  -0.22 .08 -0.28 .03 
Weight  0.12 .34 0.09 .49 
BMI 0.01 .96 0.02 .87 
Resting SBP -0.10 .43 -0.12 .34 
Resting DBP -0.12 .35 -0.13 .33 
VO2 peak 0.31 .01 0.41 .001 
Total cholesterol 0.08 .54 0.23 .07 
Triglycerides  -0.11 .42 -0.72 .58 
HDL -0.04 .74 -0.06 .64 
HOMA -0.10 .42 -0.03 .82 
Qrisk2 -0.22 .08 -0.19 .13 
Inflammatory markers     
WBC -0.11 .38 -0.07 .57 
Fibrinogen  -0.22 .09 -0.23 .07 
hsCRP 0.05 .71 0.004 .97 
ESR -0.02 .87 -0.02 .89 
Wellbeing     
Vitality  0.24 .07 0.21 .11 
HADS anxiety  -0.19 .13 -0.04 .75 
HADS depression  -0.07 .61 0.04 .75 
Global fatigue index 0.04 .78 0.12 .37 
EuroQol -0.16 .22 -0.00 .99 
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; VO2 peak, highest volume of oxygen; HDL, high density 
lipoprotein; WBC, white blood cells; HsCRP, high sensitivity C-reactive protein; ESR, erythrocyte sedimentation rate; HOMA, homeostasis 
model assessment insulin resistance; Qrisk2, is an algorithm used to predict 10 years probability of cardiovascular diseases; Vitality, score 
ranges 1 (low vitality) – 7 (high vitality); HADS, hospital anxiety and depression scale (0-21); Global fatigue, score ranges from 0 (no fatigue) 
– 50 (severe fatigue), EuroQol, European assessment for quality of life 
 
Table 4. Linear regression model for factors associated with HRR1 and HRR2 
Variable  HRR1 HRR2 
 β t (p) β t (p) 
Group -1.27 -0.51 (.61) -0.02 -0.01 (.99) 
Sex 4.04 1.54 (.13) 8.77 2.94 (.005) 
Age   -0.24 -1.74 (.09) 
VO2 peak 0.71 2.56 (.01) 0.99 3.12 (.003) 
R2 and p-value of the model R2 P R2 p 









This study showed that parasympathetic function, assessed by post exercise HRR, was similar 
in patients with RA and patients with DM. Level of inflammation in RA patients was not 
significantly different from DM patients. CVD risk factors varied and were slightly higher in 
DM patients, but measures of wellbeing were poorer in RA. Multivariate analyses revealed that 
cardiorespiratory fitness was the only factor which was independent of other variables 
associated with HRR1, fitness and age were the independent predictors of HRR2.   
HRR is a simple, valid method to assess the ANS, and in particular parasympathetic activity 
(29). To our knowledge, this is the first study to compare parasympathetic activity between 
patients with RA and DM using HRR. Contrary to expectations, HRR was not different 
between RA patients and DM patients. The only other study to compare autonomic function in 
patients with RA and DM showed that compared to RA patients, DM patients had a poorer 
response to the valsalva manoeuvre and deep breathing test, which both reflect parasympathetic 
function (34). In the current study, we had type 2 DM or pre- DM patients, whereas, in the 
previous study, both type 1 and type 2 DM patients were included. Given that autonomic 
function has been reported to be poorer in type 1 DM (45) this could explain the different 
findings. Another notable difference between the current study and the previous study is the 
method of assessment. We assessed parasympathetic function following ETT, but the previous 
study used the valsalva and deep breathing test. This means that the conditions of the 
assessment are different with regards to the cardiovascular activation, as valsalva maneuverer 
and deep breathing test reflect the parasympathetic activity while resting whereas HRR reflects 
the parasympathetic reactivation after an exercise bout. However, in the absence of relevant 
studies, this remains a speculation.    
Contrary to our expectations, inflammation was not significantly different between RA and 
DM. In contrast, a significant difference in inflammation between RA and DM patients using 
CRP was reported in some studies (31;32). One of the studies had larger populations of 294 
RA patients and 194 DM patients (31), whereas, in the other study, the number of RA patients 
(48 RA) was similar to the sample size in the current study, but the number of DM patients was 
larger (48 DM) (32). Another similarity between the latter study and the current study is that 
patients were matched based on age and sex. An important difference perhaps is that the 
participants in the current study were recruited for an exercise trial. Therefore, a possible reason 
is that patients with RA in the current study had well-controlled disease activity as these RA 




Cardiorespiratory fitness was the only outcome measure which was independently associated 
with both HHR1 and HHR2. The association between cardiorespiratory fitness and 
parasympathetic activity is well established in both healthy and clinical populations (46), and 
this association was also apparent in older men (47). This moderate association between 
cardiorespiratory fitness can be attributed to the improved baroreflex sensitivity (46). The 
baroreflex sensitivity has an important role in response to the increased blood pressure, which 
occurs during ETT. Increased stimulation from the baroreceptors via the vagus nerve to the 
cardioregulatory and vasomotor centres in the medulla oblongata (origin of the 
parasympathetic nervous system) causes stimulation of the parasympathetic nervous system, 
which decreases the heart rate (48). Thus, the better the cardiorespiratory fitness, the better 
parasympathetic modulation of the heart after exercise. Given the association between 
cardiorespiratory fitness indicated by VO2 peak and HRR, additional analyses were made to 
identify independently associated variables as well as to explore if patients group was a 
predictor for HRR. The results indicated that cardiorespiratory fitness was an independent 
predictor for HRR1 and HRR2, however, sex had an effect only in HRR2 and was a significant 
predictor for HRR2.  
This difference in the variables associated with HRR1 and HRR2 has been reported (49). . This 
difference can be due to the difference in information reflected by HRR1, which reflects 
parasympathetic reactivation whereas HRR2 reflects  parasympathetic reactivation in 
combination with sympathetic withdrawal (30). 
The number of studies comparing ANS, inflammation, and CVD risks between RA and DM as 
two separate conditions is very limited. To our knowledge, only three studies compared RA 
and DM patients including one study that compared ANS (34), and two studies that compared 
inflammation and CVD risks only between RA and DM patients (31;32). In line with previous 
research, we reported similar CVD risk factors in patients with RA and DM. For example, 
Stamatelopoulos et al. (32) also reported lower weight and BMI and higher total cholesterol 
and HDL in RA. In contrast, Van Halm et al. (31), reported higher total cholesterol  but lower 
HDL in DM relative to RA, and no differences was observed in weight or BMI of RA and DM 
patients. The differences in total cholesterol and HDL reported in the latter study could be 
explained due to the higher use of lipids lowering drugs (i.e. statins) in RA than DM patients 
which have resulted in lower levels of cholesterol in RA patients than DM patients. RA patients 
demonstrated higher resting heart rate in the current study which is not reported in many 




al. (34), showing no difference in resting heart rate between RA and DM patients. It is difficult 
to explain why there was no difference in resting heart rate, however, it could be due to 
differences in inclusion criteria. For example, apart from inclusion of women only, the range 
of age included in the DM group was between 12-80 years, whereas, for RA it was 25-66 years. 
The variations in the results from studies suggest the need for further studies in larger 
populations to confirm these findings. However, overall, these studies suggest that some CVD 
risk factors in RA are comparable to DM patients, which suggests that CVD risk factors in RA 
patients need to be addressed clinically in a similar way to DM patients. Qrisk2 was used to 
compare the 10 years CVD risk in both groups. Qrisk2 was used due to its more suitability for 
the comparison, as it includes diagnosis of RA or DM as an independent risk factor (40;50). 
The current study found higher Qrisk2 in DM patients than RA patients. The higher Qrisk2 in 
DM patients is due to the higher individual CVD risk in DM patients, as DM patients in the 
current study had higher weight and BMI which are incorporated in the risk algorithm, resulting 
in higher Qrisk2 scores in DM patients. 
Most of measures of wellbeing were poorer in RA patients than DM patients, except for 
anxiety. Similar findings using different forms of psychological wellbeing assessments were 
reported in a large population-based study comparing different chronic diseases including 
chronic obstructive pulmonary disease, RA, and DM patients (51). Comparing RA and DM, 
this study reported that RA patients had poorer wellbeing than DM patients (51). This included 
higher prevalence of anxiety and depression, poorer quality of life, impaired psychological 
wellbeing, and higher levels of fatigue (51). It is worth emphasising that these differences in 
wellbeing were found in the absence of differences in the physiological measures that were 
taken. Therefore, the current study adds to the suggestion that patients with RA need attention 
with regard to the measures of wellbeing to minimise the burden of the disease (52). Despite 
the finding that none of these measures of wellbeing were related to parasympathetic activity, 
long term burden of poor wellbeing such as depression associate with high risk of CVD (53). 
The management of RA is mostly focused on treating the symptoms and reducing progression 
of the disease with less focus given to addressing the psychological burden of the disease (52). 
It is worth noting that even though our RA sample were well-controlled, measures of wellbeing 
were poorer than DM. This can suggest that RA patients with severe disease activity are more 
likely to have poorer measures of wellbeing than our RA sample. However, without making a 
direct comparison in measures of wellbeing between RA patients with high disease activity and 




The study is not without limitations. It is possible that the small sample size could have 
contributed to the lack of difference in inflammation. However, it should be emphasised that 
even though the sample size was smaller than previous studies, the participants were matched 
for age and sex. Another limitation is the absence of a healthy control group, which would have 
added information about the difference between RA patients and DM patients in comparison 
to the healthy control group. Therefore, future studies should examine the influence of 
inflammation on HRR in patients with RA, DM, as well as a healthy control group. 
Furthermore, RA patients that were matched with DM had well-controlled disease activity to 
enable them to participate in an exercise intervention study, therefore, it would be interesting 
to compare DM patients with RA patients with severe disease activity. Thus, further research 
should compare HRR between different levels of disease activity in patients with RA. In order 
to determine the disease activity of RA patients, DAS28 is helpful to determine the disease 
activity for patients with RA, however, DAS28 was not available for all of our RA patients.    
In conclusion, the results of the current study indicated that there were no differences in 
parasympathetic activity or inflammation between RA and DM patients. Cardiorespiratory 
fitness was an independent factor for parasympathetic activity in both groups of the patients. 
Despite the higher CVD risks in DM patients, some of the CVD risk factors in patients with 
RA were comparable to DM patients, which also mandate the need for CVD management in 
RA similar like what is established in DM patients (31). Future research should investigate the 
effect of CVD management on CVD risk and compare it between RA and DM patients. Given 
the association between CVD and poor measures of wellbeing, the current study also showed 
that measures of wellbeing were poorer than for DM, which emphasises the need for 
psychological management of patients with RA. Future research should investigate the effect 
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The studies presented in this thesis focused on the autonomic nervous system (ANS) in patients 
with rheumatoid arthritis (RA). ANS consists of the sympathetic and the parasympathetic 
nervous systems, two systems that work in synergy to maintain cardiovascular autonomic 
balance. Autonomic dysfunction, which is a disruption of the balance in the activity of 
sympathetic and parasympathetic nervous system (i.e. increased sympathetic and reduced 
parasympathetic), is known to be associated with increased risk for cardiovascular diseases 
(CVD) (1;2). The risk of CVD in RA is increased compared to the general population and 
multifactorial, with autonomic dysfunction being implicated as one of the risk factors for CVD 
in this population (3). As discussed in the first chapter, there are various non-invasive methods 
to assess ANS: heart rate variability (HRV), heart rate recovery (HRR), and Ewing’s test 
battery are the most commonly used methods. 
HRV was used in the study presented in Chapter 2 to explore the association between induced 
myocardial ischemia during exercise tolerance test (ETT) (using ST/HR index), and the overall 
activity of ANS while resting. Subsequently, the factors associated with parasympathetic 
reactivation reflected by heart rate recovery (HRR) following ETT including a range of factors 
reflecting CVD risk, RA-related disease activity, and measures of wellbeing were explored 
(Chapter 3). In the next chapter, the effects of a 3-month exercise intervention on 
parasympathetic activity (using HRR), as well as the CVD risk factors (including 
cardiorespiratory fitness), markers of inflammation and measures of wellbeing were 
investigated (Chapter 4). Finally, since inflammation was one of factors associated with 
parasympathetic activity in RA patients (Chapter 3), parasympathetic activity (using HRR) was 
compared between two populations [RA and diabetes mellitus (DM)] with similar CVD risk 
profiles but different levels of inflammation (Chapter 5). The study presented in Chapter 5 
compared inflammatory markers, a range of CVD risk factors, and measures of wellbeing in 
these populations and the association of these factors with HRR. The following paragraphs 
provide a summary of the findings reported in this thesis, the implications of these findings, 






Cardiovascular disease risk factors associated with autonomic nervous system  
Association between a marker of ischemia and autonomic nervous system 
Chapter 2 aimed to investigate the association between resting HRV using frequency domain 
analyses and ST/HR index as a marker of ischemia during ETT and in patients with RA. As 
hypothesized, there was an association between this marker of ischemia and ANS. This may 
suggest that poor parasympathetic function at rest indicated by high frequency (HF) 
component, as well as a disrupted balance between the sympathetic and parasympathetic 
nervous system at rest (i.e. LF/HF), may associate with myocardial ischemia (indicated by 
ST/HR index) during ETT.  
Chapter 3 revealed associations between parasympathetic activity following ETT and factors 
that can contribute to myocardial ischemia. Myocardial ischemia is caused by atherosclerosis. 
Accumulation of triglycerides on the arterial wall (4) as well as high blood pressure (5) are 
known as factors that contribute to the development of atherosclerosis. Inverse association 
between resting parasympathetic tone and myocardial ischemia was reported in Chapter 2, and 
the inverse association between parasympathetic activity following ETT and factors that 
contribute to myocardial ischemia (triglycerides, and systolic blood pressure) were reported in 
Chapter 3. Therefore, it was not surprising to find the same inverse association between 
parasympathetic activity and Framingham risk score, which includes total cholesterol, blood 
pressure, as well as other CVD risks. 
The study presented in Chapter 2 was the first to use heart rate adjusted ST segment (i.e. ST/HR 
index) as marker of ischemia during exercise testing in RA, and to report an association 
between this marker and reduced HRV. Other studies in autoimmune diseases including RA 
have suggested that coronary artery disease and sudden cardiac death are associated with 
reduced HRV (6-8). Therefore, given the high risk of unrecognized myocardial infarction (MI) 
in RA compared to patients without RA (9), it could be beneficial to use ST/HR index during 
an exercise tolerance test in patients with RA for the early detection of myocardial ischemia. 
The advantage of using the ST/HR index is that it takes the achieved HR into account, therefore 
even if a patient is not able to exercise until exhaustion because of joint problems, this 
measurement will still provide information regarding ischemia. However, further investigation 
is needed to investigate the association between ST/HR index and CVD events in RA. 
Furthermore, it was found that ST/HR index has good accuracy to detect ischemic changes in 




in patients with RA which will identify if ST/HR index is indeed related to clinically relevant 
CVD measures.    
 
Individual cardiovascular risk factors associated with autonomic nervous system 
Chapter 3 aimed to explore the association between a range of CVD risk factors, RA-related 
disease activity, and measures of wellbeing with the ANS, in particular parasympathetic 
activity following exercise testing using HRR. As hypothesized, many CVD risk factors 
including age, resting systolic blood pressure, triglycerides, insulin resistance (i.e. HOMA), 
and Framingham risk score, were inversely associated with HRR, whereas cardiorespiratory 
fitness indicated by VO2 peak was positively associated with HRR. RA-related disease activity 
variables including higher WBC, fibrinogen, CRP, and ESR, were associated with poorer HRR. 
Associations were also found for measures of wellbeing; poor vitality was associated with poor 
HRR and better quality of life was associated with better HRR. Interestingly though, none of 
these factors were independently associated with HRR. This may suggest that it is the overall 
CVD risk and disease-related burden that contributes to changes HRR, instead of one or several 
individual factors. 
The study presented in Chapter 3 was the first study to investigate HRR and the factors related 
to it in a sample containing men and women with RA. Furthermore, the study also explored the 
association between a wide range of CVD risk factors and psychological wellbeing in a 
systematic manner, which has not been done before in other studies (an overview of these 
studies is given in Chapter 1). It is important to know which factors are related to ANS, in 
particular, the parasympathetic nervous system, given that poor parasympathetic activity has 
been suggested to contribute to increased risk of CVD (1;2). Therefore, knowing which factors 
are associated with ANS would help with the development of interventions to improve ANS. 
Based on the findings in this chapter, it can be suggested that reducing the overall CVD risk 
and disease-related burden will have a positive effect on ANS in RA.    
 
Comparison between rheumatoid arthritis and diabetes mellitus (impact of inflammation on 
autonomic nervous system) 
In the last experimental chapter, a different approach was taken to specifically explore the 




both conditions share similar CVD risk profile but have different levels of inflammation 
(Chapter 5). RA is a condition characterised by systemic inflammation, whereas, DM has low-
grade systemic inflammation. Therefore, the study aimed to compare parasympathetic activity 
using HRR following exercise tolerance between age- and sex-matched RA and DM patients. 
The secondary aim was to compare inflammation as well as CVD risk factors and measures of 
wellbeing and the association of these variables with HRR in both populations. No difference 
in HRR was observed and despite inflammation being increased in RA, this difference did not 
reach statistical significance.  
The studies investigating the difference in the ANS between RA and DM patients are limited. 
Therefore, the study presented in Chapter 5 investigated the difference in ANS between two 
chronic conditions which are prone to develop CVD and have similar CVD risk factors. To the 
best of my knowledge, only one study has investigated the difference in ANS between RA, 
DM, and healthy control participants using cardiovascular autonomic reflex tests, where DM 
patients were reported to have poorer ANS than RA or healthy participants (11). Thus, further 
studies are required to investigate the difference in ANS between RA and DM patients using 
difference measures of ANS.  
In Chapter 3 an inverse association between parasympathetic activity and inflammation was 
reported, which was not confirmed in Chapter 5, where none of the inflammatory markers were 
associated with parasympathetic activity. It is difficult to explain the reason why there was no 
association in the study presented in Chapter 5. Both populations have a similar CVD risk 
profile, and therefore, it could be speculated that the overall CVD risk profile has a stronger 
association with parasympathetic reactivation than inflammation. For example, 
cardiorespiratory fitness was associated with parasympathetic reactivation in both Chapter 3 
and 5. It should also be acknowledged that the cross-sectional designs of these studies only 
allow for the examination of associations but do not provide information about cause and effect. 
Therefore, in order to get a better understanding of the role of inflammation in ANS, additional 
intervention or experimental studies are needed to explore the impact of changing inflammation 
on ANS. To our knowledge, this has not been done in patients with autoimmune disease.    
 
Cardiorespiratory fitness and parasympathetic activity     
The association between cardiorespiratory fitness and parasympathetic activity was found in 




patients in Chapter 3. In Chapter 5, VO2 peak was an independent factor associated with HRR 
in a sample combining RA and DM patients. Behavioural interventions, including exercise, 
have been found to improve autonomic function , in particular, in many clinical populations 
(12;13). Furthermore, exercise has been shown to reduce CVD risk and inflammation in RA 
patients (14;15). Therefore, the study presented in chapter 4 aimed to investigate the effects of 
a 3-month semi-supervised exercise intervention on parasympathetic reactivation-HRR, CVD 
risk, RA-related disease activity, and measures of wellbeing. However, the intervention was 
not successful in improving HRR or VO2 peak. It was suggested that the lack of improvement 
in VO2 peak could have resulted in the lack of improvement in HRR. These findings suggest 
that without improvement in VO2 peak, HRR is less likely to improve. 
A sub-analysis of the data revealed that when the sample was split into two groups based on 
improvement and no-improvement in HRR, it was found that those with poorer 
parasympathetic activity-HRR and CVD risk at baseline were more likely to gain benefits from 
exercise intervention (Chapter 4).  
Autonomic function has been reported to improve after exercise programmes. The 
improvement in autonomic function following exercise programmes is suggested to be due to 
improvement in cardiorespiratory fitness which subsequently improves the vagal modulation 
of the heart making the parasympathetic effect on the heart effective on reducing the heart rate 
after exercise (16). The improvements in HRR following an exercise intervention has been 
reported in a group of women with RA following 10 weeks of supervised high intensity 
exercise training (17). Despite the difference in the sample sex, and level of supervision, , an 
improvement in VO2 peak was reported in the latter study, which may have prompted the 
improvement in HRR. Therefore, this may suggest that exercise interventions should focus on 
improvement of cardiorespiratory fitness to gain beneficial effect on parasympathetic 
reactivation. Furthermore, the study reported in Chapter 4 also suggested that the exercise 
programme might have an impact on positive psychological wellbeing, without the 
improvement in cardiorespiratory fitness.     
 
Limitations    
There were some limitations in the studies presented in this thesis, which were mostly discussed 




from an exercise intervention study, which involved patients with well-controlled disease 
activity. This makes it difficult to generalise the results presented in this thesis to RA patients 
with severe disease activity. However, the studies in this thesis still highlight some interesting 
findings (i.e. association between ANS and CVD risk factors) and open up further questions 
related to parasympathetic activity in RA and how it compares to another condition with similar 
CVD risk profiles such as DM Furthermore, the cross-sectional design of Chapter 2, 3, and 5 
do not allow investigations around causality between the associated variables. The lack of a 
comparison group in Chapter 2 and 3 is another limitation that would have allowed a direct 
comparison between RA and another population. In addition, DAS28 would have added more 
information about the disease activity of our RA cohort, however, DAS28 was not available 
from all RA patients to be able to include it into our analyses.  
In Chapter 2, two minutes short-term HRV is a method that is not often used in clinical 
research. Although a wealth of information can be obtained from HRV based on several hours 
or minutes of heart rate recording, this may not always be possible in population-based studies 
or epidemiological research (18). Furthermore, the study utilised the minimum requirement 
(which is two minutes) for heart rate recording to obtain HRV parameters (19), which is a 
method that was previously used in epidemiological studies (18;20). In Chapter 4, it was 
unknown whether the RA sample size was enough to investigate the effect of exercise on HRR, 
as the power calculation performed initially was for the main outcome of the main study 
(i.e.VO2 peak).. In Chapter 5, the lack of healthy control participants to investigate the 
difference in parasympathetic activity as well as inflammatory markers between RA 
patients/DM patients and healthy individuals.  
 
Recommendations for future research 
A number of future studies can arise from the findings reported in Chapter 2. There is evidence 
that ST/HR index has shown good sensitivity with clinical measures of coronary artery disease 
such as angiography in other populations (10). It is therefore very likely that this is also the 
case for patients with RA, however, this remains to be confirmed. Thus, subsequent research 
could investigate the association or the sensitivity of ST/HR index with a clinically established 
measure of coronary artery disease in patients with RA. Although, the difference in HRV 
between RA patients and healthy control participants is known, the difference in ST/HR index 




designs should be employed to examine the relationship between ST/HR index and coronary 
artery disease (e.g., MI), which will help to explore if ST/HR index can predict future CVD 
events in patients with RA. 
Due to the similarity in the values of HRR reported in Chapter 3 with HRR recovery of healthy 
participants reported in other studies (21;22), it would be interesting to compare HRR between 
RA patients and healthy participants in one study, as direct comparison between the HRR 
reported from different studies is difficult due to the difference in methodology. Another 
interesting comparison group would be patients with established CVD. The current data only 
allows for the examination of associations, by adding comparison groups without and with 
established CVD, it will be possible to examine if HRR in RA is indeed different from these 
populations. Furthermore, numerous studies have indicated that HRR is a predictor of CVD 
mortality in other populations (23-25), therefore, similar longitudinal design should be 
employed to investigate if HRR is a predictor of CVD mortality in patients with RA. Such a 
study would also allow for the establishment of clinical cut off points specific for patients with 
RA, as the current clinical cut off point were obtained from other populations and difficult to 
be generalised to patients with RA.  
In Chapter 5, the impact of inflammation on ANS was explored by using two different 
populations. The impact of inflammation on ANS can also be investigated in a different way 
by stimulating the vagus nerve e.g., the cholinergic anti-inflammatory pathway via the 
stimulation of α7 nicotinic acetylcholine receptor (α7nAChR) of the vagus nerve has been 
suggested as a method to reduce inflammation in RA (26). Stimulating these receptors via non-
invasive transcutaneous electrical stimulation of the vagus nerve has been shown to effectively 
increase the parasympathetic activity in a healthy population (27). Therefore, it can be used as 
a method to investigate if treatment using this method can reduce inflammation as well as 
improving ANS over a period of time in RA patients.  
Another method is to investigate the influence of inflammation on ANS is by examining the 
effects of pharmacological treatment on ANS.  For example, by exploring the changes in ANS 
following successful treatment of tumour necrosis factor-α inhibitors (TNF-α inhibitors). 
Given the mixture of medications taken by patients with RA, future studies could also compare 
the effects of different commonly used treatments on ANS in RA. This may help to identify 




In addition to the inverse association between parasympathetic activity and blood pressure 
reported in the cross-sectional study in Chapter 3, one of the interesting findings in the study 
presented in Chapter 4 is the improvement in blood pressure after the exercise intervention. 
Given the benefits of exercise training for the treatment of hypertension (28;29), it would be 
interesting to investigate the effect of exercise intervention in comparison to the effect of anti-
hypertensive medications in patients with RA. Previous studies which reported positive effects 
of exercise training on autonomic function have used supervised exercise training in patients 
with RA (17;30). Future studies should investigate the difference in the effects of semi-
supervised versus supervised exercise training on HRR as well as cardiorespiratory fitness. 
Furthermore, perhaps an additional study should investigate the difference between high 
intensity and moderate intensity of exercise training on HRR and cardiorespiratory fitness in 
RA patients. Furthermore, as it was assumed that in Chapter 4 that the lack of improvement in 
HRR is due to the lack of improvement in cardiorespiratory fitness indicated by VO2 peak, 
further study should confirm this hypothesis. In order to test this hypothesis, a longitudinal 
study can be deployed to investigate the effect of exercise intervention on VO2 peak as well as 
HRR using high intensity aerobic exercise versus low intensity aerobic exercise in patients with 
RA. This would identify if exercise targeting improvement in cardiorespiratory fitness can 
result in a subsequent improvement in parasympathetic activity.  
The study presented in Chapter 5 revealed that several CVD risk factors are comparable 
between RA and DM patients. Unlike DM, CVD management receives less attention in RA 
(31), therefore, future studies should investigate the effects of CVD management on ANS in 
patients with RA. This would be helpful in establishing guidelines similar to thosefor DM. 
Although it was not associated with the parasympathetic activity in Chapter 5, poorer measures 
of wellbeing reported in this study in comparison to DM indicate that they need to be addressed 
in RA patients to reduce the burden of the disease. It has been reported that improvement of 
psychological wellbeing can reduce CVD mortality in healthy populations and reduce death 
rates in other clinical populations (32). Therefore, future studies need to investigate the effect 
of interventions aimed at improving psychological wellbeing in RA and the effect of 








This thesis identified associations between ANS with CVD risk factors, RA-disease related 
activity and measures of wellbeing. Parasympathetic activity following exercise testing was 
not improved after 3-month semi-supervised exercise intervention. However, the exercise 
intervention improved some of the CVD risk factors, and the improvement was more noticeable 
in patients with poorer CVD risk profiles. When ANS was compared with DM, the 
parasympathetic activity following exercise testing was similar, inflammatory markers were 
not different, some CVD risk factors were comparable, and measures of wellbeing were poorer 
in RA. Cardiorespiratory fitness was an independent predictor for parasympathetic activity in 
both populations, which suggests that by improving cardiorespiratory fitness, the 
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STANFORD HEALTH ASSESSMENT QUESTIONNAIRE 
 
For the items below, please tick the ONE response which best describes your usual 












1. DRESSING AND 
 GROOMING 
 Are you able to: 
 - Dress yourself, 
  including tying 
  shoelaces and 
  doing buttons? 
 



































 Are you able to: 
 - Stand up from an 
  armless straight chair? 
 



























 Are you able to: 
 - Cut your meat? 
 
 - Lift a full cup or glass 
  to your mouth? 
 
 - Open a new carton of  







































 Are you able to: 
 - Walk outdoors on  
  flat ground? 
 































Please tick any aids and devices that you 
usually use for any of these activities: 
 
 Cane 
 Walking frame 
 Crutches 
 Wheelchair 
 Special or built-up chair 
 Devices used for dressing  
  (button hook, zipper pull,  
   long handled shoe horn etc.) 
 Built-up or special utensils 
 Other (please specify) 
 
  ............................................. 
Please tick any categories for which you 
usually need help from another person: 
 
 




For the items below, again please tick the ONE response which best describes your 














 Are you able to: 
 - Wash and dry your 
  entire body? 
 
 - Take a bath? 
 
 - Get on and off the 






































 Are you able to: 
 - Reach and get down 
  a 5lb object (e.g. a bag 
  of potatoes) from just 
  above your head? 
 
 - Bend down to pick up 















































































 Are you able to: 
 - Open car doors? 
 
 - Open jars which have 
  been previously 
  opened? 
 







































 Are you able to: 
 - Run errands and shop? 
 
 - Get in and out of a car? 
 
 - Do chores such as 
  vacuuming, housework 



































Please tick any aids or devices that you 
usually use for any of these activities: 
 
 Raised toilet seat 
 Bath seat 
 Jar opener  
  (for jars previously opened) 
 Bath rail 
 Long handled appliances for reach 
 Other (please specify) 
 
  ............................................. 
Please tick any categories for which you 




 Gripping and opening things 














































Subjective Vitality Scale 
